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1. intRodução GERaL
Esta dissertação, que apresento à faculdade de Medicina da universidade do 
Porto, resulta de uma investigação clínica na área da lipodistrofia relacionada com o 
vírus da imunodeficiência humana. 
O meu interesse pelas lipodistrofias começou em 1997 quando o Professor 
Doutor José Luís Medina me convidou para o representar na Primeira conferência de 
Lipodistrofia Diabética e apresentar o caso clínico de duas irmãs com síndrome de 
berardinelli-Seip. uma delas foi seguida por mim na consulta externa de Endocrino-
logia durante o internato complementar realizado sob orientação do Dr José Pedro 
Lima reis.
Nesse ano fui a Bruxelas à Primeira Conferência de Lipodistrofia Diabética do 
tipo Berardinelli-Seip apresentar o caso clínico dessas 2 irmãs com lipodistrofia ge-
neralizada congénita do tipo berardinelli-Seip, fui membro do comité para o estudo 
da lipodistrofia diabética e participei na elaboração do primeiro protocolo de diag-
nóstico e tratamento desta doença. A minha participação foi emocionante por duas 
razões: primeiro, porque tive o grato prazer de conhecer pessoalmente o Professor 
Seip e segundo, porque pela primeira vez, como interna do terceiro ano do internato 
complementar tive o prazer e o privilégio de conhecer pessoalmente vários proemi-
nentes investigadores na área das lipodistrofias que apenas conhecia dos artigos 
que lera até à exaustão para preparar a minha primeira comunicação em inglês. o 
stress induzido provocou uma alteração epigenética que terá condicionado todo o 
meu futuro.
Em 1998, o professor Leonel van Maldergem (sendo eu também coautora) 
apresentou um trabalho no “European Society of Human Genetics congress” intitu-
lado “berardinelli-Seip Syndrome: a new Portuguese disease?” (European Journal of 
Human Genetics 1998; 74: P1-160), colocando a hipótese de que no século Xvi ocor-
rera uma mutação e os portugueses teriam “disseminado” a doença para o brasil, 
Europa e ceilão (Sri-Lanka), já que, muitos dos doentes estudados - e na altura eram 
menos de 100, ou tinham ancestralidade ou sobrenomes portugueses. 
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Lembro que nessa altura não se sabia quase nada acerca da genética deste 
tipo de lipodistrofia. E será, pela primeira vez em 1999, o professor Abhimanyu Garg 
de Dallas, texas a descobrir um gene associado à doença: “A gene for congenital ge-
neralized lipodystrophy maps to human chromosome 9q34. J clin Endocrinol Metab 
1999; 84: 3390”.
Dois anos mais tarde, a professora Jocelyne Magré de Paris identificou em vá-
rios doentes e nas nossas próprias doentes um outro gene: “Identification of the 
gene altered in berardinelli-Seip congenital lipodystrophy on chromosome 11q13”. 
o trabalho foi publicado na nature Genetics (nature Genetics 2001; 28: 365-370), 
tendo como coautores eu e o Professor JL Medina.
Anos mais tarde, ao fazer uma pesquisa bibliográfica, fiquei surpreendida ao 
verificar a existência de doentes com fenótipo semelhante ao dos portadores de li-
podistrofia tipo Berardinelli Seip, mas que correspondiam a uma forma adquirida 
de lipodistrofia associada à infeção VIH. Nessa altura, ainda se desconhecia de que 
forma a infeção VIH se relacionava com a lipodistrofia.
Em 1999, carr e colaboradores, descreveram pela primeira vez uma forma de 
lipodistrofia que se associava à terapêutica antirretrovírica “Diagnosis, prediction, 
and natural course of Hiv-1 protease-inhibitor-associated lipodystrophy, hyperlipidae-
mia, and diabetes mellitus: a cohort study” Lancet 1999; 353:2093.
Quando em 2005 o Professor Doutor José Luís Medina me convidou a iniciar 
um trabalho de investigação tendo como objetivo o meu doutoramento pareceu-nos 
interessante estudar esta forma nova de lipodistrofia.
Em 16 de fevereiro de 2006 efetuei provas de avaliação do ano probatório de 
doutoramento e obtive a inscrição definitiva como estudante de doutoramento.
Durante os últimos 6 anos, como estudante de doutoramento “em tempo par-
cial”, desenvolvi em colaboração com de colegas de outras especialidades e sob in-
dicação dos meus, orientador e coorientador, e do Professor Doutor Davide carvalho, 
investigação na área da lipodistrofia VIH. Os nossos resultados refletem-se nas dez 
publicações que fazem parte desta tese mas também nas 62 comunicações de tra-
balhos originais em reuniões científicas, 45 ações de ensino pós-graduado, 4 bolsas 
de investigação, 5 prémios nacionais e 2 prémios internacionais.
introDução GErAL
	 	 
Dos onze artigos que constituem esta tese, o primeiro é o ponto de partida da 
minha viagem pelo mundo das lipodistrofias, iniciada com as lipodistrofias congéni-
tas, nomeadamente a de tipo berardinelli-Seip. Esse artigo, de que eu e o Professor 
Doutor José Luís Medina somos coautores, identificou um novo gene alterado no 
cromossoma 11 associado à lipodistrofia congénita generalizada de tipo Berardinelli-
Seip.
o primeiro e o segundo artigo fazem parte da introdução desta tese. o segun-
do é um artigo de revisão que se foca na etiopatogenia das lipodistrofias genéticas 
e adquiridas, com ênfase na forma mais comum – a lipodistrofia associada ao VIH 
– desde a etiologia às complicações. Nele, analisamos o papel relativo dos diferentes 
tipos de tecido adiposo, nomeadamente o efeito protetor cardiovascular do tecido 
adiposo subcutâneo. Discutimos também os fatores relacionados com a redistribui-
ção do tecido adiposo nos doentes infetados pelo viH, nomeadamente o impacte da 
terapêutica antirretrovírica, o papel da inflamação, fatores genéticos, lipotoxicidade 
e cortisol. Também fizemos uma revisão dos mecanismos da insulinorresistência, 
dislipidemia, síndrome metabólico e das sequelas associadas à lipodistrofia VIH, no-
meadamente disfunção endotelial, doença e mortalidade cardiovascular.
Ao avançar com a investigação, sentimos a necessidade de um método simples 
e objetivo para definir lipodistrofia embora, ao longo dos anos, já tivessem surgido 
metodologias diferentes com essa finalidade: a autodeclaração pelo doente, a ava-
liação clínica subjetiva do médico baseada na sua experiência e um método definido 
por carr complexo e pouco prático para uso na clínica diária, “Hiv lipodystrophy case 
definition” Lancet 2003; 361:726. 
Dessa necessidade de uma definição simples e objetiva surge o terceiro artigo 
– “Fat Mass Ratio: an objective tool to define lipodystrophy in HIV-infected patients un-
der antiretroviral therapy”, que nos permitiu definir de um modo objetivo, baseado na 
gordura corporal avaliada por densitometria, a presença de lipodistrofia, fixar pontos 
de corte de acordo com o género e precisar, pela primeira vez, um ponto de corte para 
lipodistrofia para o sexo feminino. Parece-nos que o “Fat Mass Ratio” (FMR) é uma fer-
ramenta de diagnóstico que permitirá a comparação de diferentes estudos e que tam-
bém poderá ser útil para monitorizar a progressão da lipodistrofia nesta população.
A avaliação da composição corporal dos doentes é feita na prática clínica, com 
medidas antropométricas. Os doentes que têm lipodistrofia associada ao VIH podem 
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ter vários padrões de composição corporal passível de identificação clínica, nomea-
damente por antropometria, mas a bioimpedância elétrica poderá tornar-se numa 
ferramenta útil e fácil porque permite uma avaliação da massa gorda e da massa não 
gorda e nos dá um quadro da composição corporal que não é possível apenas com 
antropometria. Essa avaliação é descrita no quarto artigo – “Assessment of body fat 
composition disturbances by bioimpedance analysis in Hiv infected patients”.
Se por um lado, a terapêutica antirretrovírica mudou o curso da história da 
infeção VIH, originando reduções significativas na morbilidade e mortalidade asso-
ciada à SiDA, por outro lado, está associada a alterações da composição corporal 
(lipodistrofia) e alterações metabólicas, incluindo insulinorresistência, dislipidemia e 
hipertensão arterial. o síndrome metabólico refere-se a uma constelação de fatores 
de risco cardiovascular e é por si, um fator de risco de morbi-mortalidade e diabetes 
tipo 2. O objetivo no artigo nº 5 – “Impact of lipodystrophy on the prevalence and 
components of metabolic syndrome in Hiv-infected patients” foi avaliar a prevalência 
do síndrome metabólico e determinar se os doentes com ou sem lipodistrofia têm 
uma prevalência diferente deste síndrome.
Se nos primeiros anos da infeção pelo viH o “wasting syndrome” era a “mar-
ca” da SiDA, com a introdução da terapêutica antirretrovírica altamente ativa e com 
a subsequente supressão da replicação viral e aumento dos cD4+ a sua incidên-
cia diminuiu de forma drástica. Mais recentemente, assistimos ao aparecimento de 
obesidade nos doentes infetados pelo viH. os dados relativos à obesidade nesta 
população eram ainda escassos e a obesidade per se pode também contribuir para 
o aumento do risco cardiovascular. A publicação nº 6 – “Prevalence of obesity and its 
relationship to clinical lipodystrophy in Hiv-infected adults on anti-retroviral therapy” 
aborda esse tema.
Em contraste com outras alterações metabólicas, poucos e controversos estu-
dos existiam sobre os efeitos da terapêutica antirretrovírica na hipertensão arterial 
dos doentes infetados pelo viH. E, em alguns estudos, o risco de hipertensão arterial 
nos doentes infetados pelo VIH associava-se com lipodistrofia, ao contrário do que 
acontece nas lipodistrofias genéticas, onde a diabetes é uma característica comum, 
mas não a hipertensão arterial. Dada esta controvérsia, a publicação nº 7 – “Cen-
tral/peripheral fat mass ratio is associated with increased risk of hypertension in Hiv-
infected patients” teve como objetivo estimar a associação da composição corporal, 
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lipodistrofia definida pela clínica e pelo FMR e insulino-resistência na prevalência de 
hipertensão arterial.
A terapêutica antirretrovírica combinada associa-se também à insulinorresis-
tência e à diabetes. No artigo nº8 – “Lipodistrophy defined by Fat Mass Ratio in HIV 
infected patients is associated with high prevalence of glucose disturbances and in-
sulin resistance”, procuramos comparar a prevalência de alterações da homeostasia 
da glicose e de insulinorresistência em doentes infetados pelo viH sob terapêutica 
antirretrovírica de acordo com a presença de lipodistrofia definida pela clínica e pelo 
fMr e em diferentes padrões de distribuição da gordura corporal e estabelecer os 
principais responsáveis destas alterações. 
A terapêutica antirretrovírica também se associa à dislipidemia e doença car-
diovascular. recentemente, têm sido implicados na aterosclerose acelerada fatores 
de risco emergentes, nomeadamente, apolipoproteina A1, apolipoproteina b, Lp (a), 
fibrinogénio, PCR de alta sensibilidade, homocisteína, microalbuminúria e o NT-proB-
nP. na publicação nº 9: ”Emerging laboratory cardiovascular risk factors in Hiv-infec-
ted patients with objectively defined lipodystrophy” comparamos os lípidos séricos e 
os fatores de risco cardiometabólicos em doentes infectados pelo viH sob terapêu-
tica antirretrovírica de acordo com a presença de lipodistrofia definida pela clínica e 
pelo fMr e quatro padrões de distribuição da gordura corporal. 
como dissemos, a terapêutica antirretrovírica nos doentes infetados pelo viH 
está associada a alterações metabólicas, incluindo dislipidemia, insulinorresistência 
e a lipodistrofia [diminuição da gordura periférica (lipoatrofia) com ou sem acumula-
ção de gordura abdominal/visceral (lipohipertrofia)]. As alterações hormonais causa-
das pelo aumento (na lipohipertrofia) ou redução da gordura subcutânea (na lipoatro-
fia) podem ser fulcrais para as alterações metabólicas observadas nos doentes com 
lipodistrofia associada ao VIH. No artigo nº 10 avaliámos a relação entre hormonas 
derivadas do adipócito (adiponectina, leptina, resistina, tnf-a), hormonas orexigéni-
cas (ghrelina), fatores protrombóticos (PAi-1) e insulinorresistência em doentes infe-
tados pelo viH sob terapêutica antirretrovírica de acordo com a presença de lipodis-
trofia definida pelo FMR e quadro padrões de distribuição da gordura corporal. 
A determinação da espessura da íntima média carotídea tem sido usada como 
um marcador precoce de aterosclerose e é um fator de risco independente para 
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doença cardiovascular. na publicação 11: “carotid intima media thickness is asso-
ciated with body fat abnormalities in Hiv-infected patients” estudámos a espessura 
da íntima média carotídea em doentes infetados pelo viH sob terapêutica antirretro-
vírica, de acordo com a presença de lipodistrofia definida pelo FMR e quatro padrões 
de distribuição da gordura corporal. 
Assim, estas onze publicações abordam inicialmente aspetos das lipodistrofias 
de causa genética, depois das lipodistrofias adquiridas, nomeadamente a associada 
ao VIH, nas vertentes da etiopatogenia, definição objetiva, avaliação da composição 
corporal, alterações metabólicas (obesidade, hipertensão, insulinorresistência, dia-
betes, dislipidemia, síndrome metabólico, fatores de risco cardiovasculares emer-
gentes), inter-relações da composição corporal com as adipocinas e finalmente a 
aterosclerose prematura, avaliada pela espessura da íntima média carotídea.
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A introdução ao tema das lipodistrofias é constituída pelas publicações 1 e 2.
 Publicação 1: Identification of the gene altered in Berardinelli-Seip congeni-
tal lipodystrophy on chromosome 11q13. nature Genetics 2001; 28: 365-
370.
 Publicação 2: Lipodystrophy: the metabolic link of Hiv and genetic forms.
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Identification of the gene altered in Berardinelli-Seip 
congenital lipodystrophy on chromosome 11q13
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Lipodystrophy:
The metabolic link of HIV infection with insulin-resistance syndrome
Paula Freitas1, Davide Carvalho2, Selma Souto3,
António Sarmento4, José Luís Medina5
AbstrAct
Human lipodystrophies are a heterogeneous group of diseases with generalized or partial fat loss, rare genetic or 
more frequent acquired forms, old or recent, such as HIV-related lipodystrophy. Lipodystrophies are associated 
with metabolic alterations including insulin resistance (IR), diabetes, dyslipidemia and early cardiovascular (CV) 
disease. Adipose tissue from different localizations (visceral and subcutaneous) has markedly divergent roles 
regarding metabolism. Lipoatrophy and lipohypertrophy can occur together or separately in patients with lipodys-
trophies.
In this review, we focus on the etiopathogenesis of genetic and acquired lipodystrophy, with the emphasis on its 
most common form, HIV lipodystrophy, from the etiology to complications. We analyze the relative role of the 
different kinds of adipose tissue, namely the protective effect of subcutaneous adipose tissue in relation to CV. 
We discuss the factors related to fat redistribution in HIV-infected patients, namely the impact of antiretroviral 
therapy, the role of inflammation, genetic factors, lipotoxicity and cortisol. We also review the mechanisms of IR, 
dyslipidemia, metabolic syndrome and the clinical sequelae associated with HIV and HIV-lipodystrophy, namely 
endothelial dysfunction and CV disease and mortality.
Keywords: Genetic lipodystrophy; HIV-lipodystrophy; etiopathogenesis; metabolic complications
introduction
Human lipodystrophies are a heterogeneous group of diseases characterized by generalized or partial 
fat loss. If localized, they are often associated with fat hypertrophy in other depots, varying according 
to the type of lipodystrophy. Genetic lipodystrophy is generally related to severe metabolic alterations 
including insulin resistance (IR) and its associated complications, such as glucose intolerance and dia-
betes, dyslipidemia, hepatic steatosis, polycystic ovaries, acanthosis nigricans and early cardiovascular 
(CV) complications (1, 2).  Lipodystrophies can be genetic, which is usually uncommon, or acquired. The 
autosomal recessive congenital generalized lipodystrophy (CGL) and autosomal dominant familiar par-
tial lipodystrophy (FPL) are the two most common types of genetic lipodystrophy (2). Lipodystrophies 
have been reported in the medical literature for more than 100 years (2, 3). However,  about 13 years ago, 
new lipodystrophy syndromes were recognized that are associated with viral infection, specifically with 
the human immunodeficiency virus, in patients treated with combined antiretroviral therapy (cART) (4).
This has become the most frequent form of lipodystrophy (2).  Some first-generation antiretroviral drugs 
used in HIV patients are strongly related with peripheral lipoatrophy and metabolic alterations (1).
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Human lipodystrophies leads to severe metabolic alterations resulting in premature CV complica-
tions. On the other hand, high adiposity, such as that seen in obesity, also increases metabolic altera-
tions and leads to increased CV risk. So, it seems that the two extremes, the absence or the excess of fat 
mass, are associated with the same metabolic and CV complications. The consequences of increased fat 
depots are markedly dependent upon their localization. Adipose tissue in the lower part of the body is 
able to expand and can therefore accumulate excessive energy from diet, store  triglycerides, and it ap-
pears to be protective at the metabolic level (5). By contrast, accumulation of fat in the upper part of the 
body is deleterious. Therefore decreased peripheral subcutaneous adipose tissue (SAT), and even more 
increased visceral adipose tissue (VAT), are strongly associated with metabolic alterations and IR (1).
With regards to the HIV-associated lipodystrophy, the available data suggest that this condition is 
caused by a complex interaction involving side effects of cART, disease related inflammation, and indi-
vidual characteristics (6).  At present, HIV-infected patients are exposed to an increased metabolic risk, 
like the general population, resulting from ageing, increased weight and fat gain, high fat and energy 
food and marked sedentariness. Moreover, a number of additional factors could worsen their metabolic 
profile, such as  the ongoing HIV infection, the presence of lipodystrophy and the continuous use of 
antiretroviral drugs (7). HIV-associated lipodystrophy is also associated with premature aging (8) resem-
bling  metabolic laminopathies and progeria (1). Premature aging of HIV-infected patients affects bone, 
brain, vascular wall, muscles, kidney and liver, and results of the combined effects of long-term HIV-1 
infection, depleted immune responses, the toxicity of some antiretrovirals and lipodystrophy. Cellular 
senescence seems to result from prelamin-A accumulation induced by some antiretroviral drugs, mi-
tochondrial dysfunction and oxidative stress. In addition, increased cytokine release in lipodystrophy 
further contributes to premature aging and therefore, to early CV and hepatic disease risks (9).
 We focus in adipocyte dysregulation in genetic and acquired lipodystrophy, with emphasis on the 
most common form, HIV-lipodystrophy, from the etiology to complications.
Adipose tissue biology - three different adipose tissue compartments
Adipocytes are a dynamic and highly regulated population of cells. Adipose tissue is characterized 
by a marked cellular heterogeneity among its cellular components: adipocytes, preadipocytes, fibro-
blasts, macrophages, lymphocytes, endothelial cells and multipotent stem cells, able to differentiate into 
several cell types. Adipose tissue can release regulatory factors (adipokines, cytokines, or chemokines) 
or metabolites (FFAs) capable of influencing other surrounding cells, thus establishing active cross-
talk among cells within adipose tissue (9). Overall, fat tissue consists of approximately one third mature 
adipocytes. The remaining two thirds are a combination of small blood vessels, nerve tissue, fibroblasts 
and preadipocytes in various stages of development. Preadipocytes have the ability to proliferate and 
differentiate into mature adipocytes, conferring a constant functional plasticity on adipose tissue (10).
Preadipocytes mature in two steps: differentiation and then hypertrophy. During the early maturation 
stage, an increased number of mitochondria are required (11, 12), resulting in small adipocytes, which are 
highly sensitive to insulin and that secrete high levels of adiponectin (12). By contrast, older adipocytes 
increase in size (hypertrophy), lose their functional activities and become resistant to insulin. They ex-
hibit decreased numbers of mitochondria with impaired mitochondrial reactive oxygen species (ROS), 
generated by the respiratory chain, which could have dual effects on adipocyte differentiation. New 
adipocytes form constantly to replace lost adipocytes, to the extent that 50 % of adipocytes in the hu-
man subcutaneous fat mass are replaced approximately every eight years. Preadipocytes are recruited to 
become lipid-filled mature adipocytes at the same rate that adipocytes die, and in this way the fat mass 
is in constant flux, and adipocyte number is kept constant. Cell death of fat cells in white adipose tissue 
occurs primarily by necrosis-like cell death, which involves macrophage recruitment and a subsequent 
inflammatory response. This has been implicated in the metabolic complications of obesity. Increased 
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visceral fat mass leads to IR and a low-grade inflammation status in which many adipokines and other 
adipocyte and macrophage factors are involved (13).
Adipose tissue is not homogeneous, but is rather a tissue with specific regional compartments with 
varying roles and metabolic functions (14). Individually considered, adipose tissue compartments have 
stronger associations with physiological and pathological processes than does total adipose tissue mass 
(15-17). The upper-body adipose tissue, including visceral fat, is involved in fat storage after meals and the 
release of free fatty acids (FFA) between meals to feed the liver, muscles and other organs, therefore 
sparing glucose for the brain. Visceral fat has a more lipolytic profile than subcutaneous fat. Peripheral 
lower-body fat, in the femoro-gluteal region, is mainly used for its storage capacity, thereby buffering 
excess fat (7). The femoro-gluteal fat depot is relatively insensitive to lipolytic stimuli and highly sensi-
tive to anti-lipolytic stimuli, and may play a protective role by acting as a “sink” for circulating FFA 
(18). This uptake of FFA prevents ectopic fat storage in the liver, skeletal muscle, and pancreas, which 
causes IR and beta-cell dysfunction (19). The excessive lipolytic capacity of visceral fat (and probably 
subcutaneous upper-body depots as well) results in a condition referred to as lipotoxicity (see section 
below on lipotoxicity) (7). The reasons for the lower degree of expansibility of visceral adipocytes remain 
unknown. Visceral adipose tissue (VAT) differs histologically from subcutaneous adipose tissue (SAT): 
it has smaller adipocytes and a larger supply of nerves and vessels; VAT has many of the characteristics 
of brown adipose tissue turned into white adipose tissue (20).
Lipohypertrophy and lipoatrophy
Adipose tissue can be subject to different influences and undergo different transformations. SAT 
has a lower mitochondria content and this contributes to adipocyte apoptosis and therefore, to more 
lipoatrophy. VAT, with a higher number of resident macrophages (21) and more 11β hydroxysteroid 
dehydrogenase activity than SAT (22), is predisposed to hypertrophy. Hypertrophied VAT from HIV-in-
fected patients displays mitochondrial dysfunction but not impairment of adipogenic gene expression in 
comparison with SAT (23). cART can differentially alter fat development depending on the environment 
and physiology of the different compartments. In the case of lipoatrophy, because peripheral subcutane-
ous adipocytes cannot store triglycerides, non-lipoatrophic fat depots such as VAT probably buffer the 
increases in FFA, which worsens lipohypertrophy (8).
Subcutaneous adipocytes seem to be more susceptible to the deleterious effects of protease inhibi-
tors (PIs) than visceral adipocytes (24). Accordingly, studies performed on control human SAT explants 
reveal that some PIs increase FFA, interleukin – 6 (IL-6) and TNF-a production through the activation 
of the proinflammatory nuclear factor – kB (NFkB) pathway. This PI-induced deleterious paracrine loop 
between adipocytes and macrophages, similar to that observed in obesity, is not seen in VAT. These data 
indicate that SAT is more sensitive to the adverse effects of some PIs than VAT (8).
Adipogenesis
Individuals can differ remarkably in body fat distribution and the known differences in FFA uptake 
of the adipose tissue compartments play a role in this difference. Premenopausal female SAT takes up 
more FFAs than male (25) and upper-body SAT takes up FFAs more avidly than femoral fat in men, but 
not in women. Gene expression, mRNA transcription of FA transporters and consequently facilitated FA 
transport was greater in the upper body in men and in the femoro-gluteal region in women. This novel 
FFA disposal pathway may also play a role in the development or maintenance of body fat distribution. 
On the other hand, direct FFA uptake in subcutaneous fat differs from fatty acid uptake from a meal in 
two respects: 1) direct FFA uptake is more efficient in women than in men and 2) in men there is no pref-
erential direct FFA uptake in upper-body subcutaneous fat compared with femoral fat in women. These 
gender-based differences are consistent with this process as a mechanism to develop or maintain varia-
tions in body fat distribution between men and women, both lean and obese. To the extent that message 
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levels relate to protein content/function, 
the greater direct FFA uptake in abdomi-
nal over femoral fat in men could be due to 
the greater facilitation of inward fatty acid 
transport (Figure 1). Contrary to what is 
generally believed, upper-body subcutane-
ous fat releases ~70 % of systemic FFAs 
in lean men and women, whereas the leg 
contributes only ~20%; fatty acid uptake 
from a meal follows a similar pattern (26). In 
non-obese men, the direct uptake/storage 
of FFAs in upper-body and leg fat mirrors 
this regional difference in FFA release, 
whereas in lean women, direct FFA uptake was similar in upper-body and femoral adipose tissue. This 
imbalance between release and direct reuptake in women could redistribute fatty acids toward leg fat. In 
obese women, the total FFA reuptake in leg fat was also significantly greater than in upper-body fat. It 
may be that some populations of fat cells, such as the smaller adipocytes, take up but do not as actively 
release FFAs, whereas larger fat cells briskly release FFAs and do not take up FFAs under post-absorp-
tive circumstances. In summary, there is a mechanism for adipocyte fatty acid uptake and storage that 
has yet to be understood, but which is independent of lipoprotein lipase and not thought to exist in the 
post-absorptive state (25).
Macrophage infiltration of the human adipose organ is a well-documented phenomenon that induces 
a low-grade chronic inflammation that is associated with IR. This reaction appears to be related mainly 
to macrophage-produced cytokines (TNF-a and IL-6) capable of interfering with the normal activity 
of insulin receptors. The greater amount of macrophages and macrophage-secreted cytokines found in 
visceral fat is in line with the greater morbidity associated with these depots. Subcutaneous and visceral 
adipocytes have cell-autonomous properties due to inherently different progenitor cells that exhibit a 
different gene expression pattern. Subcutaneous white adipose tissue responds better to the anti-lipo-
lytic effects of insulin, secretes more adiponectin and less inflammatory cytokines, and is differentially 
affected by molecules involved in signal transduction as well as drugs, compared with visceral white 
adipose tissue (13).
Lipoatrophic adipose tissue is known to be characterized by smaller adipocytes, greater cell size 
variation, disruption of cell membranes, and signs of apoptosis as determined by immunohistochemistry 
staining, when compared with non-lipodystrophic adipose tissue. There is a marked difference in gene 
expression between dorsocervical and abdominal SAT, irrespective of the lipodystrophy status, that lies 
in the expression of homeobox genes involved in organogenesis and regionalization. Disparate expres-
sion of such fundamental regulators of transcription might ultimately contribute to different patterns of 
differentiation and affect the susceptibility of the adipose tissue depot to cART-induced toxicity, per-
haps making the abdominal subcutaneous and femoro-gluteal depot more vulnerable to atrophy (27).
Morphologic alterations in lipoatrophy-prone areas of SAT have been confirmed at the level of gene 
expression (9). Most studies report that these lipoatrophic areas show an abnormally low expression of 
the major adipogenic transcription factors peroxisome proliferator-activated receptor -g (PPARg), sterol-
regulatory element binding protein-1 (SREBP-1), and CCAAT/enhancer-binding protein-a (C/EBPa)
(28-30). Consequently, the expression of adipogenic differentiation-related genes is also decreased. For 
example, there is a reduction in the expression of genes for lipoprotein lipase and for the insulin-sensi-
tive glucose transporter GLUT 4 (28, 29), resulting in impaired fatty acid and glucose uptake, respectively, 
and thus leading to a deficit in the lipid-accretion capacity of SAT. Another major alteration detected, 
which is probably related to the impaired adipogenic gene expression, is reduced expression of the adi-
Figure 1. FFA uptake by gender (SAT – abdominal subcu-
taneous adipose tissue; VAT – abdominal visceral adipose 
tissue; FFA – free fatty acids)
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pokine genes adiponectin and leptin (28, 29). In addition to impaired expression of adipogenetic–related 
genes, adipose tissue from patients with lipodystrophy, mainly those receiving NRTIs (31, 32) also show a 
reduction in mitochondrial DNA (mtDNA) levels. This decrease is associated with complex alterations 
in mitochondrial function, such as reduced expression of mtDNA-encoded transcripts and compensatory 
up-regulation of dysfunctional mitochondrial mass, that likely reduce the endogenous oxidative capac-
ity of adipose tissue (33). Moreover, increased oxidative stress and apoptosis have also been reported in 
lipoatrophic SAT (34). Lipoatrophy is also accompanied by a state of chronic low-level inflammation (35).
High levels of expression of the inflammatory markers, TNF-a, IL- 6; IL-8 and IL-18 have been reported 
in SAT from HIV-1-infected lipoatrophic patients (28, 30, 35-37). Expression of TNFa and IL-6 mRNA in 
SAT of lipodystrophic patients correlates positively with tissue apoptosis and negatively with adipogenic 
marker expression, which is consistent with a role for pro-inflammatory cytokines in adipocyte viabil-
ity and differentiation (30). Unlike SAT, VAT did not exhibit impaired expression of adipogenic marker 
genes. However, it did show some similar changes in inflammatory markers, such as induction of TNF-a,
whereas others differed from that of SAT, such as, for instance, lack of monocyte chemoattractant protein 
-1 (MCP-1) induction. In contrast, mitochondrial dysfunction in VAT was found to be similar to that in 
SAT. Therefore, mtDNA depletion and signs of altered mitochondrial function are common to atrophic 
(subcutaneous) and hypertrophic (visceral, dorsocervical) depots in HIV-1 lipodystrophy, indicating that 
mitochondrial impairment cannot explain in a simple manner the final outcome for adipose depots, either 
in terms of lipoatrophy or lipohypertrophy (23). Taken together, these observations indicate that different 
responses occurring in subcutaneous and visceral fat depots in lipodystrophic patients are likely to be 
related to intrinsic differences in fat physiology and/or capacity to react to the same insult. One adipose 
depot (visceral) enlarges in size and approaches its fat storage capacity threshold (as in obesity) merely 
because another adipose depot (subcutaneous) cannot (38). A direct role for HIV-1 infection has been pro-
posed by analyzing SAT from untreated HIV-1-infected patients (“naïve”) as compared to healthy con-
trols. Early histological studies did not indicate clear mitochondrial or inflammatory-related disturbances 
(39), but subsequent gene expression studies have shown a significant decrease in the expression of the 
adipocyte differentiation controller PPARg and some impairment in the expression of genes encoding mi-
tochondrial proteins and proteins specifically related to adipocyte metabolism, including adiponectin and 
11β-steroid dehydrogenase type-1, the enzyme responsible for glucocorticoid activation (9, 29). Some signs 
of inflammatory response have also been reported (29). All these alterations are further enhanced in SAT 
from lipodystrophic patients. Therefore, it appear that HIV-1 infection initiates a first wave of alterations 
in adipose tissue that is amplified by cART and ultimately results in lipoatrophy (9).
Congenital generalized lipodystrophies 
Generalized lipodystrophies are rare disorders that may be congenital or acquired. The genetic li-
podystrophies have been reported in about 1000 patients (2). The congenital generalized lipodystrophy 
(CGL)  Berardinelli-Seip syndrome (BSCL), is an autosomal recessive disorder initially reported by 
Berardinelli (3) and Seip (40) with frequent parental consanguinity (41-44).  It has been proposed that Berardi-
nelli-Seip syndrome could be a Portuguese disease, later spread by the Portuguese across the world (45).
Patients with CGL are recognized at birth or soon thereafter due to a near-total lack of body fat and 
prominent muscularity that causes a severe and striking phenotype (Figures 2A e 2B). Diabetes devel-
ops during infancy or most often during the teenage years. Hepatosplenomegaly, umbilical prominence 
or hernia, acanthosis nigricans, voracious appetite and accelerated growth can occur. Female patients 
develop hirsutism, may have clitoromegaly, oligomenorrhea and polycystic ovaries. Other uncommon 
manifestations include hypertrophic cardiomyopathy, mild mental retardation, and focal lytic lesions in 
the appendicular bones after puberty (41, 42). Diabetes and its complications, hyperlipidemia and recurrent 
attacks of acute pancreatitis, hepatic steatosis and occasionally cirrhosis are the causes of morbidity and 
mortality (2).
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 At least 4 molecularly distinct forms of congenital lipodystrophy have been defined, with the mu-
tations of the enzyme acyltransferase 1-acylglycerol-3-phosphate O- acyltransferase 2 (AGPAT2) or 
(BSCL1- locus 1) and Berardinelli-Seip (BSCL2 - locus 2) being responsible for 95 % of gene muta-
tions. AGPAT2 has been mapped in chromosomes 9q34. AGPATs are critical enzymes involved in the 
biosynthesis of triglycerides and phospholipids from glycerol-3-phosphate. They catalyze acylation of 
fatty acids at the sn-2 position of glycerol moiety and convert lysophosphatidic acid to phosphatidic acid 
(2, 46). AGPAT2 is highly expressed in the adipose tissue, and its deficiency may cause lipodystrophy by 
limiting triglyceride or phospholipid biosynthesis (47).
Type 2 CGL is due to BSCL2 gene mutations. This gene is located in chromosome11q13 and en-
codes a protein called seipin (48). Seipin appears to play a role in lipid droplet formation and may also be 
involved in adipocyte differentiation (49-51).
Patients with BSCL2 mutations have the most severe variety of CGL and are born without any body 
fat (2). Two other genes were identified for CGL: caveolin 1 (CAV1) (52) and polymerase I and transcript 
release factor (PTRF) (53). Caveolin 1 is the main  component of caveolae, specialized microdomains 
seen in abundance on adipocyte membranes (54). It binds fatty acids and translocates them to lipid drop-
lets. PTRF (also known as cavin) is involved in biogenesis of caveolae and regulates expression of 
caveolins 1 and 3 (53).
Mortality in generalized lipodystrophies
Patients with generalized lipodystrophies are predisposed to develop acute pancreatitis, cirrhosis, 
endstage diabetic renal disease requiring transplantation, and blindness due to diabetic retinopathy. 
Many patients with FPL die of coronary heart disease or cardiomyopathy and rhythm disturbances 
(55-57). Sudden death has been reported during childhood in CGL, type 4, likely due to arrhythmias (58).
Patients with HIV-lipodystrophy are predisposed to developing coronary heart disease (59). Patients with 
congenital Berardinelli-Seip lipodystrophy frequently develop hypertrophic cardiomyopathy that can 
lead to death from cardiac failure (41). In individuals with BSCL, ventricular dysfunction and hypertro-
phic cardiomyopathy are often observed. In cardiac biopsies performed in eight individuals with BSCL, 
the presence of subendocardial fibrosis and an abnormal architecture in the left ventricular lumen was 
observed (60, 61). Hypertrophic cardiomyopathy in BSCL patients has been correlated with high plasmatic 
insulin levels, which activate the type 1 insulin-like growth receptors, present in large quantities in the 
Figure 2A: Two sisters with Berardinelli-Seip syndrome Figure 2B: Women with 
Berardinelli-Seip syndrome 
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myocardial tissue, that stimulate cell growth (62, 63).  In addition, the presence of IR and hypertriglyceri-
demia in individuals with BSCL may predispose them to premature atherosclerosis. Individuals who 
have mutations on chromosome 11 (BSCL2) seemed to present more severe symptoms than who have 
mutations in BSCL1 with a high incidence of premature deaths. Cardiomyopathy was three times more 
frequent in those with BSCL2 mutations than in individuals with alterations in BSCL1 (42).
Mandibuloacral dysplasia (MAD)-associated lipodystrophy
MAD is characterized by skeletal abnormalities such as mandibular and clavicular hypoplasia and 
acroosteolysis (64), progeroid manifestations, partial or generalized lipodystrophy and metabolic compli-
cations with other clinical features (65, 66). Patients with MAD harbor mutations in lamin A/C (LMNA) 
or zinc metalloproteinase (ZMPSTE24) (67, 68). ZMPSTE24 is involved in post-translational proteolytic 
processing of prelamin A to mature lamin A (2).
Autoinflammatory syndromes
A syndrome of joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced 
(JMP) lipodystrophy was reported by Garg in three patients, belonging to two pedigrees, who were from 
Portugal and Mexico (69). Three other patients have been reported from Japan (70, 71). Mutations in PSMB8 
may trigger an autoinflammatory response resulting in infiltration of adipose tissue with lymphocytes 
and other immune cells and adipocytes (2). The other autoinflammatory syndrome is the chronic atypical 
neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. The mode 
of inheritance seems to be autosomal recessive, but the molecular basis remains unknown (2, 72, 73).
Familial partial lipodystrophy (FPL)
FPL is characterized by the onset of fat loss from the limbs and other regions of the body, usually 
during childhood, adolescence or adulthood. Many regions of the body, such as the face, neck, and intra-
abdominal region are spared, and patients accumulate excess body fat in the non-lipodystrophic regions 
(74-76). Metabolic complications, acanthosis nigricans, oligoamenorrhea, hirsutism, polycystic ovarian 
syndrome, mild to moderate myopathy, cardiomyopathy, and conduction system abnormalities indica-
tive of multisystem dystrophy can occur (2, 55, 56, 77). The identification of the first gene for FPL, Dunnigan 
variety, i.e. LMNA, on chromosome 1q21-22 (2, 78-81), an integral component of nuclear lamin, was in 
1998. Thereafter, four other genes were identified: PPARg (82-84), a key transcription factor involved in 
adipocyte differentiation; v-AKT murine thymoma oncogene homolog 2 (AKT2) (85), involved in down-
stream insulin signaling; and cell death-inducing DNA fragmentation factor a-like effector c (CIDEC) 
(86) and perilipin 1 (PLIN1) (87), both involved in lipid droplet formation (2, 88). Adipocyte loss is due to 
premature cell death resulting from disruption of the nuclear envelope (87, 89). Defective adipocyte differ-
entiation seems to be the cause of the lipodystrophy of PPARg as AKT2 mutations. Fibrosis of adipose 
tissue with small adipocytes is responsible for the lipodystrophy of PLIN1 mutations (2, 87).
There are other rare genetic syndromes whose molecular basis remains unknown, namely atypical 
progeroid syndrome (90), Hutchinson-Gilford progeria syndrome (91), SHORT-associated lipodystrophy 
(92), and Wiedemann-Rautenstrauch syndrome (93).
Patients with FPL syndromes display mixed lipodystrophy with subcutaneous lipoatrophy and cen-
tral fat accumulation. Those with FPLD2 also have an increased amount of fat in the cervico-facial 
area compared to patients without these mutations. Therefore, a single protein mutation leads to two 
opposing fat localization phenotypes (8). Importantly, mutations in LMNA are also responsible for meta-
bolic laminopathies resembling metabolic syndrome (MS) and Hutchinson-Gilford progeria, a severe 
syndrome of premature aging (94). Prelamin A is implicated in increased oxidative stress and in the oc-
currence of cellular senescence (8).
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Acquired Lipodystrophies
Acquired generalized lipodystrophy (AGL) - Lawrence syndrome
The onset of subcutaneous fat loss in patients with AGL usually occurs during childhood (95). The 
pattern and extent of fat loss is quite variable and most patients have generalized loss of fat, but a few 
of them have areas such as intra-abdominal and bone marrow fat spared. AGL patients are highly likely 
to develop severe hepatic steatosis and fibrosis, diabetes, and hypertriglyceridemia (2). The pathogenesis 
of fat loss remains unknown. Panniculitis may precede loss of fat. Lipodystrophy can be associated with 
autoimmune diseases such as juvenile dermatomyositis (95). Chronic hepatitis with autoimmune features 
and low serum complement 4 levels, suggesting involvement of the classical complement pathway in 
the pathogenesis of fat loss, has been reported (96).
Acquired partial lipodystrophy - Barraquer-si-
mons syndrome
Fat loss occurs gradually in a symmetric fashion, 
first affecting the face and then spreading downward. 
Most patients lose fat from the face, neck, upper ex-
tremities, and trunk, and subcutaneous fat from the 
lower abdomen and legs is spared. Many patients 
accumulate excess subcutaneous fat in the hips and 
legs. Metabolic complications are rare (Figure 3). 
Misra et al suggest that the fat loss involves auto-
immune-mediated destruction of adipocytes because 
the patients have low serum levels of complement 
3 and complement 3-nephritic factor, which blocks 
degradation of the enzyme C3 convertase (95). It is 
possible that the C3-nephritic factor induces lysis of 
adipocytes expressing factor D (97).
Localized lipodystrophy
Localized lipodystrophies present with focal loss of subcutaneous fat, usually causing one or more 
dimples, and usually occurs due to subcutaneous injection of various drugs (Figure 4), panniculitis, pres-
sure, and other mechanisms (98).
Lipodystrophy associated with hiV-infection
The impressive progress resulting from the 
discovery of drugs able to control HIV infection 
on a long-term basis, has offered most patients a 
prolonged lifespan, possibly as long as that ob-
served in non-infected subjects (7). Suppression of 
viral replication has become a treatment goal that 
can be reached with the use of cART. After the 
introduction of protease inhibitors (PIs) in 1996, 
as a component of highly active antiretroviral 
therapy, the morbidity and mortality associated 
with HIV dramatically reduced (99). However, 
patients develop a syndrome of fat redistribution 
with peripheral fat loss (face, upper limbs and 
femoro-gluteal) and visceral fat accumulation, 
Figure 3: Acquired partial 
lipodystrophy - Barraquer-
Simons syndrome
Figure 4. Patient with lipohypertrophy related to subcu-
taneous administration of pegvisomant.
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generally associated with metabolic abnormalities (4, 100-103) and increased risk of CV diseases (104, 105), simi-
lar to that which occurs in congenital lipodystrophies (4, 59). Lipohypertrophy usually represents a central 
visceral fat accumulation in the abdomen and trunk, but can also be found in breasts (in women), dorsocer-
vical region (“buffalo hump”), double chin, lipomas, and within the muscle and liver (59, 106). Lipoatrophy 
and lipohypertrophy are frequently associated (mixed form), but they also can occur independently of each 
other (59). This HIV-associated lipodystro-
phy has been proposed to be a age-related 
fat redistribution condition (Figure 5) that 
could amplify age-related co-morbidities 
and lead to an earlier occurrence (8). Also, 
hyperlactenemia and bone demineralization 
can occur (107, 108).
Owing to a lack of a consensus on the 
definition of lipodystrophy and lipodys-
trophy syndrome in HIV-infected patients, 
its exact prevalence is not known (6). In the 
early 2000s, about half of HIV-infected pa-
tients undergoing cART were diagnosed as 
lipodystrophic (20-80%) (109). Abnormali-
ties in peripheral and central fat masses are 
clinically evident in 20-35 % of patients 
after approximately 12-24 months of cART 
(59, 107, 110, 111). With the new anti-retroviral 
agents, the probability of developing lipoat-
rophy has decreased in western countries as 
the pattern of cART prescription has significantly changed (112). In the study of Nguyen, lipodystrophy has 
become less frequent since 2003 (112). Two widely used thymidine analogs from the first class of ART, 
stavudine and zidovudine, are responsible for lipoatrophy and now they have been replaced by a new gen-
eration of potent NRTIs.  Although metabolic toxicity of boosted PIs is far less than that of first-generation 
protease inhibitors (PIs), they are still considered responsible for increased CV risk. The new classes of 
ART, fusion inhibitors (F20), integrase inhibitors (raltegravir) or entry inhibitors (anti-CCR5, maraviroc) 
have not yet been shown to alter metabolic parameters or fat distribution (8, 112-117).
HIV-infected patients can have 4 different phenotypes of body fat composition: no lipodystrophy, iso-
lated peripheral lipoatrophy, isolated central fat accumulation and a mixed form of lipodystrophy (or redis-
tribution syndrome) (100). About 50% of patients with HIV-associated lipodystrophy display mixed forms, 
with the loss of limb fat and marked expansion of VAT (113).  The high frequency of this association sug-
gests that these two opposite phenotypes could be, at least in part, causally related (8). Also, HIV patients 
may have a picture similar to partial lipodystrophy patients with peripheral fat atrophy with hypertrophied 
central fat depots. Thus, there are similarities between HIV lipodystrophy and genetic forms. 
HIV-lipodystrophy and related factors
There is a possible role for the virus in contributing to lipodystrophy i.e. the HIV or hepatitis infec-
tion affects fat before any ART. Monocytes are relatively resistant to HIV infection, but differentiated 
macrophages are highly susceptible and tissue macrophages have been found to harbor HIV-1 (118). In-
fected macrophages release pro-inflammatory cytokines. Systemic inflammation associated with HIV 
infection might promote monocyte migration across the vascular endothelium, leading to an increased 
number of activated macrophages in fat (118). Several studies reported that the severity of HIV infection is 
associated with an increased prevalence of lipodystrophy (59, 119), probably as a consequence of persistent 
HIV-infected macrophages in adipose tissue, which could enhance local inflammation. 
Figure 5: Patient with mixed HIV-lipodystrophy (absence of 
subcutaneous peripheral fat in arms, legs and face and increased 
abdominal fat mass)
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ART-naïve HIV-positive patients have increased TNF-a expression compared with uninfected con-
trols (29), which is consistent with increased inflammation. TNF-a alters adipocyte function and differen-
tiation, in part through the inhibition of PPARg expression (120). Infected macrophages might also release 
viral proteins (such as Vpr and Nef) that can impact adjacent adipocytes and lead to decreased PPARg
activity and the inhibition of adipogenesis (121, 122). Although lipodystrophy is uncommon in ART-naïve 
patients (113), the HIV infection of macrophages could in itself result in low-grade fat inflammation and 
lead to the release of viral proteins that affect neighboring adipocytes and decrease their differentiation.
The development of lipodystrophy and metabolic toxicities is partially related to the individual drugs 
included in cART regimens, in association with other risk factors (123), such as gender and pre-HIV-infec-
tion body composition, disease-specific factors such as the nadir levels of CD4+ lymphocytes and the dura-
tion of HIV infection (110, 123, 124). The most significant risk factors associated with lipoatrophy are exposure 
to and duration of nucleoside thymidine analogues (most commonly stavudine), age, severity of disease 
markers (CD4 lymphocyte count and plasma HIV viral load), therapy duration, and being of Caucasian 
race. On the other hand, the most common statistically significant risk factors for lipohypertrophy are 
therapy duration, PI administration, markers of disease severity, and age. We cannot forget that along the 
years, patients have done multiple regimes and combinations of antiretroviral drugs, which makes it dif-
ficult to identify different risks with different drugs and studies therefore report conflicting results (6).
Protease inhibitors
PIs affect multiple metabolic pathways and are associated with lipohypertrophy and lipoatrophy, ath-
erogenic dyslipidemia and IR, (125, 126). Studies in-vitro reported that PIs are able to alter a number of adi-
pocyte functions, including differentiation, expression of transcriptase factors involved in adipogenesis, 
cell survival,  cytokine production, mitochondrial function  and IR (127). PIs may cause lipodystrophy by 
inhibiting ZMPSTE24, resulting in accumulation of toxic farnesylated prelamin A (128), increase oxida-
tive stress and alter adipokine and cytokine production (89, 127, 129).  The adverse effect of PIs could also 
result from the induction of endoplasmic reticulum stress or the inhibition of the proteasome (130, 131).
Different PIs might affect key intranuclear genes, causing reduction in levels of RNA encoding 
SREBP-1, in turn affecting expression of PPAR g  (28). The reduction in levels of intranuclear SREBP-1 
leads to decreased adipocyte differentiation and altered release of adipocytokines (132). PIs can inhibit 
lipogenesis and stimulate lipolysis (28, 132-135), and may induce IR by inhibiting glucose transporter 4 ex-
pression (GLUT4) (136).
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)
NRTIs are analogs of naturally occurring molecules and inhibit the viral reverse transcriptase en-
zyme. The thymidine NRTIs (zidovudine, stavudine and didanosine) cause mitochondrial toxicity by 
mitochondrial DNA polymerase inhibition and by causing DNA mitochondrial mutations (31, 137, 138).
These disturbances result in apoptosis of peripheral adipocytes and lead to lipoatrophy (31). NRTIs are 
also associated with fat hypertrophy in visceral depots (113, 139, 140). Nucleoside analogues may inhibit adi-
pogenesis and adipocyte differentiation, promote lipolysis, and exert synergistic toxic effects with those 
of PIs (31, 141-143).  Moreover, NRTIs promote lipolysis and the subsequent efflux of non-esterified fatty 
acids from adipose tissue (142, 144).
Mitochondrial toxicity and fat redistribution
In western countries, long-term HIV-infected patients present several age-related comorbidities ear-
lier than the general population (145), and display signs of premature aging (8). New hypotheses were re-
cently suggested on the pathophysiology of fat redistribution, proposing that mitochondrial toxicity was 
involved in lipoatrophy and in fat hypertrophy. HIV-associated lipodystrophy could be an age-related 
fat redistribution that could amplify age-related comorbidities and their earlier occurrence (8). Mito-
chondria play important roles in adipocyte differentiation and function. At physiologically low levels, 
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ROS could act as secondary messengers to activate adipogenesis and lipogenesis, resulting in increased 
adipocyte number and size. In hepatic cells, oxidative stress activates the transcription factor SREBP1c, 
which is highly expressed in adipocytes and increases lipogenesis and lipid accumulation (146). At higher 
levels, ROS could inhibit differentiation (8).
Excessive VAT releases increased visceral adipocyte-FFAs, adipokines and cytokines. Indeed, acti-
vated macrophages, which have an M1 proinflammatory phenotype, invade expanded adipose tissue; upon 
invasion, their production of proinflammatory cytokines and chemokines increases. This could lead to 
the decreased secretion of adiponectin by adipocytes in response to TNF-a (36). Increased abdominal fat 
lipolysis increases ectopic fat deposition within tissues (liver, skeletal muscle and heart). Subsequently, 
these derivatives overwhelm mitochondrial oxidative capacity and activate stress kinases, leading to IR. 
This situation, known as lipotoxicity, associates with ectopic depots of triglycerides in non-adipose tissues 
that buffer excess fatty acid derivatives (147). Moreover, a paracrine loop is present between adipocytes and 
macrophages; macrophage-secreted cytokines (TNF-a and IL-6) activate the NFkB pathway in adipo-
cytes, resulting in increased IL-6 and FFA production. Saturated FFA can, in turn, activate the Toll-like 
receptor-4 (TLR-4) on macrophages and adipocytes, thereby increasing the proinflammatory loop. This 
paracrine loop has been reported in obesity as a result of macrophages infiltrating fat (148).
Cortisol and fat redistribution
Patients with hypercortisolism also have an acquired form of lipodystrophy (1), characterized by fat hy-
pertrophy in the upper body with increased VAT  and decreased limb fat. Cortisol could activate adipocyte 
differentiation and hypertrophy, mainly in visceral fat depots, because of the higher expression of gluco-
corticoid receptors (GR-a) and the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) that transforms 
inactive cortisone into active cortisol in adipocytes from central depots (22). In addition, cortisol induces  IR 
and increased lipolysis in adipocytes (22). It has been hypothesized that glucocorticoid activation is involved 
in cART-linked central fat hypertrophy (8). Higher ratios of urinary cortisol:cortisone metabolites and high-
er subcutaneous 11β-HSD-1 expression are observed in patients with severe lipodystrophy compared with 
those without (149). In cART-naïve patients 11β-HSD-1 expression increases in both abdominal and thigh 
SAT after 12 months of ART, only in patients with lipohypertrophy or without lipoatrophy (150). Because 
TNF-a expression in fat is related to that of 11β-HSD-1 (149), inflammation is linked to glucocorticoid acti-
vation (8). TNF-a activates 11-β-hydroxysteroid dehydrogenase (HSD)-type 1, and this enzyme’s activity is 
higher in visceral fat compared with subcutaneous fat. Visceral fat is able to locally produce cortisol, which 
could act inside adipocytes and increase lipid accumulation (151). Other hormones, such as growth hormone 
and testosterone, can modulate the activity of 11β-HSD-1. It is interesting to note that HIV-infected pa-
tients with lipodystro-
phy often present with 
a relative decrease in 
growth hormone (152)
and testosterone levels. 
Moreover, when pa-
tients with visceral fat 
hypertrophy are treated 
with growth hormone, 
a reduced amount of 
visceral fat is reported, 
together with improved 
metabolic status (Fi-
gure 6) (153). Figure 6: Genetic and adquired lipodystrophies (CGL – congenital generalized lipodystrophy; BSS – Berardinelli-Seip syndrome; cART – combined antiretroviral therapy; NRTI - nucleoside and 
nucleotide reverse transcriptase inhibitors ; PI – protease inhibitors; FPL – familial partial lipodystrophy; 
MADL – mandibuloacral dysplasia associated lipodystrophy; adapted from Agarwal & Garg. Ann Rev 
Genomics Human Genet 2006; 7: 175-199)
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Aging
In the general population, age is associated with central fat redistribution, mitochondrial impairment 
and increased levels of pro-inflammatory cytokines (154). Aging adipocytes release more pro-inflamma-
tory cytokines than young ones (155). Aging is physiologically associated with fat redistribution, oxida-
tive stress and low-grade inflammation. In the general population, the proinflammatory state interacting 
with the genetic background potentially triggers the onset of age-related inflammatory diseases such as 
atherosclerosis, sarcopenia and frailty. Decreased immune response leading to immunosenescence is 
also probably involved in early aging (8, 156). Aging and some cARTs result in mitochondrial dysfunction 
and oxidative stress, which lead to cellular senescence. Moreover, some PIs induce the accumulation of 
the pro-senescent protein prelamin A (8).
Genetic factors and HIV-lipodystrophy
A role for genetics is also probable in HIV-lipodystrophy. TNF-a gene promoter polymorphism is 
associated with lipodystrophy, but this association has not been confirmed in larger studies (157). Interest-
ingly, stavudine-induced lipoatrophy is linked to the HLA-B100*4001 allele, which is located in close 
proximity to the TNF-a gene; this observation further supports the theory that there is a role for inflam-
mation in lipoatrophy (158). Apo C3-455 also plays a role in lipoatrophy, and two variants of the adipo-
genic β2 receptor seems to be involved in fat accumulation, whereas PPARg variants are not involved 
(159). The toxicity of ART also depends on a patient’s metabolism, partly genetically determined.
Role of inflammation
Even if infectivity of adipocytes by HIV has been contested, the ability of the virus to modify adipocyte 
phenotype has been shown in some studies (160, 161). Moreover, macrophages and dendritic cells present in 
lipodystrophic adipose tissue could be infected, which could modify their characteristics (7). Macrophage 
infiltration is observed in adipose tissue from patients with HIV-related lipodystrophy together with de-
creased adipokine and increased pro-inflammatory cytokine production (162). Some anti-retrovirals increase 
oxidative stress and the generation of reactive species, which results in decreased production of adiponec-
tin and leptin by adipocytes and increased production of pro-inflammatory cytokines (7).
Lipotoxicity
Lipotoxicity is a possible explanation for the development of metabolic syndrome (MS) and diabetes 
in multiple pathological situations, from obesity to lipodystrophies of distinct origin. According to the 
lipotoxicity theory, excess availability of fatty acids or a limited capacity to metabolize them in organs 
and tissues elicits most of the alterations that are characteristic of MS, especially IR. The toxicity of fatty 
acids toward β-cells may lead to altered insulin production. Actually, high FA levels can induce a reduc-
tion in GLUT2 on β cell surfaces and induce a decrease in insulin secretion (19). Increased availability and, 
ultimately, increased accumulation of fat into skeletal muscle tends to promote IR; and fatty acid levels in 
liver that exceed the capacity of this organ to oxidize or export them lead to the increased accumulation 
of fat that is often associated with MS. All of these events could result from alterations in fat metabolism 
or excess intake of fat-enriched nutrients, but they could also arise as a result of intrinsic alterations in the 
capacity of adipose tissue to store and thereby buffer against excess accumulation of fatty acids in other 
tissues and organs (163). One hypothesis consistent with the appearance of MS in ART-associated lipodys-
trophy syndrome is lipotoxicity resulting from limitations in the capacity of subcutaneous fat to store the 
appropriate amounts of fat and the subsequent diversion of fatty acids to ectopic sites (164). Several argu-
ments in support of lipotoxicity as a major contributor to MS in distinct human pathologies come from the 
paradoxically common metabolic alterations found in the obesity and in lipodystrophies of genetic origin. 
According to the lipotoxicity theory, the fat stored in adipose tissue is biologically inert and the observed 
metabolic alterations are primarily caused by the increased exposure of cells to non-esterified fatty acid. 
Thus, in obese patients, it is not the amount of fat stored in adipose tissue that elicits metabolic dysfunc-
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tions, but rather the balance between the availability of those fatty acids to tissues and organs and the 
capacity of the organs to eliminate them through triglyceride storage in adipose tissue, or oxidation (165). A 
complementary concept is the idea that there is a threshold for adipose tissue expansibility; once reached, 
as in obese individuals, appropriate storage of fatty acids in their inert, esterified form inside adipocytes is 
impaired, determining the extent of lipotoxicity (164). Either a total or partial lack of adipose tissue storage 
capacity causes an increase in circulating lipid levels and is associated with ectopic lipid accumulation in 
non-fat tissues such as liver, skeletal muscle and pancreas. These alterations lead to non-alcoholic fatty 
liver diseases, hepatic and muscle IR and development of type 2 diabetes. Adipokine deficiency further 
contributes to metabolic alterations (e.g. hyperphagia) owing to an associated leptin deficiency, which also 
contributes to positive energy balance and potential lipotoxicity through increased fat intake (94).
Insulin resistance
IR occurs in about one-third of patients on certain PI-based regimens, although the thymidine NRTIs 
have also been associated (166). Asymptomatic type 2 diabetes mellitus is diagnosed in 5-10 % of patients 
(126). The new-generation PIs appear to have a milder IR effect and the prevalence of diabetes is lower 
than the described in the early 2000s. Its prevalence, however, remains higher than in the general popu-
lation at the same age. In particular, patients with severe lipodystrophy are more prone to develop IR (7).
The pathogenesis of glucose metabolism disorders is still unclear and, although a direct effect of potent 
antiretroviral combinations is certainly involved, it is likely that multiple factors play a role, including 
genetic predisposition, cytokine and hormonal alterations, changes in the immune system, non-antiret-
roviral drug-induced toxic effects, opportunistic diseases, and perhaps the HIV infection itself (167). Risk 
factors for the development of IR in HIV-positive population include duration of ART, PI treatment, 
concurrent fat redistribution syndrome, dyslipidemia, increasing age, hepatitis C virus co-infection, as 
well as pharmacological treatment with pentamidine or megestrol acetate (100, 167-169).
PIs (including indinavir, amprenavir, nelfinavir, and ritonavir) have been shown to induce IR in vitro 
by reducing glucose transport mediated by the glucose transporter 4, a receptor involved in glucose up-
take (136). The deleterious impact of some PIs on adipocytes through the inhibition of GLUT4 transport-
ers was directly demonstrated in healthy controls, given these molecules for a few weeks (169-171). Several 
PIs can interfere with nuclear transcription factors, leading to decreased adiponectin levels, which also 
leads to IR (123). Some PIs might also cause mitochondrial toxicity (172). Additionally, the increase in FFA 
levels associated with PIs, as well as with fat redistribution, might also have a role in the development 
of IR (see lipotoxicity) (173).
Dyslipidemia
A number of HIV-infected patients present with dyslipidemia, increased cholesterol, low-density 
lipoprotein (LDL)-cholesterol and triglycerides together with decreased HDL. This profile has been as-
sociated with the presence of a MS, resulting from an increased visceral fat amount with IR (7).
In patients receiving cART the prevalence of hyperlipidemia ranges from 28 to 80% in different stud-
ies (167, 174), and it includes hypertriglyceridemia in the majority of cases (123). Dyslipidemia is frequently, 
but not always, associated with fat redistribution syndrome: although lipid and glucose metabolism 
alterations are more common in patients with body-fat abnormalities, they are also observed in those 
without these morphological changes (167).
 Several pathogenetic mechanisms have been proposed to explain cART-associated hyperlipidemia, 
which seems to result from a complex and multifactorial pathologic process: possibly HIV infection 
itself, leading in some cases to permanent low grade inflammation with abnormal levels of some pro-
inflammatory cytokines; lipodystrophy itself, as in the genetic forms, with decreased lower-body fat 
depots and increased visceral fat; antiretroviral molecules (PIs, NNRTIs and some NRTIs) (7).
Various mechanisms involved in ART-related dyslipidemia have been described: reduction in the 
catabolism of VLDL, increased VLDL production, impaired catabolism of FFA, increased liver triglyc-
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eride synthesis, increased secretion of apolipoprotein B-containing lipoproteins, reduced expression of 
LDL receptors, reduced degradation of SREBP, and reduction in FXR (farnesoid X receptor) (175). The 
first hypothesized mechanism is based upon the structural similarity between the catalytic region of 
HIV-1 protease and two human proteins involved in lipid metabolism: the cytoplasmic retinoic acid-
binding protein type 1 (CRABP-1) and the low-density lipoprotein-receptor-related protein (LRP). PIs 
probably bind to CRABP-1 and erroneously inhibit the formation of cis-9-retinoic acid, leading to in-
creased apoptosis of peripheral adipocytes, decreased lipid storage and increased lipid release into the 
bloodstream. Similarly, PIs may inhibit the normal functioning of LRP and interfere with fatty acid 
storage in the adipocytes (167, 176). Furthermore, data from in vitro and in vivo studies suggest that PIs may 
prevent proteasomal degradation of nascent apolipoprotein B, a key protein component of circulating 
triglycerides, leading to increased production of VLDL particles. An upregulation of metabolic path-
ways leading to an excessive production of VLDL can also be caused by the PI-induced intra-hepatocyte 
accumulation of nuclear transcription factors involved in the metabolism of apolipoprotein B, such as 
SRBPs. In addition, the levels of lipoprotein particles containing apolipoprotein C-III and apolipopro-
tein E are increased in PI-treated patients (176-179).
Metabolic syndrome
In the general population, MS is described as an association of increased upper-body fat, particularly 
in the visceral area, with IR responsible for and revealed by metabolic alterations, including increased 
LDL, decreased HDL, increased triglycerides, increased glycemia or diabetes and increased blood pres-
sure (180-182). All these parameters constitute a constellation of major CV risk factors (180). This situation 
also includes low-grade inflammation and a prothrombotic state (7).
The pathophysiology of MS is complex – genetic factors, aging and weight gain associated with sed-
entariness and food habits constitute major risk factors. Also, decreased mitochondrial function related to 
aging (183) and an age-related redistribution of fat towards the central, visceral areas are involved, leading to 
IR and metabolic abnormalities (7).
The components of the HIV lipodystrophy syndrome(s) bear a striking resemblance to those of MS 
(123). Both can present hyperinsulinemia, glucose intolerance, central or abdominal obesity, hypertension, 
atherogenic lipid profile, hyperuricemia, prothrombotic states and proinflammatory states (123).
Liver lesions of nonalcoholic steatohepatitis (or NASH) are a complication of MS, with a possible 
evolution towards severe liver 
complications such as cirrhosis. 
HIV-infected patients, with IR in 
the context of a severe lipodys-
trophy, present an increased risk 
of liver lesions (184). Moreover, as 
HCV infection has been associ-
ated with steatosis and hepatic IR 
resulting from viral or metabolic 
effects, HCV co-infection could 
aggravate the metabolic and liver 
status of HIV-infected patients (185).
HIV-infected patients with MS are 
more likely to have higher values 
of carotid intima-media thickness 
(cIMT) and detectable coronary 
artery calcium score (Figure 7) 
(186).
Figure 7: The relationship between HIV infection, lipodystrophy, 
ART, insulin resistance, adipokines, metabolic alterations, metabolic 
syndrome and cardiovascular disease risk
IR, Adipokines and Lipodystrophy in HIV infection
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Clinical sequelae associated with HIV and HIV-lipodystrophy
Different studies suggest that the CV risk is increased among HIV-infected patients on cART and 
the responsible mechanisms are complex: in addition to the direct effect of the virus on the vasculature, 
toxicity of antiretroviral drugs and the set of metabolic alterations aggregated in the MS are involved 
(187). Whether the increased CV risk is due to HIV infection itself, to ART, or to a synergistic interaction 
between these factors, remains to be established (167). HIV infection itself may increase CV risk. The 
HIV surface glycoprotein gp120 can stimulate endothelial cell production of tissue factor, an early step 
in the development of atherosclerosis (188). Both HIV infection and ART promote atherosclerosis and its 
clinical manifestations through inflammatory mechanisms involving endothelial cells, either directly or 
indirectly, and also by the lipid alterations they induce (189, 190).
Furthermore, some data suggest that endothelial dysfunction, impaired fibrinolysis, and excess in-
flammation are more common in HIV-positive patients than in general population, and may contribute 
to an increased CV risk (191). At the same time, cIMT and coronary calcification assessments suggest in-
creased incidence of atherosclerotic disease and premature occurrence of arterial atherosclerotic lesions 
among HIV-infected individuals (192). Surrogate markers of atherosclerosis, including abnormal cIMT 
(193, 194), altered endothelial reactivity (195), abnormal coronary calcium scores (196), higher than expected C-
reactive protein levels and abnormal proinflammatory and prothrombotic indices (197), all suggest a state 
of increased atherosclerotic risk (123).
Endothelial cells have been shown to be variably permissive for HIV infection. The HIV virus itself 
is able to penetrate coronary artery and brain microvascular endothelial cell membranes and to initiate 
inflammatory and biochemical intracellular reactions (198, 199). The activation of endothelium induced by 
either HIV infection itself or by a leukocyte-mediated inflammatory cascade triggered by the same virus 
leads to the increased expression of endothelial cellular adhesion molecules, such as intercellular adhe-
sion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), E-selectin, P-selectin, thrombo-
modulin, tissue plasminogen activator (tPA), and PAI-1. A significant association between increasing 
serum concentrations of adhesion molecules and risk of future myocardial infarction has been shown in 
apparently healthy men and women, and these molecules are now considered as soluble biomarkers of 
endothelial inflammation and early atherosclerosis (200, 201). Increased serum levels of ICAM-1, VCAM-
1, E-selectin, and thrombomodulin were demonstrated in patients with advanced HIV infection and op-
portunistic diseases, and a correlation between ICAM-1 concentrations and the progression of disease 
as well as the reduction of CD4 lymphocyte count was also reported. If circulating adhesion molecules 
indicate vascular endothelium injury, it seems clear that endothelium injury is associated with the pro-
gression and severity of HIV disease (202). cART should reduce the endothelial damage by controlling 
HIV infection, but it would also contribute to stimulating endothelial activation by deranging both lipid 
and glucose metabolism (167). Some PIs, as ritonavir and indinavir are able to directly cause endothelial 
dysfunction, with mitochondrial DNA damage and cell death, independently of lipid profile (203). cART 
may promote atherosclerosis both by direct effects on endothelial cells and by indirect effects associated 
with metabolic disturbances (167).
Elevated serum levels of PAI-1, tPA, and CRP, as well as reduced serum levels of adiponectin could 
be considered biochemical markers of endothelial dysfunction, metabolic alterations, and  CV risk in 
HIV-infected patients (192). Some authors suggested that the pathogenetic mechanism responsible for 
carotid lesions associated with HIV infection may be more similar to an inflammatory process than the 
classical atherogenesis (204, 205). Some retrospective and prospective studies have shown that the incidence 
of myocardial infarction in HIV-positive subjects treated with ART tends to be higher than in the gen-
eral population, particularly in those receiving a PI-based treatment (206). However, reports from large 
observational studies demonstrate that there is still considerable controversy regarding the association of 
cART, particularly PI-based combinations, with increased incidence of coronary heart disease risk (167).
Moreover, prospective studies involving large cohorts of HIV-infected patients have documented 
an increased incidence of myocardial infarction and cerebrovascular diseases in association with a pro-
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longed exposure to cART. However, the absolute risk of CV events remains low, and should be bal-
anced against the remarkable benefits from cART in terms of improvement in immune function and 
related morbidity and mortality (167).
In other words, incidence of CV disease in successfully cART-treated HIV-infected patients is low. 
However, the risk of CV disease is increased compared with that of uninfected people. This fact is due in 
great part to a higher prevalence of underlying traditional CV risk factors that are mostly host dependent. 
HIV may additionally contribute through immune activation, inflammation, and immunodeficiency. In a 
more modest way than HIV infection, the type of ART may also contribute, mainly through the impact 
on metabolic and body fat parameters, and possibly through other factors that are currently unclear. 
From the CV perspective, the benefits of ART outweigh any potential risk (207, 208).
concLusions
Human lipodystrophies are a heterogeneous group of diseases with generalized or partial fat loss. 
They include rare genetic conditions or more frequent acquired forms, and may be old, or more recent, 
such as HIV-related lipodystrophy. Almost all lipodystrophies are associated with metabolic altera-
tions including IR, diabetes, dyslipidemia and early CV disease. In this new context of increased aging 
of HIV-infected patients with high incidences of smoking status, over-nutrition and reduced exercise, 
lipodystrophy, dyslipidemia, altered glucose tolerance with IR, low-grade infection with the ongoing 
drug-induced inflammation, increased metabolic and CV complications are to be expected. It is impor-
tant to be aware of these alterations and to apply risk-modification strategies to reduce CV risk in the 
HIV-infected patients. 
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Os objetivos dos trabalhos apresentados na presente dissertação estão defini-
dos nas publicações 3 a 11.
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4. mÉtodos
todos os trabalhos apresentados nesta dissertação decorreram na consulta do 
Serviço de Endocrinologia do centro Hospitalar de São João e estão detalhados no 
material e métodos das publicações 3 a 11.
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Abstract
Human immunodeficiency virus (HIV) infection and its treatment with antiretroviral therapy (ART) have been
associated with lipodystrophy. Different clinical methodologies have been used to define the syndrome. The aim
of this study was to propose gender-specific reference values using objective measurements for defining lipodystro-
phy in HIV-infected patients. Using dual-energy X-ray absorptiometry (DXA), total body composition was analyzed
in 221 HIV-infected patients under ART (146 men). We used fat mass ratio (FMR) as the ratio between the percent
of the trunk fat mass and the percent of the lower-limb fat mass. One hundred forty patients (63.6%) presented
clinically defined lipodystrophy. In men, the optimal cutoff value for the FMR was 1.961 (area under the receiver
operating characteristic curve [AUC]: 0.74 [95% confidence interval (CI): 0.66e0.82], p! 0.001), with a sensitivity
58.3%, a specificity 83.7%, a positive predictive value (PPV) of 89.6% and a negative predictive value (NPV) of
45.5%. In women, the optimal cutoff value for the FMR was 1.329 (AUC: 0.74 [95% CI: 0.63e0.86],
p! 0.001), with a sensitivity 51.4%, a specificity 94.6%, a PPV of 90.5%, and an NPV of 66.0%. The FMR eval-
uated by DXAwith the gender-specific cutoffs defined here is an objective way to define HIV-related lipodystrophy.
Key Words: Fat mass ratio; gender; HIV; lipodystrophy.
Introduction
Human immunodeficiency virus (HIV) infection and its
long-term treatment with combined antiretroviral therapy
(ART) have been associated with morphologic abnormalities,
namely, lipodystrophy. HIV-associated lipodystrophy has
been linked to adverse metabolic parameters that predict in-
creased cardiovascular disease risk. The term ‘‘HIV-associated
lipodystrophy syndrome’’ refers to changes in fat distribution,
including peripheral reduced fat deposition (lipoatrophy) in
the face and limbs, appearance of dorsocervical fat pads
and multiple lipomas, fat gain in breasts, abdominal girth,
and visceral adipose tissue (VAT) (1e4). It soon became clear
that some patients had mainly lipoatrophy, others had
increased trunk and abdominal fat accumulation, and a subset
of patients had a mixed picture of both morphologic features,
and the picture of the syndrome seemed to represent a clinical
continuum (5). The pure phenotypes (only lipoatrophy or only
diffuse fat accumulation) occurred in fewer than 10% of
patients with clinical diagnoses of these disorders (6).
Different methodologies have been used to assess the
prevalence of the syndrome: patient self-report, clinical
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evaluation, and a complex case report definition. This last def-
inition attempted to develop an objective case definition of
lipodystrophy, including age, sex, duration of HIV infection,
HIV disease stage, waist to hip ratio, anion gap, serum
high-density lipoprotein (HDL) cholesterol concentration,
trunk to peripheral fat ratio, percentage leg fat, and intra-
abdominal to extra-abdominal fat ratio. The use of such crite-
ria has shown a sensitivity of 79% and a specificity of 80% for
the diagnosis of lipodystrophy (6). However, the model is
complex, with limited clinical usefulness. In the Carr’s model
of lipodystrophy definition, patients with isolated abdominal
obesity were excluded. Also, by definition, any lipoatrophy
is considered as presence of lipodystrophy with or without
any fat accumulation (6). Most reports have defined HIV-
associated lipodystrophy (clinical lipodystrophy) based on
self-report of change, confirmed on examination by a health
care provider (1). The lack of standardized values of fat
distribution in the general population (both gender) and the
heterogeneity of clinical manifestations of lipodystrophy
complicated this further. Dual-energy X-ray absorptiometry
(DXA) is an extensively used and reproducible technique,
but it is unable to distinguish between intra-abdominal and
subcutaneous fat and to identify facial lipoatrophy (7,8).
The detection of minimal body fat changes and, if possi-
ble, its objective measurements, may enable us to prevent
or minimize further abnormalities. Therefore, there is
a need for a simple, evidence-based, and validated definition
of lipodystrophy (9).
In 2005, Bonnet et al proposed for the first time an objective
method for the definition of HIV infection lipodystrophy in
men, the ‘‘fat mass ratio’’ (FMR) that seemed to allow a more
accurate and earlier diagnosis (10). FMR is defined as the ratio
of the percentage of the trunk fat mass to the percentage of the
lower-limb fat mass by DXA. It should, however, be empha-
sized that this cutoff point was estimated for HIV-infected
men; thus, its application to women is uncertain.
Implementation of this FMR index in studies of HIV
patients will allow for more standardized estimates of
lipodystrophy frequency, causes, and response to prevention
or treatment strategies, at least in the mixed form of fat
mass redistribution (10). Thus, the aim of this study was to
estimate the reference values of FMR for defining HIV-
associated lipodystrophy in a population of HIV-infected
patients with clinically diagnosed lipodystrophy.
Methods
Subjects
As part of a cross-sectional study, 221 noninstitutionalized,
HIV-infected adult patients (146 men and 75 women), con-
secutively referred from the Infectious Diseases Outpatient
Clinic to the Endocrinology Consultation of Hospital S~ao
Jo~ao, were evaluated. Only patients on therapy were included,
because lipodystrophy is related to ART. The study protocol
was approved by the Hospital Ethical Committee, and all
patients provided informed consent.
Clinical Assessment
Clinical lipodystrophy was defined as a peripheral lipoa-
trophy with or without a central fat accumulation as assessed
by both patients (patients with at least 1 lipodystrophic fea-
ture, identified by lipodystrophy-specific physical examina-
tion, were asked to report whether he/she had noticed any
change in fat volume in the cheeks next to the nose, lateral
aspect of the face, legs, arms, and buttocks) and the clinician.
Patients were classified as without clinical lipodystrophy
when none of the previously described features were present.
Presence of central fat accumulation or abdominal promi-
nence was defined by the measurement of waist circumfer-
ence using the International Diabetes Federation criteria for
metabolic syndrome (11). All clinical assessments were
performed by the same practitioner (PF). The patients were
analyzed in 4 different groups according to the presence or
absence of either lipoatrophy or abdominal prominence.
Dual-Energy X-Ray Absorptiometry
Body composition was assessed with whole-body DXA
(DXAdLunar Expert XL, 1999). DXAmeasurement was per-
formedwhile the patient was in a supine position, with standard
positioning of the arms and feet. Markers used in this study for
trunk and lower limbs that defined regions of interest were those
indicated by the manufacturer. Regional fat mass values were
grouped and analyzed for the following anatomical regions:
arms, legs, trunk, and total body. The FMR was calculated as
the ratio between the percentage of the trunk fat mass and the
percentage of the lower-limb fat mass (FMR5% of the trunk
fat mass/% of the lower-limb fat mass) (10).
Statistical Analysis
Statistical analysis was performed using the SPSS version
17.0 software (SPSS Inc., Chicago, IL). All probabilities
were 2 tailed, and p values less than 0.05 were regarded as
significant.
Data were described as mean and standard deviation (SD)
for quantitative variables and compared using the Student’s
t-test or the Mann-Whitney test, as appropriate. Furthermore,
analysis of variance was used for the comparison between
quantitative variables. Categorical variables were described
as counts and proportions and compared using the chi-
square or Fisher’s exact test.
The area under the receiver operating characteristic (ROC)
curve (AUC), which plots sensitivity (‘‘true positive rate’’)
against 1� specificity (‘‘false positive rate’’), was used to
describe the performance of the diagnostic value of each
FMR index. Additionally, the likelihood ratios (LR) were cal-
culated for the comparison of the new FMR index threshold
performance with the previously established one (10).
Results
In 221 (146 male and 75 female) HIV-positive patients
treated with ART, 140 (63.6%) presented clinically defined
lipodystrophy. The sample characteristics according to gender
are illustrated in Table 1. As it can be observed, no
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differences were observed regarding age, duration of seropos-
itivity from HIV diagnosis, and duration of treatment between
men and women. Consistent with previous results in the liter-
ature, women had significantly higher mean values of adipos-
ity, both measured by the body mass index (BMI) and by fat
mass estimated by DXA (2). However, men were more
frequently clinically defined as lipodystrophic and also
presented a significantly higher mean FMR.
Regarding the prevalence of lipodystrophy features, we
observed that 39% of the males and 79.7% of the females
had abdominal fat accumulation evaluated by the measure-
ment of abdominal circumference, and 70.5% of the males
and 50% of the females had clinical lipoatrophy (Table 1).
In what concerns classes of fat mass distribution (Table 1),
70.5% of men were classified as clinically lipodystrophic
(CL), but only 23.3% had associated abdominal prominence
Table 1
Sample Characteristics According to Gender
Sample characteristics Men (N5 146) Women (N5 75) p Value
Age (years), mean (SD) 46.6 (11.1) 46.4 (12.5) 0.664
Duration of seropositivity from HIV diagnosis (years), mean (SD) 7.7 (3.7) 8.4 (4.1) 0.113
Duration of HART treatment (years), mean (SD) 6.7 (3.8) 6.6 (4.1) 0.802
CD4, mean (SD) 557.1 (303.2) 570.7 (315.1) 0.901
HIV RNA (!50), n (%) 110 (85.3) 63 (92.9) 0.132
HIV risk factor, n (%)
Injecting drug user 35 (26.9) 9 (15.5)
Homosexual contact 21 (16.2) 0 (0) !0.001
Heterosexual contact 71 (54.6) 48 (82.8)
Others 3 (2.3) 1 (0.5)
Weight (kg), mean (SD) 69.4 (11.4) 64.1 (12.7) 0.001
Body mass index (kg/m2), mean (SD) 24.5 (3.7) 26.2 (5.6) 0.035
Circumferences (cm), mean (SD)
Waist 90.9 (10.4) 91.2 (13.4) 0.970
Hip 93.0 (6.7) 97.3 (10.5) 0.005
Thigh 47.1 (4.2) 48.8 (6.9) 0.358
Arm 27.0 (2.4) 26.8 (3.6) 0.700
Fat mass (%), mean (SD)
Total 16.7 (8.0) 33.7 (10.1) !0.001
Trunk 20.4 (9.7) 33.6 (10.2) !0.001
Leg 12.2 (9.1) 32.5 (12.8) !0.001
Arm 15.0 (8.6) 42.6 (11.4) !0.001
Fat mass (kg), mean (SD)
Total 12.0 (7.6) 22.2 (10.5) !0.001
Trunk 7.8 (5.0) 11.3 (5.5) !0.001
Leg 2.6 (2.0) 6.7 (3.8) !0.001
Arm 1.2 (0.9) 3.3 (1.9) !0.001
Fat mass ratioa 2.00 (0.97) 1.14 (0.42) !0.001
Free fat mass (kg), mean (SD) 55.7 (7.0) 43.8 (4.1) !0.001
Clinically defined lipodystrophy, n (%) 103 (70.5) 37 (50.0) 0.003
Abdominal prominence, n (%) 57 (39.0) 74 (79.7) !0.001
Fat distribution, n (%)
Without CL and without AP 20 (13.7) 4 (5.4)
Without CL and with AP 23 (15.8) 33 (44.6)
With CL and without AP 69 (47.3) 11 (14.9)
With CL and with AP 34 (23.3) 26 (35.1) !0.001
Abbr: SD, standard deviation; HIV, human immunodeficiency virus; ART; CD4, T lymphocytes; CL, clinically defined lipodystrophy; AP,
abdominal prominence.
aFat mass ratio5 trunk % of fat mass to the lower-limb % of fat mass.
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(AP) (mixed syndrome), whereas only 15.8% presented AP
without CL. On the other hand, 79.7% of women presented
AP, and mixed syndrome was present in 35.1% of the cases.
Clinical lipodystrophy was present in 50% of women. In our
sample, men had a significantly higher mean FMR than
women (Table 1).
When we stratified patients according to the presence or
absence of clinical lipodystrophy and by gender, those with
clinically defined lipodystrophy had a significantly higher
mean FMR (total and by gender) (Table 2). In this sample,
a significant linear increase of the mean FMR was observed
with increasing age in both genders ( p! 0.05) (Table 3).
However, this effect was not observed for BMI. Furthermore,
the mean FMR increased with increasing thirds of waist cir-
cumference in men but not in women.
Fat Mass Ratio Threshold
Considering the clinical assessment of lipodystrophy as the
case definition criteria, the optimal cutoff value for the FMR
for the total sample was 1.501 (AUC: 0.76 [95% confidence
interval (CI): 0.69e0.82], p! 0.001), with a sensitivity of
62.1%, a specificity of 81.3%, a positive predictive value
(PPV) of 84.5%, and a negative predictive value (NPV) of
57.2% (Fig. 1).
However, as described in Table 1, there were significant
differences between men and women regarding both the prev-
alence of clinically defined lipodystrophy and the percentage
and quantity of fat mass measured by DXA. Thus, a stratified
gender analysis of the optimal cutoff point of the FMR was
performed.
Figures 2 and 3 illustrate the comparison between the clin-
ical diagnosis of lipodystrophy and FMR measured by DXA
by gender using ROC curves. In men, the optimal cutoff value
for the FMR was 1.961 (AUC: 0.74 [95% CI: 0.66e0.82],
p! 0.001), with a sensitivity of 58.3%, a specificity of
83.7%, a PPV of 89.6%, and an NPV of 45.5%. In women,
the optimal cutoff value for the FMR was 1.329 (AUC:
0.74 [95% CI: 0.63e0.86], p! 0.001), with a sensitivity of
51.4%, a specificity of 94.6%, a PPV of 90.5%, and an
NPV of 66.0%. Additionally, the sensitivity, the specificity,
and the positive and negative LR were calculated for compar-
ison between the present proposed thresholds with the one
earlier described (6). These results are presented in Table 4.
Discussion
Lipodystrophy is a general term used to describe various
features and degrees of fat redistribution, including lipoatro-
phy and lipohypertrophy, in different body regions (12). De-
spite the subjective nature of the clinical assessment of
Table 2
Fat Mass Ratio Mean According to the Presence of
Clinically Defined Lipodystrophy
Fat mass ratio
Without
lipodystrophy
With
lipodystrophy
p ValueMean (SD) Mean (SD)
Total 1.22 (0.53) 2.00 (0.97) !0.001
Men 1.45 (0.60) 2.23 (1.00) !0.001
Women 0.96 (0.24) 1.34 (0.48) !0.001
Abbr: SD, standard deviation.
Table 3
Body Mass Index and Fat Mass Ratio Mean According to
Demographic and Anthropometric Characteristics
Characteristics
Men Women
BMI,
mean
(SD)
FMR,
mean
(SD)
BMI,
mean
(SD)
FMR,
mean
(SD)
Age range (years)
20e29 23.3 (3.6) 1.05 (0.51) 27.4 (6.7) 0.81 (0.14)
30e39 24.1 (3.9) 1.68 (0.80) 24.0 (4.8) 0.95 (0.42)
40e49 24.0 (3.7) 1.97 (0.95) 26.5 (6.8) 1.25 (0.48)
50e59 25.8 (3.8) 2.36 (0.89) 27.3 (5.6) 1.34 (0.28)
�60 25.0 (2.9) 2.30 (1.14) 27.9 (3.9) 1.20 (0.34)
p 0.165* 0.001* 0.275* 0.019*
Waist circumference thirds (cm)
0e84 20.8 (2.0) 1.60 (0.82) 21.0 (2.8) 1.02 (0.41)
85e94.5 24.2 (2.0) 2.17 (1.01) 25.7 (2.0) 1.29 (0.56)
�95 28.1 (2.8) 2.17 (1.95) 31.4 (5.0) 1.15 (0.22)
p !0.001* 0.002* !0.001* 0.130*
Abbr: SD, standard deviation.
*p Value for trend.
Fig. 1. Receiver operating characteristic curve for the com-
parison between the clinical diagnosis of lipodystrophy and
fat mass ratio measured by dual-energy X-ray absorptiometry.
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lipodystrophy, investigators report high concordance (e.g.,
98%) between the subjects’ and investigators’ assessments
of the presence of lipodystrophy, although the diagnostic re-
liability of those changes is highly variable (13). The accu-
racy of the clinical definition of lipodystrophy is dependent
on the skills of the observer, which means that expert ob-
servers have a higher accuracy. Hence, this method is difficult
to be generalized to less-experienced, smaller centers. In this
study, all the participants were evaluated by the same
observer (PF).
Lipodystrophy in HIV-1 infected patients is considered to
be an adverse effect of ART, not limited to a specific drug or
a class of drugs (14). HIV-associated lipodystrophy may af-
fect up to half the HIV-infected patients receiving ART
(15,16). This is one of the reasons why we have chosen to
study only patients on ART.
Bonnet et al (10) proposed for the first time that FMR was
an easy and objective method to define lipodystrophy, based
on a DXA body composition evaluation. A population of
241 negative and 162 HIV-infected men was studied, includ-
ing 34 naive patients and 128 ART-treated patients, with or
without clinical lipodystrophy. The 2 main reasons for the
proposal of this index were that 80% of the trunk fat mass
is perivisceral and 98% of limb fat mass is subcutaneous
and that the HIV-associated lipodystrophy syndrome might
result from a subcutaneous fat mass loss, an accumulation
of perivisceral fat mass, or both. The threshold chosen for de-
fining lipodystrophy by DXAwas 1.5, corresponding to 1 SD
above the mean of FMR in HIV-negative men. The FMR
threshold was similar for naive HIV-infected men and con-
trols. The FMR for HIV-treated patients with clinical lipodys-
trophy was very high (2.00� 0.97) and largely above the
threshold value, and the mean of FMR for HIV-treated
patients without clinical lipodystrophy was equal to the
threshold value. Bonnet et al concluded that the use of the
FMR should allow a more accurate and earlier diagnosis of
lipodystrophy (10).
In our sample of 221 (146 men and 75 women) HIV-
infected patients, no significant differences were found re-
garding age, duration of HIV disease, and ART between
both genders. Men were heavier, had lower mean BMI and
lower total, trunk, leg, and arm fat mass. The FMR was sig-
nificantly higher in males vs females, which led to the estima-
tion of a gender-based threshold.
Using an ROC curve analysis to define the cutoff value of
FMR for lipodystrophy, the best relationship between sensi-
tivity and specificity of FMR for the diagnosis of lipodystro-
phy was obtained with a 1.961 threshold for men and 1.329
for women. If we use the 1.5 threshold, we obtain a sensitivity
of 62.1 and a specificity of 81.3 for the total sample. Instead
Fig. 3. Receiver operating characteristic curve for the com-
parison between the clinical diagnosis of lipodystrophy and
fat mass ratio measured by dual-energy X-ray absorptiometry
in women.
Table 4
Sensitivity, Specificity, and Positive and Negative
Likelihood Ratios Using 2 Different Thresholds for FMR
Index
FMR
index
thresholds
Sensitivity
(%)
Specificity
(%)
Positive
likelihood
ratio
Negative
likelihood
ratio
Men
1.5 71.8 65.1 2.06 0.43
1.961 58.3 83.7 3.58 0.49
Women
1.5 32.4 100 þN 0.68
1.369 51.4 94.6 9.50 0.51
Abbr: FMR, fat mass ratio.
Fig. 2. Receiver operating characteristic curve for the com-
parison between the clinical diagnosis of lipodystrophy and
fat mass ratio measured by dual-energy X-ray absorptiometry
in men.
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of comparing HIV-infected with noneHIV-infected patients,
we compared patients with and without clinical lipodystro-
phy. This decision was because of the clinical problem of dis-
tinguishing the lipodystrophic patients within an HIV-infected
adult population.
We presented different thresholds of FMR for men and
women, because either in the general population or in patients
with or without lipodystrophy, there are significant differ-
ences between them. In his model of HIV lipodystrophy
case definition, Carr et al did not present separate case defini-
tions by gender, because it did not improve the sensitivity and
specificity of the case definition (6). However, some of the pa-
rameters evaluated (ratio of waist to hip circumference, HDL
cholesterol, ratio of trunk to limb fat, intra-abdominal to
extra-abdominal fat ratio, and percentage leg fat) already
took into account gender differences.
In our data, 70.5% of the males had clinical lipoatrophy,
and 39% had abdominal fat accumulation. These results are
quite similar to those observed in the FRAM (Fat Redistribu-
tion And Metabolic in HIV infection) study: men had evi-
dence of a syndrome of subcutaneous lipoatrophy, with
lower-body depots affected more than upper-body depots.
FRAM is a cross-sectional study of HIV-infected patients us-
ing clinical examination and magnetic resonance imaging to
study regional adipose tissue distribution (1,2). AP was found
to be an important factor impacting the FMR, particularly in
men, probably because, in our sample, men had less fat mass
evaluated by DXA and women had a high AP (Tables 1 and
3). We did not observe an effect of hip circumference on the
FMR. In our data, we observed a smaller number of mixed
syndrome (namely in men), but this could also be ascribed
to the method used to define AP.
We observed that 50% of women had clinical lipoatrophy
and 79.7% had abdominal fat accumulation. These gender
differences may be caused by the fact that women had
more total body fat than men. In fact, our National Obesity
Survey found a 17.2% prevalence of obesity and 46.1%
prevalence of overweight in 40- to 49-yr-old women, mainly
visceral obesity (47.8% of women with waist circumference
O80 cm). In men, 51.3% were overweight and 16.8%
were obese (52.1% of men with waist circumference
O94 cm) (17).
In FRAM study, HIV-infected women with clinical periph-
eral lipoatrophy had less subcutaneous adipose tissue in pe-
ripheral and central sites and less VAT than HIV-infected
women without peripheral lipoatrophy. Peripheral lipoatrophy
was more frequent in HIV-infected women than in the con-
trols, whereas central lipohypertrophy was similar. These
data also point out the need of a gender-specific threshold
for the FMR.
Increasing age is associated with truncal abdominal fat de-
position in both genders in noneHIV-infected population
(18). In our sample, the FMR increased with age in both gen-
ders, but this effect was not statistically significant for BMI.
This is in agreement with previous reports (10). For the first
time, we demonstrated that the increase in FMR with age is
also present in women. Previously, Snead et al demonstrated
that age induces an underestimation of the upper-body adi-
pose tissue by DXA; hence, the age-associated increase in
FMR that we observed is probably not related to methodolog-
ical problems (18).
FMR has also been used in the evaluation of genetic lipo-
dystrophy, and the authors discussed the need of different
thresholds according to the fat mass redistribution (19). Our
proposed threshold values enabled a more precise identifica-
tion of lipodystrophic patients.
In conclusion, FMR evaluated by DXA is an objective tool
to define HIV-related lipodystrophy, allowing a more clini-
cally useful definition for identification of patients with ab-
normal fat distribution. Use of gender-specific FMR
thresholds as a diagnostic tool in metabolic studies of HIV-
infected patients would enable the comparison of different
studies and should be useful to monitor lipodystrophy pro-
gression in this population.
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ABSTRACT. HIV-lipodystrophy syndrome is characterized by
different patterns of body fat distribution (BFD) which are
identified by clinical and body composition (BC) assessment,
including bioimpedance analysis (BIA). Our aim was to com-
pare BC in HIV-infected patients on combination antiretrovi-
ral therapy (cART) according to 4 distinct phenotypes of BFD
(G1-no lipodystrophy, G2-isolated central fat accumulation,
G3-lipoatrophy, G4-mixed forms of lipodystrophy) and as-
sessed factors associated with them. Anthropometry and BIA
were performed in 344 HIV-1 patients. G2 and G4 pheno-
type patients had significantly higher fat mass (FM) but no
differences were observed in fat-free mass (FFM) and total
body water among the 4 phenotypes. Significant negative
associations were found between the presence of lipoatrophy
and female gender, body mass index (BMI), waist (WC), hip
(HC) and thigh circumferences, and total body FM estimated
by BIA. After adjustment for gender, cART duration and BMI,
G3 had significant lower WC [odds ratio (OR)=0.84; 0.78-
0.90] and HC (OR=0.88; 0.81-0.96) mean. Independently of
gender, cART duration and BMI, G2 remained significantly
associated with higher WC (OR=1.11; 1.05-1.18) and HC
(OR=1.15; 1.07-1.23) mean, and with FM estimated by BIA
[FM as %, OR=1.17 (1.09-1.26); and FM as kg, OR=1.15 (1.06-
1.25)]. There was a significant positive association between
G4 and female gender (OR=1.66; 1.01-2.75), BMI (OR=1.10;
1.04-1.17) and WC (OR=1.15; 1.09-1.21). The similar FFM
along the BFD spectrum describes the actual BC of these pa-
tients without sarcopenia. In a clinical setting, BIA is an easy
and useful tool to evaluate fat mass and FFM and gives us a
picture of BC that was not possible with anthropometry.
(J. Endocrinol. Invest. 34: e321-e329, 2011)
©2011, Editrice Kurtis
INTRODUCTION
The introduction of highly active antiretroviral therapy,
into clinical use in 1996 ushered in a new era of treat-
ment for HIV disease with markedly suppressed viral repli-
cation, increased CD4+ T-cell counts, and dramatically
decreased morbidity, hospitalizations, and mortality (1-
9). However, long-term adverse events associated with
combination antiretroviral therapy (cART) have been rec-
ognized, particularly the lipodystrophy syndrome (10, 11).
Lipodystrophy is common, affecting nearly half of all pa-
tients receiving cART (12, 13). The term HIV-associated
lipodystrophy syndrome refers to alterations in body fat
distribution and metabolic alterations (impaired glucose
or lipid metabolism). The body-fat distribution changes
are typically identified by physical examination and pa-
tient self-report (14). HIV-infected patients may exhibit
different patterns and varying degrees of severity of
changes in body fat. Lipodystrophy studies are further
hampered by the potential presence of two distinct phe-
notypes: peripheral lipoatrophy and central lipoaccumu-
lation. Both can occur together and also separately. Al-
though they are usually considered as different process-
es, it is unclear whether they are part of the same pro-
cess or they are independent processes (15-19).
The preservation of lean body mass (primarily muscle) in
lipoatrophy distinguishes this condition from HIV wast-
ing syndrome, which is defined as the generalized loss
of body fat and lean body mass with an involuntary
weight loss >10% of baseline body weight (17, 20).
The diagnosis of lipodistrophy is difficult. Clinical diag-
nosis has been the most common way, but since it is not
uniform it does not allow comparisons among different
studies. There are different methods for objective mea-
surement of body fat content, including anthropometry,
bioelectrical impedance analysis (BIA), dual-energy x-ray
absorptiometry (DXA), computed tomography (CT), mag-
netic resonance imaging (MRI), and ultrasonography.
However, there are limitations with each technique (9).
BIA measures the opposition of body cells and tissues to
the flow of an alternating electric current. Many studies
have applied the basic technique of BIA to estimate body
composition in various clinical and research settings.
However, most BIA devices cannot measure segmental
body fat. Anthropometry and BIA are cheap methods
and they have been widespread in units assessing body
composition for years. BIA is a method widely available
in HIV treatment centers and it is not invasive and does
not require as much training as anthropometry (21).
The aim of this study was to compare the body compo-
sition using anthropometry and BIA in HIV-infected adult
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patients on cART according to the 4 distinct phenotypes
of body fat distribution (no lipodystrophy, isolated central
fat accumulation, lipoatrophy, and mixed forms of lipo-
dystrophy) and assessed factors associated with them.
METHODS
Subjects
As part of a cross-sectional study, 344 HIV-infected non-institu-
tionalized Caucasian adults, 238 men and 106 women, consec-
utively referred from the Infectious Diseases Outpatient Clinic,
were evaluated in Endocrinology Consultation of São João Hos-
pital. Only patients on cART were included. The study protocol
was approved by the Hospital Ethics Committee and each pa-
tient provided informed consent.
Clinical assessment
For each patient the following information was collected using
a standardized protocol: demographic data (age, gender), HIV
infection and ART duration, HIV risk factor, and characterization
of the infection. We used the “Centers for Disease Control and
Prevention” (CDC) HIV staging classification. This classification
considered 3 clinic stages: A [asymptomatic HIV infection, acute
(primary) HIV infection with accompanying illness or a history of
acute HIV infection, or persistent generalized lymphadenopa-
thy]; B (symptomatic conditions not included among conditions
listed in clinical category C and that meet at least one of the fol-
lowing criteria: (A) the conditions are attributed to HIV infection
or are indicative of a defect in cell-mediated immunity; or (B)
the conditions are considered by physicians to have a clinical
course or to require management that is complicated by HIV in-
fection); and C (conditions indicators of AIDS); and also consid-
ers laboratorial categories or subdivisions of the above cate-
gories according to the CD4+ cell counts (22).
Weight, height, circumferences of neck, waist, hip, thigh and
arm were measured. Body weight was measured using TANITA
(Tanita®, model TBF 300) scale, in patients wearing light clothes
without shoes, and height was measured to the nearest cen-
timeter in the standing position using a wall stadiometer (Holtain
Limited Crymych, Dyfed®).
Neck circumference (NC) was measured in the midway of the
neck, between midcervical spine and midanterior neck. In men
with a laryngeal prominence (Adam’s apple), it was measured
just below the prominence. Hip circumference was measured
with the subject standing erect with arms by the sides, with the
feet together and the gluteal muscles relaxed. The measurer sat
at the side of the subject so that the level of maximum posteri-
or extension of the buttocks can be seen. An inelastic tape was
placed around the buttocks in a horizontal plane. To ensure con-
tiguity of the two parts of the tape from which the circumfer-
ence was to be determined, the cross-handed technique of mea-
surement was used. An assistant checked the position of the
tape on the opposite side of the subject’s body. The tape was
in contact with the skin but did not compress the soft tissues.
Fatty aprons were excluded from the hip circumference mea-
surement. The waist was measured at the end of a gentle expi-
ration midway between the lowest rib and iliac crest, with the
patient standing, and the hips were measured at the greater
trochanter level. All circumferences were taken with the subjects
standing upright, with the face directed toward, and shoulders
relaxed. Thigh circumference was measured around the thigh
of the left leg midway between the crotch and the knee when
the subject is in a standing position. Arm circumference was
measured in the mid-upper arm circumference of the left arm. All
measurements were performed by the same observer using stan-
dard techniques (23).
Clinical lipoatrophy (CL) was defined as a peripheral lipoatro-
phy assessed by both patient and practitioner. Patients with at
least one light, moderate or severe subjective lipoatrophic fea-
ture, identified by lipoatrophy-specific physical examination were
asked to report whether he/she had had any change in fat in the
cheeks next to the nose, lateral aspect of the face, legs, arms,
buttocks. Patients were classified as without CL, when none of
the previously described features were present (24). Presence
of central fat accumulation or abdominal prominence was de-
fined by the measurement of waist circumference (WC) using
the International Diabetes Federation criteria for metabolic syn-
drome (25). The clinical assessment was performed by the same
practitioner (PF). The patients were categorized in 4 different
groups according to the presence or absence of either lipoat-
rophy or abdominal prominence: 1) no lipodystrophy – patients
without CL and without abdominal prominence; 2) isolated cen-
tral fat accumulation – patients without CL and with abdominal
prominence; 3) lipoatrophy – patients with CL and without ab-
dominal prominence; 4) mixed forms of lipodystrophy – patients
with CL and with abdominal prominence.
Body composition was assessed with BIA (TANITA®, model TBF
300). BIA measurement was performed while the patient was in
an orthostatic position, with a standard positioning of the feet.
The subjects abstained from strenuous exercise, excess alcohol
consumption, and use of diuretic substances prior to the exam.
BIA allowed the evaluation of body composition, with quantifi-
cation of total body mass either as percentage or in kg of fat
mass (FM) and fat-free mass (FFM) and total body water (TBW).
FM, FFM, TBW were estimated from BIA data.
The CD4+ cell count was determined by flow cytometry and
plasma HIV-1 RNA loads were measured by a quantitative RT-
PCR (Roche Diagnostic Systems, Inc., Branchburg, NJ, USA),
which had a lower limit of detection of 50 copies/ml.
Statistical analysis
Statistical analysis was performed using the SPSS version 17.0
software (SPSS Inc., Chicago, Illinois, USA). All probabilities were
two-tailed and p values <0.05 were regarded as significant.
Data were described as mean and SD for quantitative variables
and compared using the Student-t test or the Mann-Whitney
test as appropriate. For the comparison between the 4 groups
of fat distribution and the BIA evaluation parameters the Krusk-
all-Wallis test was used. Categorical variables were described
as counts and proportions, and compared using the chi-square
or Fisher’s exact test.
To estimate the association between the 4 distinct phenotypes
of body fat distribution and the clinical and demographic char-
acteristics of the patients, unconditional logistic regression mod-
els were computed and odds ratios (OR) with their respective
95% confidence intervals (95% CI) estimated.
RESULTS
In the 344 HIV-1 infected patients (238 men and 106
women) on cART, included in this study, 59.6% present-
ed CL. Table 1 shows the characteristics of the study sam-
ple according to the 4 distinct phenotypes of body fat
distribution (15.1% with no lipodystrophy; 25.3% with iso-
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lated central fat accumulation; 32.3% with lipoatrophy
and 27.3% with mixed form of lipodystrophy). Patients
with lipoatrophy and mixed forms of lipodystrophy were
more frequently males, had significantly longer HIV in-
fection duration and length of cART (p<0.001). Patients
with isolated central fat accumulation and mixed forms
of lipodystrophy were older, and presented significantly
higher mean of all the anthropometric parameters
(p<0.05), with the obvious exception of height. Patients
with lipoatrophy had the lowest weight, body mass in-
dex (BMI), and neck, waist, hip, thigh, and arm circum-
ferences, but not the lowest waist/hip circumference ra-
tio.
Regarding BIA, patients with isolated central fat accumu-
lation and mixed forms of lipodystrophy had significantly
higher fat mass. There were no differences between the 4
groups of patients in FFM and TBW (Table 1).
Patients with lipoatrophy and mixed forms of lipodystro-
phy had significantly higher CD4+ cell count and viral
suppression. No significant differences were observed
between CDC classification and the pharmacologic
groups of cART between the 4 groups. In what concerns
the HIV risk factor, patients with no lipodystrophy and
lipoatrophy were more frequently injecting drug users
and patients with isolated central fat accumulation and
mixed forms of lipodystrophy were more frequently be-
longed heterosexual contact group.
In Tables 2 to 4 results regarding the associations be-
tween the prevalence of lipoatrophy, central fat accu-
mulation, and mixed forms of lipodystrophy and patients
characteristics, namely demographic, clinical, and an-
thropometric information, can be observed. Crude sig-
nificant negative associations were found between the
presence of lipoatrophy (Table 2) and female gender,
BMI, waist, hip and thigh circumferences, and total body
fat mass (both in total kg and percentage) estimated by
BIA. On the other hand, crude linear significant positive
associations were found between the presence of lipoa-
trophy and HIV infection duration (p for trend <0.001)
and the cART duration (p for trend <0.001) (Table 2). Af-
No lipodystrophy Isolated central fat Lipoatrophy Mixed form of p
accumulation lipodystrophy
No. (%) 52 (15.1) 87 (25.3) 111 (32.3) 94 (27.3)
Gender [no. (%)]
Male 43 (82.7) 42 (48.3) 97 (87.4) 56 (59.6) <0.001
Female 9 (17.3) 45 (51.7) 14 (12.6) 38 (40.4)
Age [yr, mean (SD)] 41.0 (10.9) 46.1 (12.3) 43.4 (9.2) 51.1 (10.9) <0.001
HIV infection duration [yr, mean (SD)] 6.6 (3.5) 6.6 (4.0) 9.4 (4.1) 8.6 (3.7) <0.001
ART duration [yr, mean (SD)] 5.1 (3.6) 4.9 (3.7) 8.0 (3.9) 7.8 (3.5) <0.001
Weight [kg, mean (SD)] 64.6 (8.2) 79.0 (14.1) 61.6 (9.9) 71.7 (12.9) <0.001
Heigth [m, mean (SD)] 1.68 (0.10) 1.64 (0.09) 1.68 (0.08) 1.64 (0.10) 0.002
BMI [(kg/m2), mean (SD)] 23.0 (2.4) 29.4 (4.6) 21.8 (2.9) 26.5 (3.4) <0.001
Neck circumference [cm, mean (SD)] 36.2 (3.4) 37.6 (3.8) 36.0 (3.3) 38.4 (4.3) 0.002
Waist circumference [cm, mean (SD)] 84.1 (6.8) 102.1 (10.8) 83.0 (6.9) 97.4 (8.6) <0.001
Hip circumference [cm, mean (SD)] 93.6 (4.2) 104.2 (8.5) 88.9 (5.1) 94.8 (5.8) <0.001
Thigh circumference [cm, mean (SD)] 46.6 (4.0) 51.9 (5.3) 44.7 (3.6) 47.8 (7.8) <0.001
Arm circumference [cm, mean (SD)] 26.0 (2.8) 29.0 (2.8) 25.4 (3.0) 27.9 (4.6) <0.001
Waist/hip ratio 0.90 (0.08) 0.98 (0.08) 0.93 (0.06) 1.02 (0.07) <0.001
CD4 cell count [cells/mm3, mean (SD)] 491.1 (363.8) 515.0 (292.5) 542.6 (288.8) 634.8 (375.2) 0.011
HIV RNA (<50) [no. (%)] 39 (78.0) 71 (85.5) 102 (91.9) 85 (91.4) 0.048
HIV risk factor [no. (%)]
Injecting drug user 16 (30.8) 14 (16.1) 48 (43.2) 11 (11.8) <0.001
Homosexual contact 7 (13.5) 5 (5.7) 14 (12.6) 12 (12.9)
Heterosexual contact 29 (55.8) 67 (77.0) 43 (38.7) 67 (72.0)
Others 0 (0.0) 1 (1.1) 6 (5.4) 3 (3.2)
CDC [no. (%)]
A 26 (50.0) 52 (60.5) 62 (56.4) 51 (54.8)
B 4 (7.7) 1 (1.2) 0 (0.0) 1 (1.1) 0.106
C 22 (42.3) 33 (38.4) 48 (43.6) 41 (44.1)
ART [no. (%)]
PI 31 (62.0) 51 (60.7) 63 (56.8) 45 (48.4) 0.296
NNRTI 22 (44.9) 37 (44.0) 53 (47.7) 48 (52.2) 0.719
NRTI 47 (95.9) 80 (95.2) 109 (98.1) 91 (98.9) 0.228
BIA
Fat mass [%, mean (SD)] 17.6 (5.5) 31.7 (8.3) 14.9 (5.5) 24.4 (6.9) <0.001
Fat mass [kg, mean (SD)] 11.3 (3.7) 25.1 (8.9) 9.4 (4.6) 15.9 (8.8) <0.001
FFM [kg, mean (SD)] 53.0 (7.5) 53.3 (9.8) 52.2 (7.2) 53.4 (12.0) 0.940
TBW [kg, mean (SD)] 38.8 (5.5) 39.0 (7.2) 39.3 (5.3) 39.5 (8.0) 0.923
BMI: body mass index; ART: antiretroviral therapy; PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse
transcriptase inhibitor; BIA: bioimpedance analysis.
Table 1 - Sample characteristic according to 4 distinct phenotypes of body fat distribution.
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ter adjustment for gender, cART duration and BMI, lipoa-
trophy remained significantly associated with lower waist
(OR=0.84; 95%CI: 0.78-0.90) and hip (OR=0.88; 95%CI:
0.81-0.96) circumferences mean. Almost fully opposite
results were observed, when isolated central fat accu-
mulation occurrence was assessed (Table 3). Isolated cen-
tral fat accumulation was significantly associated with fe-
male gender (OR 3.16; 95% CI: 1.92-5.18) and all the an-
thropometric measures evaluated, in the crude analysis.
Conversely, lower HIV infection duration and cART du-
ration were significantly associated with isolated central
fat accumulation. Independently of gender, cART dura-
tion and BMI, isolated central fat accumulation remained
significantly associated with higher waist (OR=1.11;
95%CI: 1.05-1.18) and hip (OR=1.15; 95%CI: 1.07-1.23)
circumferences mean, and with FM estimated by BIA [FM
as %, OR=1.17 (1.09-1.26); and fat mass as kg, OR=1.15
(1.06-1.25)].
The associations observed considering the mixed forms
of lipodystrophy are presented in Table 4. After the pre-
viously referred adjustments, there was a significant pos-
itive association between this phenotype and female gen-
der (OR=1.66; 95%CI: 1.01-2.75), BMI (OR=1.10; 95%CI:
1.04-1.17), and WC (OR=1.15; 95%CI: 1.09-1.21) as it
was observed when isolated central fat accumulation oc-
currence was assessed. Similar significant associations
were observed between mixed forms of lipodystrophy
and lipoatrophy regarding HIV infection and cART dura-
tion, hip and thigh circumference and FM estimated by
BIA.
Finally, these same associations were estimated for pa-
tients with no lipodystrophy. As it can be observed in
Table 5, the associations are opposite to the ones ob-
served for the mixed form of lipodystrophy. Patients with
no lipodystrophy were more frequently males, had low-
er HIV infection and cART duration, lower BMI and WC,
and higher hip and thigh circumferences, independent-
ly of gender, duration of treatment, and BMI.
DISCUSSION
Body composition in HIV-infected patients and its corre-
lation with body fat distribution is an important issue. BIA
is operator-independent, repeatable, non-invasive, wide-
ly available method of body composition evaluation that
requires less training than anthropometry and is less ex-
pensive than DXA (21). BIA gives us an evaluation of
body composition, namely the amount of FM, FFM and
TBW in a reproducible way and not operator-dependent
like certain anthropometric parameters. BIA may also be
an useful method in the evaluation of CL evolution (9).
BIA was an established method to monitor nutritional sta-
OR (95% CI) OR (95% CI)* OR (95% CI)**
Crude Adjusted Adjusted
Age
<30 1 1 1
30-39 1.38 (0.46-4.14) 0.83 (0.25-2.76) 1.15 (0.27-4.82)
40-49 1.46 (0.50-4.33) 0.85 (0.26-2.78) 1.08 (0.26-4.40)
>49 0.72 (0.24-2.18) 0.38 (0.11-1.25) 0.68 (0.16-2.87)
Gender
Male 1 1 1
Female 0.23 (0.12-0.42) 0.22 (0.12-0.40) 0.10 (0.05-0.24)
HIV infection duration
≤3 1 1 1
4-9 3.03 (1.14-8.09) 1.67 (0.49-5.64) 0.97 (0.24-3.94)
≥10 5.31 (1.98-14.26) 3.89 (1.02-14.8) 1.89 (0.38-9.47)
cART duration
≤3 1 1 1
4-9 2.64 (1.38-5.04) 2.69 (1.40-5.22) 3.93 (1.76-8.78)
≥10 4.09 (2.04-8.19) 4.43 (2.16-9.08) 4.71 (1.97-11.23)
CD4
>200 1 1 1
100-200 0.26 (0.03-2.11) 0.22 (0.03-1.89) 0.21 (0.02-2.07)
<100 1.11 (0.44-2.80) 1.14 (0.42-3.09) 1.10 (0.34-3.49)
PI 0.96 (0.85-0.91) 0.96 (0.59-1.56) 0.92 (0.51-1.66)
NNRTI 1.09 (0.70-1.70) 1.04 (0.64-1.68) 1.04 (0.58-1.86)
NRTI 2.90 (0.36-24.52) 3.37 (0.38-30.0) 4.88 (0.51-46.4)
BMI 0.69 (0.64-0.76) 0.64 (0.58-0.72) 0.64 (0.58-0.72)
Waist circumference 0.88 (0.85-0.91) 0.82 (0.78-0-86) 0.84 (0.78-0-90)
Hip circumference 0.78 (0.74-0.83) 0.77 (0.72-0.82) 0.88 (0.81-0.96)
Thigh circumference 0.83 (0.79-0.88) 0.81 (0.76-0.87) 0.97 (0.91-1.03)
% fat 0.73 (0.79-0.87) 0.83 (0.79-0.87) 0.95 (0.89-1.02)
kg fat 0.78 (0.73-0.83) 0.78 (0.72-0.83) 0.89 (0.81-1.00)
*odds ratio (OR) adjusted for gender and duration of treatment (with the exception of disease duration). **OR adjusted for gender, duration of treatment
and body mass index (BMI) (with the exception of disease duration). cART: combination antiretroviral therapy; PI: protease inhibitor; NNRTI: non-nucleoside
reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; CI: confidence interval.
Table 2 - Patients characteristics associated with lipoatrophy.
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tus in HIV-infected patients before the introduction of
cART, when patients had almost exclusively the wasting
syndrome, mainly characterized by losses of both fat and
FFM (and the lipodystrophy syndrome had not been yet
described) (26). By evaluating FFM, BIA allowed some
estimation of the degree of sarcopenia that these pa-
tients could present. Before the highly active antiretrovi-
ral therapy (HAART) era, the patients usually presented
wasting syndrome associated with sarcopenia, on the
other hand, our patients regardless the categorization
according to body fat distribution presented similar FFM
levels.
In well-trained hands, clinical diagnosis of lipoatrophy is
straightforward either in severe or in incipient cases. Be-
sides the presence of lipoatrophy in face and limbs, pa-
tients may have accumulation of central fat. WC mea-
surement and the waist/hip ratio had been successfully
used to assess central obesity (27), but with limited sen-
sitivity and specificity (28).
In our study, we found that patients with CL had signifi-
cantly higher waist/hip ratio and lower WC (data not
shown), but, when patients were categorized in the 4 in-
dependent groups according to their fat distribution, WC
was higher in patients with abdominal prominence inde-
pendently of the presence of lipoatrophy (i.e. in patients
with isolated central fat accumulation and mixed forms
of lipodystrophy) and lower in patients with CL and with-
out abdominal prominence (AP) (i.e. patients with lipoa-
trophy). The higher waist/hip ratio was present in patients
with AP independently of the presence of lipoatrohy (i.e.
patients with isolated central fat accumulation and mixed
forms of lipodysytrophy), however patients with lipoat-
rophy had a higher ratio than patients with no lipodys-
trophy. The BIA measures the electric properties of the
whole body. However, several sources of variance (e.g.,
blood viscosity, albumin concentration, hematocrit, skin
temperature, hydration status, having a recent meal, ex-
ercising, among others) may affect the whole-body
impedance measurements (29, 30). The BIA methods are
related to the conducting volume or mass in the body.
Body fat per se, because it is non-conductive, is not mea-
sured by BIA, but is calculated as the difference between
body weight and the derived estimate for FFM. Hence,
any BIA-based estimate of body fat is subject to cumu-
lative errors associated with the prediction of FFM. This
is a limitation of all two-compartment models where fat is
defined as the difference between body weight and FFM
(30). This method is particularly insensitive to redistribu-
tion of body compartments (21). In our patients, those
with isolated central fat accumulation and mixed forms
of lipodystrophy, had a higher FM (in % and kg), and
those with lipoatrophy had a lower FM, but no differ-
OR (95% CI) OR (95% CI)* OR (95% CI)**
Crude Adjusted Adjusted
Age
<30 1 1 1
30-39 1.41 (0.43-4.61) 2.84 (0.80-10.2) 2.94 (0.66-13.1)
40-49 0.80 (0.24-2.63) 1.36 (0.38-4.85) 1.14 (0.43-5.03)
>49 1.21 (0.37-3.92) 2.44 (0.69-8.63) 1.85 (0.43-7.99)
Gender
Male 1 1 1
Female 3.16 (1.92-5.18) 3.50 (2.08-5.89) 3.41 (1.88-6.19)
HIV infection duration
≤3 1 1 1
4-9 0.39 (0.20-0.77) 0.77 (0.32-1.87) 0.62 (0.23-1.71)
≥10 0.26 (0.12-0.53) 0.61 (0.08-0.72) 0.47 (0.13-1.68)
cART duration
≤3 1 1 1
4-9 0.39 (0.22-0.67) 0.37 (0.21-0.66) 0.18 (0.08-0.39)
≥10 0.20 (0.09-0.42) 0.32 (0.17-0.62) 0.20 (0.08-0.49)
CD4
>200 1 1 1
≤200 0.46 (0.16-1.36) 0.41 (0.13-1.28) 0.21 (0.02-2.07)
PI 1.19 (0.72-1.95) 1.26 (0.74-2.16) 1.65 (0.89-3.06)
NNRTI 0.89 (0.55-1.45) 0.73 (0.54-1.54) 0.76 (0.41-1.38)
NRTI 0.28 (0.07-1.15) 0.22 (0.05-1.06) 0.18 (0.03-1.10)
BMI 1.28 (1.20-1.37) 1.28 (1.20-1.37)) 1.28 (1.20-1.37)
Waist circumference 1.12 (1.08-1.15) 1.13 (1.09-1.16) 1.11 (1.05-1.18)
Hip circumference 1.22 (1.17-1.23) 1.20 (1.14-1.26) 1.15 (1.07-1.23)
Thigh circumference 1.17 (1.11-1.23) 1.14 (1.08-1.21) 1.03 (0.97-1.08)
% fat 1.18 (1.14-1.22) 1.20 (1.14-1.26) 1.17 (1.09-1.26)
kg fat 1.17 (1.13-1.22) 1.16 (1.11-1.20) 1.15 (1.06-1.25)
*odds ratio (OR) adjusted for gender and duration of treatment (with the exception of disease duration). **OR adjusted for gender, duration of treatment
and body mass index (BMI) (with the exception of disease duration). cART: combination antiretroviral therapy; PI: protease inhibitor; NNRTI: non-nucleoside
reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; CI: confidence interval.
Table 3 - Patients characteristics associated with isolated central fat accumulation.
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ences were observed when we compared the amount of
FFM and TBW between the 4 groups. This means that
BIA objectively quantify the amount of FM but is unable
of discriminating their localization. On the other hand,
body fat is the compartment measured with the least pre-
cision because of propagation error as it is calculated by
subtracting FFM from body weight. Moreover, 90% of
the measured whole-body impedance is determined by
the impedance of the limbs which contain less than half
of the FFM. Therefore, the method is particularly insen-
sitive to redistribution of body compartments.
The AP is the great contributor for the FM and the loss of
FM in the extremities in patients with mixed forms of
lipodystrophy (with lipoatrophy and with AP) cannot be
identified by BIA. Some authors considered that body
composition empirical prediction equations from BIA may
no longer be valid in populations of HIV-infected patients
with a high incidence of fat redistribution (31-34). BIA es-
timates of body cell mass are well correlated with muscu-
lar performance (30). Suppression of the catabolic effects
of viremia, decreased incidence of opportunistic infections,
or increased physical activity of patients are plausible ex-
planations for a gain in appendicular muscle mass in pa-
tients receiving successful antiretroviral treatment (35).
To evaluate the abdominal fat we used WC. In our pa-
tients, the mean WC was similar in patients with lipoatro-
phy and no lipodystrophy but they had a higher waist/hip
ratio, which could mean that visceral fat is increased in
these patients. Actually, studies using abdominal CT or
MRI have demonstrated that many patients at risk for
lipodystrophy have increased intraabdominal fat and de-
creased subcutaneous fat, even if they have not been di-
agnosed with lipodystrophy. And, even patients with low-
er WC had a higher ratio visceral fat/subcutaneous fat in
CT (14, 36). The most recent BIA devices, for example,
Tanita viscan analyser – TAN 2007, allows the identifica-
tion of visceral and subcutaneous trunk fat.
In our analysis, we separate patients with lipoatrophy
from central fat accumulation or abdominal prominence
what is not always clear in previous papers. A significant
number of studies have subsumed analyses of lipoatro-
phy and lipohypertrophy under the term lipodystrophy
and therefore they may have failed to reveal associations
applying to one but not the other. And, adding to the
riddle is the lack of a consistent definition of lipodystro-
phy in the literature. We only compared our results with
previous studies that made the categorization between
lipoatrophy and central fat accumulation and not with
those which referred lipodystrophy.
Aiming at the elucidation of the relative contribution of
different risk factors – drugs, disease, and host – to fat re-
distribution, Lichtenstein reviewed large epidemiologic
OR (95% CI) OR (95% CI)* OR (95% CI)**
Crude Adjusted Adjusted
Age
<30 1 1 1
30-39 2.52 (0.31-20.46) 2.11 (0.25-17.56) 1.95 (0.25-16.85)
40-49 5.58 (0.72-43.50) 5.14 (0.65-40.94) 4.75 (0.57-39.41)
>49 11.31 (1.46-87.41) 10.77 (1.36-85.10) 9.82 (1.20-80.77)
Gender
Male 1 1 1
Female 1.71 (1.06-2.78) 1.78 (1.09-2.95) 1.66 (1.01-2.75)
HIV infection duration
≤3 1 1 1
4-9 2.60 (1.04-6.49) 2.72 (1.08-6.84) 2.65 (1.05-6.68)
≥10 2.22 (0.87-5.69) 2.19 (0.85-5.64) 2.31 (0.89-5.98)
cART duration
≤3 1 1 1
4-9 3.48 (1.73-7.02) 3.60 (1.78-7.29) 3.96 (1.92-8.16)
≥10 2.82 (1.31-6.11) 2.88 (1.33-6.27) 3.58 (1.60-8.00)
CD4
>200 1 1 1
≤200 1.23 (0.55-2.76) 1.30 (0.57-2.99) 1.24 (0.52-2.97)
PI 0.61(0.38-0.98) 0.54 (0.33-0.88) 0.53 (0.32-0.88)
NNRTI 1.37 (0.86-2.20) 1.51 (0.93-2.45) 1.51 (0.92-2.48)
NRTI 2.32 (0.28-19.15) 2.78 (0.33-23.68) 3.47 (0.38-31.29)
BMI 1.07 (1.02-1.12) 1.08 (1.03-1.13)) 1.10 (1.04-1.17)
Waist circumference 1.05 (1.03-1.07) 1.06 (1.04-1.08) 1.15 (1.09-1.21)
Hip circumference 0.99 (0.96-1.02) 0.09 (0.96-1.02) 0.87 (0.82-0.92)
Thigh circumference 1.00 (0.96-1.04) 1.00 (0.96-1.04) 0.94 (0.88-0.99)
% fat 1.03 (1.01-1.06) 1.03 (1.00-1.07) 0.98 (0.93-1.04)
kg fat 1.02 (1.00-1.05) 1.02 (0.99-1.05) 0.90 (0.83-0.96)
*odds ratio (OR) adjusted for gender and duration of treatment (with the exception of disease duration). **OR adjusted for gender, duration of treatment
and body mass index (BMI) (with the exception of disease duration). cART: combination antiretroviral therapy; PI: protease inhibitor; NNRTI: non-nucleoside
reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; CI: confidence interval.
Table 4 - Patients characteristics associated with mixed form of lipodystrophy.
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studies using multivariate analysis. In studies assessing
lipoatrophy, the most common statistically significant risk
factors were: use of specific nucleoside analogues, in-
creasing age, presence of markers of disease severity
(CD4/HIV RNA), duration of therapy and white race (17).
Also, in our patients, duration of therapy, in parallel with
length of HIV disease, were associated with lipoatrophy.
In studies assessing central fat accumulation the most com-
mon statistically significant risk factors were duration of
therapy, markers of disease severity, and protease inhibitor
use. Bonfaty also showed an increasing relation between
the number of years of therapy and lipoatrophy, howev-
er, he found no relation between central fat accumulation
and duration of ART (37). In our results, lesser duration of
the disease and treatment were associated with central fat
accumulation. In what concern gender, men had a signif-
icantly lower adjusted risk of presenting with any alteration
than women and a significantly lower risk of central fat ac-
cumulation and mixed fat redistribution, whereas risk of
lipoatrophy was similar between genders (17). Female gen-
der was positively associated with central fat accumulation
and negatively with lipoatrophy. Like us, also Shevitz found
that central fat accumulation was associated with female
gender and high BMI and fat depletion was associated
with low BMI (38). The risk of FM redistribution has been
associated with increase age. The physiological ageing
process also is linked to body-fat changes that may bias
the redistribution seen in HIV-1-infected patients (39). An
increase of FMmay be seen in both genders with increas-
ing ageing. Additionally, a redistribution of body fat in-
cluding a decrease in the size of lower limbs and an in-
crease in truncal FMmay be seen with ageing both in men
and women (40). Also, Lichtenstein found that fat accu-
mulation was associated with age, BMI gain, and viral sup-
pression and duration cART and suggests that lipoatrophy
is related to effective control of HIV-1 infection or use of
drugs (namely, stavudine, and indanavir) in patients with
more advanced HIV-1 disease and fat accumulation was
associated with several correlates of immunologic recovery
(24). With regard to the influence of HIV disease itself,
there is certainly evidence that a nadir CD4+ T-cell count
of <100×106 L–1 is associated with increased risk of lipoa-
trophy while on treatment, irrespective of the virological
or immunological response to therapy (41). Lichtenstein
concluded that rigorous multivariate analysis controlling
for numerous variables reveal multiple risk factors, sug-
gesting that the pathogenic mechanisms for fat redistri-
bution are likely the result of complex interactions between
host, disease, and drug factors (17).
We observed that injecting drug users had a low preva-
lence of isolated central fat accumulation and mixed
forms and a high prevalence of lipoatrophy. The lipoat-
rophy could be explain by the fact of these patients be-
ing diagnosed for a long time and used older agents of
OR (95% CI) OR (95% CI)* OR (95% CI)**
Crude Adjusted Adjusted
Age
<30 1 1 1
30-39 0.47 (0.16-1.40) 0.61 (0.19-1.93) 0.70 (0.21-2.40)
40-49 0.32 (0.11-0.96) 0.41 (0.13-1.29) 0.43 (0.13-1.47)
>49 0.18 (0.06-0.59) 0.21 (0.06-0.70) 0.29 (0.08-1.06)
Gender
Male 1 1 1
Female 0.42 (0.20-0.88) 0.41 (0.19-0.88) 0.44 (0.20-0.96)
HIV infection duration
≤3 1 1 1
4-9 0.54 (0.25-1.15) 0.51 (0.23-1.10) 0.42 (0.19-0.95)
≥10 0.22 (0.09-0.55) 0.22 (0.09-0.55) 0.14 (0.05-0.37)
cART duration
≤3 1 1 1
4-9 0.41 (0.22-0.79) 4.18 (1.69-10.34) 0.36 (0.18-0.71)
≥10 0.25 (0.10-0.61) 1.66 (0.68-4.06) 0.17 (0.06-0.43)
CD4
>200 1 1 1
≤200 1.52 (0.59-3.88) 1.32 (0.50-3.49) 1.33 (0.47-3.75)
PI 1.24 (0.68-2.29) 1.35 (0.72-2.53) 1.28 (0.68-2.44)
NNRTI 0.94 (0.51-1.72) 0.92 (0.50-1.71) 0.98 (0.52-1.86)
NRTI 0.44 (0.09-2.26) 0.35 (0.06-1.98) 0.34 (0.05-2.25)
BMI 0.87 (0.80-0.94) 0.83 (0.76-0.91) 0.83 (0.76-0.91)
Waist circumference 0.93 (0.90-0.96) 0.91 (0.87-0.94) 0.51 (0.79-0.92)
Hip circumference 0.97 (0.94-1.01) 0.96 (0.92-1.00) 1.11 (1.03-1.20)
Thigh circumference 0.96 (0.91-1.01) 0.95 (0.89-1.00) 1.02 (0.96-1.09)
% fat 0.93 (0.90-0.97) 0.93 (0.89-0.97) 1.02 (0.94-1.10)
kg fat 0.91 (0.86-0.95) 0.90 (0.85-0.95) 0.95 (0.85-1.06)
*odds ratio (OR) adjusted for gender and duration of treatment (with the exception of disease duration). **OR adjusted for gender, duration of treatment
and body mass index (BMI) (with the exception of disease duration). cART: combination antiretroviral therapy; PI: protease inhibitor; NNRTI: non-nucleoside
reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; CI: confidence interval.
Table 5 - Patients characteristics associated with no lipodystrophy.
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cART, that were associated with greater toxicity. The low-
er prevalence of central fat accumulation, probably has to
do with nutritional factors, since many times the food in-
take in these patients is poor, and even some inject drugs
may be central anorexiant.
In our data, the CD4 count increased progressively from
the phenotype “no lipodystrophy” to “isolated central
fat accumulation”, to “lipoatrophy” and by the end to
“mixed forms of lipodystrophy”. Patients with longer
treatment, tend to have higher CD4 counts. Alternative-
ly, that may also be associated with the robustness of the
imumnological recovery itself.
In what concern the results of BIA, the mixed forms of
lipodystrophy are in fact a mixture between the lipoat-
rophy and central fat accumulation phenothypes. As it
happens in the patients with isolated central fat accu-
mulation, the patients with mixed forms of lipodystrophy
were more frequently women, had a higher BMI and WC,
but on the other hand they are more like patients with
lipoatrophy since, the mixed forms of lipodystrophy were
also associated a more time of disease and length of
treatment but lower hip and thigh circumference and low-
er fat mass evaluated by BIA. In what concern patients
with no lipodsytrophy, the results are almost the opposite
to the mixed forms of lipodystrophy.
Strengths
The results of BIA demonstrate an increase in FM in pa-
tients with isolated central fat accumulation and mixed
forms, an objective way to evaluate body fat. Patients with
lipoatrophy and no lipodystrophy had lower FM. Howev-
er, the FFM is similar among the 4 groups. This picture of
body composition is not possible to have with anthro-
pometry.
As all participants were treated with cART we excluded
any bias resulting from this risk factor for lipodystrophy.
Conclusions
In HIV-infected patients treated with cART for a long pe-
riod of time there were no differences between the 4
phenotypes of patients (no lipodystrophy, isolated cen-
tral fat accumulation, lipoatrophy, and mixed forms of
lipodystrophy) in FFM and TBW, however, patients with
AP (with and without lipoatrophy) had significantly high-
er FM, using BIA. The similar FFM along the fat distribu-
tion spectrum describes the actual body composition of
these patients and excludes sarcopenia. In a clinical set-
ting, BIA is an easy and useful tool to evaluate FM and
the amount of FFM and gives us a picture of body com-
position that was not possible with anthropometry.
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Impact of Lipodystrophy on the prevalence and
components of metabolic syndrome in HIV-
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Abstract
Background: In HIV-infected patients, combination antiretroviral therapy (cART) is associated with clinical lipodystrophy
(CL) and metabolic abnormalities (MA). This study aimed to evaluate the prevalence of the metabolic syndrome (MS)
and its components, and to determine whether patients with or without CL had a different prevalence of MA.
Methods: We evaluated 345 HIV-infected patients on cART using two different MS definitions (NCEP-ATPIII-2005
and IDF-2005) and the Framingham risk score.
Results: CL was present in 58.7% of the patients. The prevalence of the MS was 52.2% (ATPIII) and 43.2% (IDF), and
it was not significantly different between patients with (W) or without (WT) CL, regardless of the definition used
(ATPIII WCL 52.9% vs WT CL 51.1%; p = 0.738; IDF WCL 41.3% vs WTCL 46.0%; p = 0.379). Moderate concordance
was observed between the 2 definitions (kappa = 0.484; p < 0.001) and after gender stratification there was good
concordance in women (kappa = 0.759; p < 0.001). Patients with CL had lower waist circumference and HDL-C and
higher triglycerides levels. In women, CL was significantly associated with MS, hypertriglyceridemia and low HDL
cholesterol independently of age, cART and BMI. Patients with CL had a significantly higher risk of coronary heart
disease at 10 years, measured by the Framingham risk score, than patients without CL. Those with CL and with MS
had higher frequencies of moderate and high risk categories than those without MS.
Conclusions: The prevalence of the MS was high in these HIV-infected patients with an age average of 40 years
and this finding could explain why HIV patients have an increased risk for cardiovascular disease (CVD).
Keywords: Metabolic syndrome, Cardiovascular Risk, Lipodystrophy, HIV infection
Background
Combination antiretroviral therapy (cART) has changed
the course of HIV infection, leading to a significant
reduction in AIDS related morbidity and mortality [1].
However, cART is known to be associated with changes
in fat distribution (lipodystrophy) and metabolic abnorm-
alities, including insulin resistance, dyslipidemia, and
increased blood pressure (BP) [2,3].
The Metabolic syndrome (MS), a common condition in
the general population, refers to a constellation of
cardiovascular disease (CVD) risk factors, including
increased waist circumference (WC), glucose and lipid
metabolism disorders, and hypertension [4,5]. Each of
these risk factors individually increases cardiovascular
risk, but the MS itself has shown to be a powerful inde-
pendent risk factor for cardiovascular morbi-mortality
and diabetes [6]. It is still controversial if the MS
improves the identification of high risk individuals [7-9].
HIV-infected lipodystrophic patients share several com-
ponents of the MS. The prevalence of the MS in HIV-
infected patients has been reported to range from 4.4 to
45.4% [9-23].
HIV-lipodystrophy is considered to be an adverse
effect of cART, not limited to a specific drug or class of
drugs [24]. It seems to affects up to half or even more
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HIV-infected patients receiving cART [25]. However,
few studies address the prevalence of the MS in patients
with lipodystrophy [12,14,17].
The aim of this study was to evaluate the prevalence
of the MS and of its five individual components in HIV-
infected patients on cART and to determine whether
patients with or without CL had a different prevalence
of MA.
Methods
Subjects
As part of a cross-sectional study, 345 non-institutiona-
lized, HIV-infected Caucasian adults (239 males), on
cART referred from the Infectious Diseases to the Endo-
crinology Out-patient Clinic of Hospital São João due to
lipodystrophy or any metabolic disorders were included.
Only patients on cART were included, since lipodystrophy
is mainly related to ART drugs. The study protocol was
approved by the Hospital’s Ethical Committee and all
patients provided informed consent.
Clinical assessment
For each patient the following information was collected,
using a standardized protocol: demographic data (age,
gender), duration of HIV infection, history of diabetes,
hypertension, use of antidiabetic, antihypertensive or lipid-
lowering drugs and duration of cART. Weight, height,
WC and resting BP were measured as previously described
[26]. Body weight was measured using TANITA (Tanita®,
model TBF 300) scale and height was measured to the
nearest centimetre in the standing position using a wall
stadiometer (Holtain Limited Crymych, Dyfed®).
Clinical lipodystrophy (CL) and central fat accumulation
or abdominal prominence, were defined as previously
described [27]. All clinical assessments were performed by
the same practitioner (PF). Patients were classified in 4 dif-
ferent groups according to the presence or absence of
either lipoatrophy or abdominal prominence: group 1- No
lipodystrophy (patients without clinical lipoatrophy and
without abdominal prominence); group 2- Isolated cen-
tral fat accumulation (patients without clinical lipoatro-
phy and with abdominal prominence); group 3- Isolated
lipoatrophy (patients with clinical lipoatrophy and with-
out abdominal prominence); group 4- Mixed forms of
lipodystrophy (patients with clinical lipoatrophy and with
abdominal prominence).
A venous blood sample was drawn after a 12-hour over-
night fast. All the samples were analyzed at the central
laboratory of our hospital. Plasma glucose, total choles-
terol, HDL cholesterol (HDL-C) and triglycerides were
determined using automatic standard routine enzymatic
methods. Hepatitis C was diagnosed by HCV-Ab serosta-
tus. The CD4+ cell count was determined by flow
cytometry and plasma RNA-VIH was measured by a
quantitative reverse transcriptase polymerase chain reac-
tion, which had a lower limit of detection of 50 copies/mL.
Metabolic Syndrome definitions
Two different MS definitions were used: the Third Report
of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (ATPIII) modified by
American Heart Association/National Heart, Lung, and
Blood Institute Scientific Statement (AHA/NHLBI) in
2005 [28] and the International Diabetes Federation (IDF)
definition [29].
The Framingham cardiovascular risk score was calcu-
lated for all patients using the Framingham methodology
as reported by Wilson. It incorporates age, gender, systolic
blood pressure, lipids, glucose, and smoking status into a
model that predicts the probability of coronary heart dis-
ease risk at 10 years [30].
Statistical analysis
Data were presented as mean and standard deviation (SD)
for quantitative variables when normally distributed.
When the variable distribution was different than the nor-
mal, it was expressed as median and respective 25th and
75th percentiles. For comparison between quantitative
variables Student-t test and the Mann-Whitney test were
used when appropriate. Categorical variables were
described as counts and proportions, and compared using
the chi-square or Fisher’s exact test. Kappa coefficients
were estimated to analyze the statistical agreement
between ATP III as modified by the AHA/NHLBI and IDF
definitions of MS.
Odds ratios and their respective 95% confidence inter-
vals (CI) were computed using unconditional logistical
regression models. The association between lipodystrophy
and the presence of MS and its individual components
was estimated after adjustment for sex, age, cART dura-
tion and BMI, whenever appropriate.
Statistical analysis was performed using the SPSS version
17.0 software (SPSS Inc., Chicago, Illinois, USA). All prob-
abilities were two tailed and p values < 0.05 were regarded
as significant.
Results
Of the 345 HIV-1 infected patients on cART included in
this study, 58.7% presented CL. Table 1 shows the charac-
teristics of the study sample according to the presence of
CL. Patients with CL were more frequently male, older,
had longer duration of infection, longer duration of cART
and lower weight, BMI and WC. Also, this group of
patients had significantly higher CD4+ cell counts and a
significantly higher prevalence of virological suppression.
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Table 1 Sample characteristic according to the presence of clinical lipodystrophy
Without CL With CL P
n (%) 139 (39.6) 206 (58.7)
Sex [n(%)]
Male 85 (61.2) 154 (74.8) 0.007
Female 54 (38.8) 52 (25.2)
Age [years, median (25th and 75th percentiles)] 42.0 (34.0-51.0) 45.0 (39.0-54.0) 0.006
Duration of HIV infection [years, median (25th and 75th percentiles)] 6.0 (4.0-9.0) 9.0 (6.0-11.0) < 0.001
cART [years, median (25th and 75th percentiles)] 4.0 (2.0-7.0) 8.0 (5.0-10.0) < 0.001
Weight [Kg, mean (sd)] 73.6 (14.1) 66.2 (12.4) < 0.001
Height [m, mean (sd)] 1.65 (0.09) 1.66 (0.09) 0.430
BMI [(kg/m2), mean (sd)] 27.0 (5.0) 24.0 (3.9) < 0.001
Waist circumference [cm, mean (sd)] 95.4 (13.0) 89.5 (10.5) < 0.001
Systolic BP [mmHg, median (25th and 75th percentiles)] 120.0 (110.0-135.0) 120.0 (110.0-135.0) 0.871
Diastolic BP [mmHg, median (25th and 75th percentiles)] 80.0 (70.0-80.0) 80.0 (70.0-80.0) 0.765
CD4 cell count [cells/mm3, median (25th and 75th percentiles)] 446.5 (291.5-633.8) 544.0 (362.0-749.0) 0.008
HIV RNA (< 50) [n (%)] 94 (82.5) 163 (91.1) 0.029
Hepatitis C co-infection [n (%)] 31 (25) 58 (31.4) 0.227
HIV risk factor [n (%)]
Intravenous drug user 28 (24.6) 52 (30.6)
Homosexual contact 10 (8.8) 19 (11.2)
Heterosexual contact 75 (65.8) 90 (52.9)
Others 1 (0.9) 9 (5.3) 0.073
CDC [n (%)]
A 62 (54.9) 94 (53.4)
B 4 (3.5) 0 (0.0)
C 47 (41.6) 82 (46.6) 0.037
ART [n (%)]
IP 67 (61.5) 98 (55.4) 0.310
NNRTI 47 (43.1) 83 (46.9) 0.534
NRTI 104 (95.4) 175 (98.9) 0.066
Smoking history [n (%)]
Never 60 (43.5) 70 (34.8)
Current 56 (40.6) 93 (46.3)
Former 22 (15.9) 38 (18.9) 0.272
Glucose [mg/dL, median (25th and 75th percentiles)] 91.0 (84.0-108.0) 94.5 (863.0-117.0) 0.074
Total cholesterol [mg/dL, mean (sd)] 229.5 (59.8) 220.7 (59.5) 0.182
HDL- cholesterol [mg/dL, median (25th and 75th percentiles)] 48.0 (37.0-55.0) 43.0 (35.0-53.0) 0.047
Triglycerides [mg/dL, median (25th and 75th percentiles)] 192.0 (126.0-323.0) 231.0 (149.8-365.8) 0.016
Metabolic syndrome ATP III [n (%)] 71 (51.1) 109 (52.9) 0.738
Metabolic syndrome IDF [n (%)] 64 (46.0) 85 (41.3) 0.379
Metabolic syndrome features - ATP III
High blood pressure 61 (43.9) 87 (42.4) 0.790
Hypertriglyceridemia 98 (70.5) 177 (85.9) < 0.001
Low HDL cholesterol 93 (66.9) 160 (77.7) 0.027
High waist circumference 58 (41.7) 46 (22.3) < 0.001
High fasting glucose 51 (36.7) 84 (40.8) 0.446
Number of metabolic syndrome features ATP III
0 6 (4.3) 9 (4.4) 0.242
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No significant differences in HIV risk factors or in cART
regimen composition were found between patients with or
without CL. The prevalence of hepatitis C co-infection
was 28.8%, without significant differences between patients
with or without CL. No significant differences were found
in smoking history (never, current or former) between
patients with or without CL, however, patients who were
current smokers had the highest frequency of low and
normal weight and those who never smoked had the high-
est frequency of overweight and obesity (data not shown).
No significant difference was found in fasting glucose
according to smoking history (data not shown). According
to the presence of CL, no differences were found in systo-
lic and diastolic BP, glucose and total cholesterol levels.
However, patients with CL had lower HDL-C and higher
triglycerides plasma levels (Table 1).
Regarding BMI distribution, men and women with CL,
were more frequently classified as normal when com-
pared to those without CL. Those without CL were
more frequentely classified as overweight (Table 2).
Metabolic syndrome
In our sample, the prevalence of MS was 52.2% and
43.2%, according to ATPIII and IDF criteria, respectively.
No significant differences in the prevalence of the MS
were observed in patients with or without CL, regardless
of the definition used (table 3). Moderate concordance
was observed between the 2 definitions (kappa = 0.484;
p < 0.001). After gender stratification, moderate agree-
ment was observed in men (kappa = 0.374; p < 0.001),
and good agreement in women (kappa = 0.759; p <
0.001). Using both MS criteria, no significant differences
in the prevalence of CL were found between patients
with and without MS [[with MS 60.6% (109 patients) vs
without MS 58.8% (97 patients); p = 0.822 for ATPIII]
and [with MS 57.0% (85 patients) vs without MS 61.7%
Table 1 Sample characteristic according to the presence of clinical lipodystrophy (Continued)
1 25 (18.0) 19 (9.3)
2 37 (26.6) 69 (33.7)
3 31 (22.3) 52 (25.4)
4 31 (22.3) 42 (20.5)
5 9 (6.5) 14 (6.8)
Metabolic syndrome features - IDF
High blood pressure 61 (43.9) 87 (42.4) 0.790
Hypertriglyceridemia 98 (70.5) 177 (85.9) < 0.001
Low HDL cholesterol 93 (66.9) 160 (77.7) 0.027
High waist circumference 87 (62.6) 94 (45.6) 0.002
High fasting glucose 51 (36.7) 80 (38.8) 0.687
Number of metabolic syndrome features IDF
0 5 (3.6) 9 (4.4) 0.263
1 19 (13.7) 17 (8.3)
2 35 (25.2) 51 (24.9)
3 32 (23.0) 63 (30.7)
4 35 (25.2) 39 (19.0)
5 13 (9.4) 26 (12.7)
Note - CL = Clinical lipodystrophy, MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; BMI = body mass index.
Table 2 BMI by gender and clinical lipodystrophy
Men Women
BMI
[kg/m2, (n (%)]
Without CL With CL Without CL With CL
< 18.5 1 (1.2) 9 (5.8) 0 (0.0) 8 (15.4)
≥18.5 and < 25 38 (44.7) 88 (57.1) 16 (30.2) 25 (48.1)
≥25 and < 30 31 (36.5) 47 (30.5) 20 (37.7) 15 (28.8)
≥30 15 (17.6) 10 (6.5) 17 (32.1) 4 (7.7)
p value 0.009 < 0.001
Note - CL = Clinical lipodystrophy; BMI = body mass index.
Table 3 Metabolic syndrome prevalence according to ATP
III and IDF criteria in the total of patients and by gender
and presence of clinical lipodystrophy
MS Criteria Total of patients Without CL With CL P
ATP III [n, (%)]
Total 180 (52.2%) 71 (51.1%) 109 (52.9%) 0.738
Men 130 (54.4%) 46 (54.1%) 84 (54.5%) 0.949
Women 50 (47.2%) 25 (46.3%) 25 (48.1%) 0.854
IDF [n, (%)]
Total 149 (43.2%) 64 (46.0%) 85 (41.3%) 0.379
Men 88 (36.8%) 36 (42.4%) 52 (33.8%) 0.188
Women 61 (57.5%) 28 (51.9%) 33 (63.5%) 0.227
Note - CL = Clinical lipodystrophy MS = Metabolic syndrome; ATPIII = Third
Report of the National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF
= International Diabetes Federation; BMI = body mass index.
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(121 patients); p = 0.442 for IDF]]. No significant differ-
ences according to gender and presence of CL were
observed regarding the prevalence of the MS (Table 3).
However, men and women with lipodystrophy had a sig-
nificantly different prevalence of the MS when stratified
by BMI classes, regardless the criteria used to define the
MS (Table 4). Men and women with CL presented a sig-
nificantly higher prevalence of the MS in the normal and
underweight class (Table 4). A significantly higher preva-
lence of hypertriglyceridemia, low HDL-C levels and
lower prevalence of abdominal obesity were observed in
patients with CL. No differences were found in the num-
ber of the MS features according to ATPIII and IDF cri-
teria in patients with and without CL (Table 1).
Regarding the aggregate of the MS criteria using the
ATP definition, the most frequent aggregate number was
2, except for men without CL. On the other hand, using
the IDF definition, the most frequent aggregate number
was 3, except for women without CL (table 5 and 6). No
significant increase of MS prevalence with age was
observed in patients with or without CL (data not shown).
Concerning the frequency of the individual ATPIII cri-
teria for MS, we found a significantly lower prevalence
of central obesity in men with CL and no other signifi-
cant differences were observed. No significant differ-
ences were found in the frequency of the five IDF
criteria for the MS in men (table 5).
In women with CL, using either ATPIII or IDF cri-
teria, we found a statistically higher frequency of hyper-
triglyceridemia and lower HDL-C levels. According to
ATPIII criteria, women with CL had a lower frequency
of central obesity (Table 6).
No significant differences were found between the
cumulative number MS features according to the pre-
sence of CL in both genders (Table 5 and 6).
In men, high blood pressure, high WC and the MS
were more frequent in those with isolated central fat
accumulation and mixed forms of lipodystrophy using
either ATPIII or IDF criteria. High fasting glucose levels
were significantly more frequent in patients with isolated
central fat accumulation and mixed forms of lipodystro-
phy using ATPIII criteria and without any differences
(p = 0.058) in the 4 groups of fat distribution using the
IDF criteria (table 7).
In women, no significant differences were found in high
blood pressure and high fasting glucose levels in the four
groups of fat distribution (either ATPIII or IDF criteria).
Hypertriglyceridemia, low C-HDL levels, high waist cir-
cumference and presence of the MS were more frequent
in patients with isolated central fat accumulation and
mixed forms of lipodystrophy using either ATPIII or IDF
criteria (table 8).
Men and women with CL, after adjustment for age and
cART, had significantly lower odds of having central obe-
sity, as defined by the ATPIII criteria [OR = 0.403 (95%
CI: 0.187-0.865) and OR = 0.306 (95%CI: 0.118-0.796),
respectively].
In women, CL was significantly associated with higher
odds of having MS as defined by IDF [OR = 5.290 (95%
CI: 1.502-18.635)], hypertriglyceridemia [OR = 5.917
(95%CI: 1.50-23.349)] and low HDL cholesterol [OR =
3.990 (95%CI:1.252-12.716)], independently of age,
cART and BMI (tables 9 and 10).
No significant differences were found in the five
classes of the Framingham risk score between patients
with or without CL (data not shown).
Patients with CL had a significantly higher median risk
of coronary heart disease at 10 years, measured by the
Framingham risk score, than patients without CL, [med-
ian (25th and 75th percentile) = 7.00 (4.00-14.00) and
6.00 (4.00-11.00); p = 0.049]. Independent of the pre-
sence of CL, those with MS had a higher median of the
Framingham risk score. In patients without CL, those
with MS had a higher Framingham risk score median
than those without MS, [median (25th and 75th percen-
tile) = 7.00 (4.00-12.50) and 6.00 (3.00-9.00); p = 0.007].
Also, in patients with CL, those with MS, had a higher
Framingham risk score than those without MS, [median
(25th and 75th percentile) = 9.00 (6.00-18.00) and 6.00
(4.00-9.00); p < 0.001].
In patients with CL, we found significant differences
in the Framingham risk score classes between patients
with or without MS. Patients with CL and with MS had
higher frequencies of moderate and high risk categories
than those without MS (table 11).
Table 4 MS prevalence by BMI, gender and clinical
lipodystrophy according to ATPIII criteria and IDF
Men Women
Without CL With CL Without CL With CL
ATPIII criteria
Classes of BMI
[kg/m2; (n (%)]
< 25 14 (30.4%) 41 (48.8%) 3 (12.5%) 11 (44.0%)
≥25 < 30 19 (41.3%) 33 (39.3%) 9 (37.5%) 10 (40.0%)
≥30 13 (28.3%) 10 (11.9%) 12 (50.0%) 4 (16.0%)
p value 0.002 < 0.001 0.012 0.008
IDF criteria
< 25 4 (11.1%) 11 (21.2%) 5 (18.5%) 16 (48.5%)
≥25 < 30 18 (50.0%) 32 (61.5%) 10 (37.0%) 13 (39.4%)
≥30 14 (38.9%) 9 (17.3%) 12 (44.4%) 4 (12.1%)
p value < 0.001 < 0.001 0.084 0.012
Note - CL = Clinical lipodystrophy; MS = Metabolic syndrome; ATPIII = Third
Report of the National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF
= International Diabetes Federation; BMI = body mass in
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Discussion
To our knowledge, this is the first study conducted in
HIV-infected patients focusing specifically on the role of
subcutaneous adipose tissue atrophy defined by presence
of CL on the prevalence of the MS. Another particular-
ity is that all patients were on cART. Other studies ana-
lysed the presence of the MS in naïve or on cART HIV-
infected patients, with sub-analyses concerning the pre-
sence of CL in patients with the MS [12,14,17].
cART can induce a large spectrum of metabolic distur-
bances. On the other hand, lipodystrophy per se, including
genetic lipodystrophy syndromes, is associated with lipid
and metabolic disturbances, and hasmany similarities with
the MS [2,31-35]. The effect of cART on the molecular
processes of metabolic disturbances has been extensively
studied [36] and its contribution to an increased risk of
premature and accelerated atherosclerosis in HIV infec-
tion is well recognized [37,38]. Our aim was to determine
the different patterns of metabolic alterations in patients
with or without lipodystrophy.
It is unknown if the MS is more frequent in patients
with lipodystrophy compared to either with patients
without lipodystrophy and not HIV-infected [9,17]. We
found a higher prevalence of MS compared with some
studies [9,10,12-23] but similar to another [11]. We
included all patients referred from the Infectious Diseases
Table 5 Frequency of each criterion of MS according to ATP III and IDF in men with and without clinical lipodystrophy
Men
ATPIII IDF
MS criteria Total Without CL With CL p value Total Without CL With CL p value
WC [n, (%)] 43 (18.0%) 21 (24.7%) 22 (14.3%) 0.045 98 (41.0%) 42 (49.4%) 56 (36.4%) 0.050
TG [n, (%)] 197 (82.4%) 65 (76.5%) 132 (85.7%) 0.072 197 (82.4%) 65 (76.5%) 132 (85.7%) 0.072
HDL [n, (%)] 181 (75.7%) 62 (72.9%) 119 (77.3%) 0.455 181 (75.7%) 62 (72.9%) 119 (77.3%) 0.455
BP [n, (%)] 111 (46.6%) 41 (48.2%) 70 (45.8%) 0.713 111 (46.6%) 41 (48.2%) 70 (45.8%) 0.713
GLU [n, (%)] 107 (44.8%) 35 (41.2%) 72 (46.8%) 0.407 103 (43.1%) 35 (41.2%) 68 (44.2%) 0.656
Number of MS criteria
0 8 (3.3) 3 (3.5) 5 (3.3) 8 (3.4) 3 (3.5) 5 (3.3)
1 29 (12.1) 15 (17.6) 14 (9.2) 24 (10.1) 11 (12.9) 13 (8.5)
2 72 (30.1) 21 (24.7) 51 (33.3) 60 (25.29 19 (22.4) 41 (26.8)
3 67 (28.5) 23 (27.1) 44 (28.8) 70 (29.4) 22 (25.9) 48 (31.4)
4 48 (20.1) 17 (20.0) 31 (20.3) 48 (20.2) 20 (23.5) 28 (18.3)
5 14 (5.9) 6 (7.1) 8 (5.2) 0.411 28 (11.8) 10 (11.8) 18 (11.8) 0.718
Note - CL = Clinical lipodystrophy MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; WC = waist circumference; TG = triglycerides; HDL = HDL
cholesterol; BP = blood pressure; GLU = glucose.
Table 6 Frequency of each criterion of MS according to ATP III and IDF in women with and without clinical
lipodystrophy
Women
ATPIII IDF
MS criteria Total Without CL With CL p Total Without CL With CL p
WC [n, (%)] 61 (57.5%) 37 (68.5%) 24 (46.2%) 0.020 83 (78.3%) 45 (83.3%) 38 (73.1%) 0.200
TG [n, (%)] 78 (73.6%) 33 (61.1%) 45 (86.5%) 0.003 78 (73.6%) 33 (61.1%) 45 (86.5%) 0.003
HDL [n, (%)] 72 (67.9%) 31 (57.4%) 41 (78.8%) 0.018 72 (67.9%) 31(57.4%) 41 (78.8%) 0.018
BP [n, (%)] 37 (34.9%) 20 (37.0%) 17 (32.7%) 0.639 37 (34.9%) 20 (37.0%) 17 (32.7%) 0.639
GLU [n, (%)] 28 (26.4%) 16 (29.6%) 12 (23.1%) 0.444 28 (26.4%) 16 (29.6%) 12 (23.1%) 0.444
Number of MS criteria
0 7 (6.6) 3 (5.6) 4 (7.7) 0.680 6 (5.7) 2 (3.7) 4 (7.7) 0.214
1 15 (14.2) 10 (18.5) 5 (9.6) 12 (11.3) 8 (14.8) 4 (7.7)
2 34 (32.1) 16 (29.6) 18 (34.6) 26 (24.5) 16 (29.6) 10 (19.2)
3 16 (15.1) 8 (14.8) 8 (15.4) 25 (23.6) 10 (18.5) 15 (28.8)
4 25 (23.6) 14 (25.9) 11 (21.2) 26 (24.5) 15 (27.8) 11 (21.2)
5 9 (8.5) 3 (5.6) 6 (11.5) 11 (10.4) 3 (5.6) 8 (15.4)
Note - CL = Clinical lipodystrophy MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; WC = waist circumference; TG = triglycerides; HDL = HDL
cholesterol; BP = blood pressure; GLU = glucose.
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Department to our Endocrinology Out-patient Clinic for
metabolic abnormalities, but we cannot exclude the
selection bias by the infectious disease specialist. We
found a high prevalence of lipodystrophy but there was
no selection bias for the presence of isolated lipoatrohy
or abdominal prominence. Since our main goal was to
evaluate whether the presence of lipodystrophy influ-
ences MA, only patients on cART were included. The
high MS prevalence may reflect the fact that all the
patients were on cART. Another important fact is the
low prevalence of intravenous drug users in our study
(24.6% in patients without CL and 30.6% in patients with
CL) compared with Jericó study (41.3%), which con-
curred on the low prevalence of abdominal obesity.
Studies of prevalence of MS in HIV-infected indivi-
duals compared with control populations revealed differ-
ent prevalences of MS) [9-23] and it also seems to be
higher than the 22 to 24% prevalence rate reported for
the general US population [39]. Other data suggest that
the increased prevalence of MS among HIV-infected
persons may be reflective of the burgeoning epidemic of
obesity than a predominant effect of cART [40]. Cigar-
ette smoking analysis could be important because of its
frequent association with lower BMI and higher glucose
Table 7 Metabolic syndrome and its individual components according the four different groups of fat distribution in
men
Four different groups of fat distribution
[n (%)] No
lipodystrophy
Isolated central
fat accumulation
Isolated
lipoatrophy
Mixed forms
of lipodystrophy
P
ATP III
High blood pressure 17 (39.5) 24 (57.1) 36 (37.1) 33 (60.0) 0.017
Hypertriglyceridemia 32 (74.4) 33 (78.6) 79 (81.4) 52 (92.9) 0.086
Low HDL cholesterol 29 (67.4) 33 (78.6) 74 (76.3) 44 (78.6) 0.563
High waist circumference 0 (0.0) 21 (50.0) 0 (0.0) 22 (39.3) < 0.001
High fasting glucose 13 (30.2) 22 (52.4) 40 (41.2) 32 (57.1) 0.035
Metabolic syndrome 16 (37.2) 30 (71.4) 43 (44.3) 40 (71.4) < 0.001
IDF
High blood pressure 17 (39.5) 24 (57.1) 36 (37.1) 33 (60.0) 0.017
Hypertriglyceridemia 32 (74.4) 33 (78.6) 79 (81.4) 52 (92.9) 0.086
Low HDL cholesterol 29 (67.4) 33 (78.6) 74 (76.3) 44 (78.6) 0.563
High waist circumference 0 (0.0) 42 (100.0) 0 (0.0) 56 (100.0) < 0.001
High fasting glucose 13 (30.2) 22 (52.4) 38 (39.2) 30 (53.6) 0.058
Metabolic syndrome 0 (0.0) 36 (85.7) 0 (0.0) 52 (92.9) < 0.001
Table 8 Metabolic syndrome and its individual components according the four different groups of fat distribution in
women
Four different groups of fat distribution
[n (%)] No
lipodystrophy
Isolated central
fat accumulation
Isolated
lipoatrophy
Mixed forms
of lipodystrophy
P
ATP III
High blood pressure 1 (11.1) 19 (42.2) 2 (14.3) 15 (39.5) 0.110
Hypertriglyceridemia 4 (44.4) 29 (64.4) 8 (57.1) 37 (97.4) < 0.001
Low HDL cholesterol 5 (55.6) 26 (57.8) 8 (57.1) 33 (86.8) 0.021
High waist circumference 0 (0.0) 37 (82.2) 0 (0.0) 24 (63.2) < 0.001
High fasting glucose 2 (22.2) 14 (31.1) 1 (7.1) 11 (28.9) 0.335
Metabolic syndrome 0 (0.0) 25 (55.6) 1 (7.1) 24 (63.2) < 0.001
IDF
High blood pressure 1 (11.1) 19 (42.2) 2 (14.3) 15 (39.5) 0.110
Hypertriglyceridemia 4 (44.4) 29 (64.4) 8 (57.1) 37 (97.4) < 0.001
Low HDL cholesterol 5 (55.6) 26 (57.8) 8 (57.1) 33 (86.8) 0.012
High waist circumference 0 (0.0) 45 (100.0) 0 (0.0) 38 (100.0) < 0.001
High fasting glucose 2 (22.2) 14 (31.1) 1 (7.1) 11 (28.9) 0.348
Metabolic syndrome 0 (0.0) 28 (62.2) 0 (0.0) 33 (86.8) < 0.001
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levels, however, no significant difference was found in
smoking history (never, current or former) between
patients with or without CL. Also, no significant differ-
ence was found in fasting plasma glucose levels accord-
ing the smoking history.
In our sample, the prevalence of MS was lower using
the IDF definition compared to the ATPIII criteria
either in the total of the patients or in men with or
without CL. On the other hand, in women it was higher
when the IDF definition was used. This probably mir-
rors the fact that central obesity is a compulsory criter-
ion for the IDF definition, and, women had a higher
mean of WC. Since HIV patients despite lower WC had
increased visceral fat, Capeau J proposed that a different
WC cut-off is needed for HIV patients [34]. In fact, in
our data, patients with CL after adjustment for age and
cART had significantly lower odds of having central
obesity.
No differences in the prevalence of ATPIII or IDF
defined MS between patients with and without CL were
observed, like it was previously described by Estrada
[14]. In women, CL was significantly associated with
MS, hypertriglyceridemia and low HDL cholesterol inde-
pendently of age, cART and BMI. Analyzing the data
differently, Samaras showed that the prevalence of CL
was 57.2% in the total of patients, and 73% and 79% in
Table 9 Association between lipodystrophy and the metabolic syndrome and its individual components in men
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
MS ATP III 1.017 (0.598-1.731) 0.621 (0.324-1.191) 0.931 (0.460-1.884)
High waist circumference 0.508 (0.260-0.991) 0.403 (0.187-0.865) –
Hypertriglyceridemia 1.846 (0.940-3.624) 1.677 (0.782-3.600) 2.019 (0.899-4.531)
Low HDL cholesterol 1.261 (0.686-2.319) 1.116 (0.562-2.216) 1.304 (0.639-2.661)
High fasting glucose 1.254 (0.734-2.143) 1.004 (0.540-1.868) 1.256 (0.654-2.409)
High blood pressure 0.905 (0.532-1.540) 0.458 (0.223-0.939) 0.567 (0.270-1.191)
MS IDF 0.694 (0.402-1.196) 0.519 (0.274-0.985) 1.058 (0.473-2.365)
High waist circumference 0.585 (0.342-1.001) 0.491 (0.260-0.929) –
Hypertriglyceridemia 1.846 (0.940-3.624) 1.677 (0.782-3.600) 2.019 (0.899-4.531)
Low HDL cholesterol 1.261 (0.686-2.319) 1.116 (0.562-2.216) 1.304 (0.639-2.661)
High fasting glucose 1.130 (0.661-1.931) 0.940 (0.506-1.743) 1.143 (0.599-2.180)
High blood pressure 0.905 (0.532-1.540) 0.458 (0.223-0.939) 0.567 (0.270-1.191)
Model 1 - OR crude.
Model 2 - OR adjusted for gender, age and cART.
Model 3 - OR adjusted for gender, age, duration of cART and BMI.
Table 10 Association between lipodystrophy and the metabolic syndrome and its individual components in women
Modelo 1
OR (95% CI)
Modelo 2
OR (95% CI)
Modelo3
OR (95% CI)
MS ATP III 1.074 (0.501-2.303) 0.763 (0.298-1.952) 2.730 (0.810-9.194)
High waist circumference 0.394 (0.178-0.869) 0.306 (0.118-0.796) –
Hypertriglyceridemia 4.091 (1.557-10.750) 3.091 (1.063-8.989) 5.917 (1.50-23.349)
Low HDL cholesterol 2.765 (1.174-6.513) 2.308 (0.885-6.020) 3.990 (1.252-12.716)
High fasting glucose 0.713 (0.298-1.701) 0.560 (0.204-1.534) 0.758 (0.240-2.390)
High blood pressure 0.826 (0.371-1.839) 0.511 (0.177-1.474) 0.917 (0.273-3.078)
MS IDF 1.613 (0.742-3.507) 1.461 (0.572-3.736) 5.290 (1.502-18.635)
High waist circumference 0.543 (0.212-1.393) 0.385 (0.127-1.164) –
Hypertriglyceridemia 4.091 (1.557-10.750) 3.091 (1.063-8.989) 5.917 (1.500-23.349)
Low HDL cholesterol 2.765 (1.174-6.513) 2.308 (0.885-6.020) 3.990 (1.252-12.716)
High fasting glucose 0.713 (0.298-1.701) 0.560 (0.204-1.534) 0.758 (0.240-2.390)
High blood pressure 0.826 (0.371-1.839) 0.511 (0.177-1.474) 0.917 (0.273-3.078)
Model 1 - OR crude.
Model 2 - OR adjusted for gender, age and cART.
Model 3 - OR adjusted for gender, age, duration of cART and BMI.
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those with MS defined by respectively IDF and ATPIII
criteria [17]. In our patients, we did not find any signifi-
cant differences in the prevalence of lipodystrophy in
patients with and without MS, according to both cri-
teria. In the Jericó study, as in Samaras, lipodystrophy
was more common among MS participants (50.4 vs
33.8; p = 0.0001) [12], and Squillace, also found that CL
was strongly associated with MS [22].
In the Jericó and Mangili studies, the prevalence of MS
in HIV-infected patients significantly increased with age
[12]. In our sample, we did not observe any differences in
the distribution of MS prevalence according to age. This
may reflect the homogeneity of age strata in our sample,
when compared to other studies (only 12% of our sample
were 60 years or older).
Regarding gender differences, as in our study, Mangili
reported that significantly more women than men had
MS [10].
Concerning the number of MS components, in our
study and according to IDF definition, we had 25% of
patients with two features of MS which is lower when
compared to other studies [12,17]. In the Samara study,
49% of patients had at least two features of MS, namely
elevated lipid levels [17]. In the Jericó study, the MS pre-
valence was 17%, with 69.3% of patients showing one or
more features of MS, 35.8% two or more, 4.5% three or
more and 0.1% five features [12].
Concerning the prevalence of the individual features of
MS, we found that the two least prevalent features were
high fasting glucose level (similar to Bonfatti and Sobieszc-
zyk) [18,21] and high WC, the latter being the least preva-
lent in the patients with CL. Lipid abnormalities, namely
high triglyceride and low HDL-C levels, were present in all
HIV-infected patients [9,10,12,13,16,17] and also in CL
patients, the most prevalent components of MS. Obesity is
an important risk factor for MS in the general population
and in HIV-infected individuals [40]. We found a higher
prevalence of overweight and obesity among the patients
without CL. Although not proving causation, because of
the cross-sectional nature of the study design, we can
hypothesize that the high frequency of overweight and
obesity in patients without CL may contribute to the
observed absence of difference in the MS prevalence
between patients with or without CL. To clarify the rela-
tion between obesity and MS as well as the alterations in
the fat distribution, data was analysed according to the
presence or absence of either lipoatrophy or abdominal
prominence. In men, high blood pressure and MS were
more frequent in those with isolated central fat accumula-
tion and mixed forms of lipodystrophy (ATPIII and IDF
criteria) and high fasting glucose levels were significantly
more frequent in same two groups using ATPIII criteria.
In women, hypertriglyceridemia, low C-HDL levels, high
WC and presence of MS were more frequent in those
with isolated central fat accumulation and mixed forms of
lipodystrophy using either ATPIII or IDF criteria. The
observation that patients with CL had significantly higher
risk of coronary heart disease at 10 years, measured by the
Framingham risk score, than patients without CL and that
those with CL and with MS had higher frequencies of
moderate and high risk categories than those without MS
emphasizes the importance of the clinical diagnosis of this
condition. The higher risk of CHD at 10 years of HIV lipo-
dystrophic patients was previously reported by Ena [41]. In
the De Socio study, a correlation between the Framingham
risk score and MS was observed, and patients with lipody-
strophy had a higher Framingham risk score than patients
without lipodystrophy, suggesting that the presence of
lipodystrophy has metabolic implications equivalent to
those of MS [42].
Our study had some limitations. We did not exclude
patients with diabetes or hypertension diagnosed prior to
HIV infection. We also cannot discard the influence of
the pre-HIV body composition, the cumulative exposure
time of each drug and the nadir value of CD4 factors that
could contribute to the risk lipoatrophy or abdominal
prominence that were not evaluated. It is difficult to
compare results on the prevalence of MS because of the
heterogeneity in populations regarding past and actual
cART regimens and treatment adherence. Regarding the
CD4 count we only presented the values at the time of
the cross sectional evaluation, because we did not have
access to the nadir value. Finally, there exists the possibi-
lity of selection bias. Some subjects in this study were
referred from to Endocrinology Clinics specifically for
lipodystrophy or metabolic disorders related to cART,
Table 11 Framingham risk score according clinical lipodystrophy and metabolic syndrome
Without clinical lipodystrophy With clinical lipodystrophy
Framingham risk score Without MS With MS Total Without MS With MS Total
Low risk (< 5%) [n (%)] 27 (45.8) 20 (29.4) 47 (37.0) 36 (41.9) 23 (21.5) 59 (30.6)
Average (5%-9%) [n (%)] 21 (35.6) 22 (32.4) 43 (33.9) 31 (36.0) 31 (29.0) 62 (32.1)
Moderate risk (10-19%) [n (%)] 7 (11.9) 13 (19.1) 20 (15.7) 15 (17.4) 31 (29.0) 46 (23.8)
High risk (20-39%) [n (%)] 3 (5.1) 12 (17.6) 15 (11.8) 2 (2.3) 20 (18.7) 22 (11.4)
Very high risk (> 40%) [n (%)] 1 (1.7) 1 (1.5) 2 (1.6) 2 (2.3) 2 (1.9) 4 (2.1)
p 0.078 < 0.001
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and so we might have selected for a study population
enriched for metabolic complications.
Conclusions
In women, CL was significantly associated with the
metabolic syndrome, hypertriglyceridemia and low HDL
cholesterol independent of age, cART and BMI.
Our data showed that among HIV patients on cART,
the prevalence of MS may be remarkably high, especially
when taking into account the mean age of our sample.
The observation that patients with CL had a significantly
higher risk of coronary heart disease at 10 years, measured
by the Framingham risk score, than patients without CL
and those with CL and with MS had higher frequencies of
moderate and high risk categories than those with CL but
without MS, emphasizes the importance of the clinical
diagnosis of this condition.
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AbstrAct. background: combination antiretroviral 
therapy (cArt) is associated with lipodystrophy (li-
poatrophy and lipoaccumulation) and several meta-
bolic abnormalities that together can contribute to an 
increased cardiovascular risk. the aim of this study 
was to evaluate the prevalence of obesity in patients 
on cArt according to the presence of clinical lipodys-
trophy (cL) and to analyse factors associated with obe-
sity. Methods: We evaluated 368 HIV-infected adults on 
cArt. results:  cL was present in 59.0 %. Independent-
ly of gender, patients with cL were more frequently un-
derweight [5.7% (21/368)] and of normal weight [47.3% 
(174/368)], and less frequently overweight [33.2% 
(122/368)] or obese [13.9% (51/368)]. Mean bMI was 
higher in patients with abdominal prominence regard-
less of the presence of clinical lipoatrophy. Patients 
with cL had lower waist circumference, higher waist/
hip and fat mass ratio and lower total and subcutane-
ous fat, without significant difference in visceral fat but 
with a higher visceral/subcutaneous fat ratio, as evalu-
ated by ct at abdominal level. cL was significantly less 
frequent in overweight (Or=0.21, 95%cI: 0.05-0.92) 
and obese (Or= 0.05, 95%cI: 0.01-0.26) patients, when 
compared to underweight ones, independent of age, 
gender, duration of infection, cArt regimen, virologi-
cal suppression and HIV-infection risk factor. conclu-
sions: being overweight or obese is highly prevalent 
in HIV-infected patients on cArt. Patients with clinical 
lipodystrophy were more frequently under- or normally 
weighted, and less frequently overweighed or obese. 
Obesity is a condition that should be considered in HIV 
patients on cArt.
Key-words: Lipodystrophy; HIV, obesity, fat mass ratio, abdominal level CT
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InTRODUCTIOn
HIV disease and obesity are significant public 
health problems worldwide. In the early years of 
the HIV pandemic, the wasting syndrome (pro-
nounced loss of weight, with lean body and fat 
mass loss) was the hallmark of AIDS. The wide-
spread availability of combination antiretroviral 
therapy (cART), coming into clinical use in 996,
heralded a new era in the management of HIV in-
fection with high rates of suppressed viral rep-
lication, increased CD4+ T-cell counts, reduced 
incidence of wasting syndrome and dramatically 
decreased morbidity, and mortality (-9). Shortly 
after the introduction of cART, a syndrome con-
sisting of metabolic and body fat abnormalities 
was reported, appearing to be linked with cART 
use (0, ). This syndrome, lipodystrophy, in-
cluded peripheral fat loss (lipoatrophy) and central 
fat accumulation (lipohypertrophy or abdominal 
prominence), which could be present separately 
or in combination in the same individual (mixed 
forms). Usually, but not invariably, these features 
were associated with lipid abnormalities and insu-
lin resistance (0, ). From the initial description 
of lipodystrophy, it became apparent that its indi-
vidual components greatly overlapped with diag-
nostic criteria of the metabolic syndrome, a con-
stellation of abnormalities leading to an increased 
risk of cardiovascular disease and diabetes in the 
general population (2). HIV-infected patients 
have higher risk of cardiovascular (CV) disease, 
due to several factors, which include traditional 
CV risk factors, exposure to some antiretroviral 
drugs, inflammatory cytokines, leading to accel-
erated lipolysis, dyslipidemia, lipotoxic insulin re-
sistance, and vascular inflammation (3). Another 
factor that can contribute to the increased CV risk 
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in these patients is obesity (14-16). This condition 
is associated with a chronic, systemic state of in-
flammation that may contribute to CV diseases 
and other obesity-related comorbidities (17-19).
Although lipodystrophy in HIV-infected patients 
was first reported more than 10 years ago, the 
available information on obesity in HIV-infected 
patients is still scarce (10).
The aim of the current study was to evaluate the 
prevalence of obesity in patients on antiretroviral 
therapy according to the presence of clinical li-
podystrophy and analyse the factors associated 
with obesity.
METHODS
Subjects
As part of a cross-sectional study, 368 Caucasian, 
non-institutionalized, HIV-1 infected adults treat-
ed with cART, who were outpatients followed at 
the Hospital São João, Porto, were consecutively 
evaluated. The study protocol was approved by 
the Hospital Ethics Committee and all patients 
provided signed informed consent. 
Clinical assessment
For each patient the following data were collect-
ed using a standardized protocol: demographic 
data (age, gender), duration of HIV infection, HIV 
risk factor, duration of cART and characterisation 
of the infection. The “Centers for Disease Con-
trol and Prevention” (CDC) criteria for staging of 
HIV infection were used. Weight, height, circum-
ferences of neck, waist, hip, thigh and arm were 
measured. Body weight was measured using a 
TANITA (Tanita®, model TBF 300) scale, with pa-
tients wearing light clothes without shoes. Height 
was measured to the nearest centimetre in the 
standing position using a wall stadiometer (Hol-
tain Limited Crymych, Dyfed®).
Neck circumference was measured in the mid-
way of the neck, between midcervical spine and 
midanterior neck. In men with a laryngeal promi-
nence (Adam’s apple), it was measured just be-
low the prominence. Hip circumference was mea-
sured with the subject standing erect with arms 
by the sides, with the feet together and the gluteal 
muscles relaxed. An inelastic tape was placed 
horizontally around the buttocks. To ensure con-
tiguity of the two parts of the tape from which the 
circumference would be measured, the cross-
handed technique of measurement was used. An 
assistant checked the position of the tape on the 
opposite side of the subject’s body. The tape was 
in contact with the skin but it did not compress 
the soft tissues. The waist circumference was 
measured midway between the lowest rib and 
iliac crest, at the end of a gentle expiration, with 
the patient standing. The hip circumference was 
measured at the greater trochanter. All circumfer-
ences were taken with the subjects standing up-
right, with the face directed forwards, and shoul-
ders relaxed. Thigh circumference was measured 
around the thigh of the left leg midway between 
the crotch and the knee when the subject was 
in a standing position. Arm circumference was 
measured at the mid-upper arm circumference of 
the left arm. All measurements were taken by the 
same observer with standard techniques (20).
Clinical lipodystrophy (CL) was defined as a pe-
ripheral lipoatrophy with or without a central fat 
accumulation assessed by both patient and prac-
titioner (21). Patients were classified as without CL 
when none of the previously described features 
were present. Presence of central fat accumula-
tion or abdominal prominence was defined by the 
measurement of waist circumference using the 
International Diabetes Federation (IDF) criteria for 
metabolic syndrome (22). The clinical assessment 
was performed by the same practitioner (PF). The 
patients were placed into 4 different categories 
according to the presence or absence of either 
lipoatrophy or abdominal prominence: 1) No lipo-
dystrophy - patients without clinical lipoatrophy 
and without abdominal prominence; 2) Isolated 
central fat accumulation - patients without clini-
cal lipoatrophy and with abdominal prominence; 
3) Isolated lipoatrophy - patients with clinical li-
poatrophy and without abdominal prominence; 4) 
Mixed forms of lipodystrophy - patients with clini-
cal lipoatrophy and with abdominal prominence. 
Body composition was assessed with whole-
body dual-energy X-ray absorptiometry (DXA 
– Lunar Expert XL). DXA measurement was per-
formed while the patient was in a supine position, 
with standard positioning of the arms and feet. 
Markers used in this study for trunk and lower 
limbs that defined regions of interest were those 
indicated by the manufacturer. Regional fat mass 
values were grouped and analysed for the follow-
ing anatomical regions: arms, legs, trunk and to-
tal body. The fat mass ratio (FMR) was calculated 
as the ratio between the percentage of the trunk 
fat mass and the percentage of the lower limbs 
fat mass (FMR= % of the trunk fat mass/ % of the 
lower limb fat mass) (21, 23). 
The quantification of total, visceral, and periph-
eral fat was performed with a 64-slice CT scan-
ner (Siemens Sensation 64 Cardiac). Based on 
a coronal topogram, a single 10 mm thick slice 
was obtained from each patient at the level of 
the transverse processes of L4. Fat was defined 
as the areas with an attenuation value between 
-190 and -30 Hounsfield units (24, 25). Total ab-
dominal fat was calculated by drawing a region of 
interest including all the abdomen and subcuta-
neous tissue. Visceral fat area was calculated by 
manually drawing a region of interest along the 
internal contour of the abdominal wall muscles, 
anterior border of the psoas muscles, and ante-
rior contour of the L4 vertebral body. Subcutane-
ous abdominal fat was obtained by subtracting 
the value of visceral fat from total fat. All values 
were expressed in cm2 rounded to the nearest 
decimal (24, 25). 
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The CD4+ cell count was determined by flow 
cytometry, and plasma HIV-1 RNA loads were 
measured by a quantitative reverse transcriptase 
polymerase chain reaction, which has a lower 
detection limit of 50 copies/mL, as performed in 
routine clinical care.
Statistical analysis
Statistical analysis was performed using SPSS 
version 18.0 (SPSS Inc., Chicago, Illinois, USA). 
All probabilities were two tailed and p values 
<0.05 were regarded as significant. 
Data were described as mean and standard de-
viation (SD) for normally distributed quantitative 
variables and compared using the Student-t test 
or analysis of variance. When the distribution of 
the quantitative variables was different than the 
normal, they were described as median and mini-
mum and maximum interval, and were compared 
using the Mann-Whitney test or the Kruskal-Wal-
lis test as appropriate. Categorical variables were 
described as counts and proportions, and com-
pared using the chi-square or Fisher’s exact test. 
For estimating the association between clinical 
lipodystrophy and demographic, clinical and 
anthropometric measures, odds ratios (OR) and 
their respective 95% confidence intervals (95% 
CI) were computed using unconditional logistic 
regression. 
Table 1: Sample characteristics according to the presence of clinical lipodystrophy.
Without CL With CL
N (%) 151 (41.0) 217 (59.0) p
Gender [n (%)]
  Male 89 (58.9) 165 (76.0) <0.001
  Female 62 (41.1) 52 (24.0)
Age [years, median (min-max)] 42.0 (23.0-77.0) 45.0 (24.0-87.0) 0.008
Duration [years, median (min-max)] 6.0 (0.5-17.0) 9.0 (2.0-29.0) <0.001
cART [years, median (min-max)] 4.0 (0.0-17.0) 8.0 (0.5-29.0) <0.001
Weight [kg, mean (sd)] 74.0 (14.7) 66.3 (12.5) <0.001
Height [m, mean (sd)] 1.65 (0.09) 1.66 (0.09) 0.421
BMI [(kg/m2), mean (sd)] 27.2 (5.2) 23.9 (3.9) <0.001
Waist circumference [cm, mean (sd)] 95.5 (13.5) 89.5 (10.5) <0.001
Hip circumference [cm, mean (sd)] 100.7 (9.4) 91.6 (6.2) <0.001
Thigh circumference [cm, mean (sd)] 50.5 (6.2) 46.1 (6.1) <0.001
Arm circumference [cm, mean (sd)] 28.2 (3.4) 26.6 (4.0) <0.001
Neck circumference [cm, mean (sd)] 37.1 (4.0) 37.2 (4.0) 0.944
Waist/ hip ratio [mean (sd)] 0.95 (0.09) 0.98 (0.08) 0.006
CD4 cell count [cells/mm3, median (min-max)] 446.5 (2.0-1880.0) 510.5 (9.0-1840.0) 0.008
HIV RNA (<50) [n (%)] 121 (83.4) 197 (91.2) 0.026
HIV risk factor [n (%)]
   Inject 31 (20.5) 63 (29.2)
   Homosexual 13 (8.6) 30 (13.9)
   Heterosexual 106 (70.2) 113 (52.3)
   Other 1 (0.7) 10 (4.6) 0.002
CDC [n (%)]
   A 84 (56.0) 119 (55.6)
   B 6 (4.0) 1 (0.5)
   C 60 (40.0) 94 (43.9) 0.053
ART [n (%)]
   IP 88 (60.3) 117 (54.2) 0.250
NNRTI 65 (44.8) 105 (48.8) 0.445
NRTI 139 (95.9) 212 (98.6) 0.093
Body Fat Mass by Quantitative CT
Total fat [cm2, median (min-max)] 340.5 (63.9-850.7) 215.8 (31.5-676.6) <0.001
VAT [cm2, median (min-max)] 110.8 (14.5-381.8) 115.5 (9.2-385.5) 0.886
SAT [cm2, median (min-max)] 186.2 (30.5-690.1) 78.0 (5.0-417.9) <0.001
VAT/SAT [median (min-max)] 0.52 (0.09-5.46) 1.31 (0.13-20.4) <0.001
FMR by DXA [median (min-max)] 1.09 (0.40-3.45) 1.78 (0.43-4.97) <0.001
BMI [kg/m2, n (%)]
  <18.5 3 (2.0) 18 (8.3)
>18.5 <25 56 (37.1) 118 (54.4)
>25 <30 55 (36.4) 67 (30.9)
  > 30 37 (24.5) 14 (6.5) <0.001
(BMI - body mass index; CDC - Centers for Disease Control and Prevention criteria for staging of HIV infection; VAT- visceral adipose tissue; 
SAT – subcutaneous adipose tissue; FMR - fat mass ratio; DXA - dual-energy X-ray absorptiometry; CL – clinical lipodystrophy)
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RESULTS
Of the 368 HIV-1 infected patients (254 men and 
114 women) on cART included in this study, 217
(59.0 %) presented CL. Table 1 shows the charac-
teristics of the population according to the pres-
ence of CL. Patients with CL were more frequently 
males, older, had longer duration of HIV infection, 
length of cART and lower means of weight, BMI, 
and of waist, hip, thigh and arm circumferences, 
but had higher mean of waist/hip ratio. Also, pa-
tients with CL had higher a FMR mean, and in 
quantitative CT at abdominal level, lower total fat 
and subcutaneous fat, without a statistical differ-
ence in visceral fat but with a higher visceral/sub-
cutaneous fat ratio. 
Patients with CL had a significantly higher mean 
CD4+ cell count and a higher prevalence of vi-
ral suppression. No differences were observed 
between patients with and without CL regarding 
pharmacologic groups of cART. 
Considering BMI categories, 5.7% (21/368) of pa-
tients were underweight, 47.3% (174/368) were of 
normal weight, 33.2% (122/368) were overweight 
and 13.9% (51/368) were obese. Patients with CL 
were more frequently underweight and normally 
weighted (Table 1). Stratifying by gender, similar 
results were found, and CL was more frequent 
in patients with BMI <25.0 kg/m2, regardless of 
gender (Table 2). 
Looking at the 4 groups of body fat distribution, 
males had a higher prevalence of either isolated 
lipoatrophy or no lipodystrophy while females had 
a higher prevalence of isolated central fat accu-
mulation and mixed forms of lipodystrophy. Mixed 
forms of lipodystrophy were more prevalent in old-
er patients. Patients with a longer duration of HIV 
infection and cART treatment more frequently had 
isolated lipoatrophy and mixed forms. Patients 
with isolated central fat accumulation and mixed 
forms had higher neck, waist, hip, thigh, arm cir-
cumferences and waist/hip ratio. As expected, pa-
tients with isolated lipoatrophy and mixed forms 
had higher FMR. In quantitative CT at abdominal 
level, patients with isolated central fat accumula-
tion and mixed forms had higher total, visceral and 
subcutaneous fat, but those with isolated lipoatro-
phy and mixed forms of lipodystrophy had a higher 
visceral/subcutaneous fat ratio. 
Patients with isolated lipoatrophy and mixed 
forms had a significantly higher mean CD4+ cell 
count and a higher prevalence of viral suppres-
sion. No differences were observed between pa-
tients in the 4 different fat distribution categories 
regarding CDC classification and pharmacologic 
groups of cART. Patients with isolated lipoatrophy 
were more frequently underweight; those without 
AP (patients with no lipodystrophy and patients 
with isolated lipoatrophy) were normally weight-
ed; those with AP regardless the presence of 
clinical lipoatrophy (patients with isolated central 
fat accumulation and patients with mixed forms 
of lipodystrophy), were frequently overweight and 
obese (Table 3). Also, as expected, mean BMI 
was significantly higher in patients with AP (pa-
tients with isolated central fat accumulation and 
patients with mixed forms of lipodystrophy) and 
lower in patients with isolated lipoatrophy. 
After adjustment for the demographic and clinical 
features that were significantly associated with 
CL in the univariate analysis, the presence of CL 
was significantly associated with male gender, 
older ages and cART duration. Also, a strong sig-
nificant association (OR= 3.00, 95%CI: 1.28-7.00)
was found between CL and virological suppres-
sion. Patients with CL were less frequently over-
weight (OR=0.21, 95%CI: 0.05-0.92) or obese 
(OR= 0.05, 95%CI: 0.01-0.26), when compared 
with underweight patients, and this association 
was independent of age, sex, duration of infec-
tion, cART regimen, virological suppression and 
HIV-infection risk factor (Table 4).
Table 2: Prevalence of BMI categories according to the presence of clinically defined lipodystrophy and by gender
Lipodystrophy defined by clinical
Men Women
BMI Total Without CL With CL  Total Without CL With CL
[Kg/m2, n (%)] (n=254) (n=89)  (n=165) P (n=114)  (n=62)  (n=52) p
< 18.5 11 (4.3) 1 (1.1) 10 (6.1) 0.005 10 (8.8) 2 (3.2) 8 (15.4) <0.001
>18.5 <25 133 (52.4) 40 (44.9) 93 (56.4)  41 (36.0) 16 (25.8) 25 (48.1)
>25 <30 84 (33.1) 32 (36.0) 52 (31.5)  38 (33.3) 23 (37.1) 15 (28.8)
> 30 26 (10.2) 16 (18.0) 10 (6.1)  25 (21.9) 21 (33.9) 4 (7.7)
(BMI – body mass index; CL – clinical lipodystrophy)
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Table 3: Sample characteristics according to the 4 fat distribution categories.
no Isolated Isolated Mixed forms P
lipodystrophy central fat lipoatrophy of lipodystrophy
(n=52) accumulation (n=87) (n=111) (n=94)
Gender [n (%)]
    Male 43 (82.7) 42 (48.3) 97 (87.4) 56 (59.6)
    Female 9 (17.3) 45 (51.7) 14 (12.6) 38 (40.4) <0.001
Age [years, median (min-max)] 40 (23-77) 43 (28-73) 43 (26-72) 50 (24-72) <0.001
Duration of disease 
[years, median (min-max)] 6.0 (0.50-16.0) 6.0 (1.0-17.0) 9.0 (2.0-22.0) 8.5 (2.0-19.0) <0.001
cART [years, median (min-max)] 4.0 (0.0-14.0) 4.0 (0.0-15.0) 8.0 (0.5-20.0) 8.0 (1.0-17.0) <0.001
Waist circumference [cm, mean (sd)] 84.1 (6.76) 102.1 (10.79) 83.0 (6.90) 97.4 (8.65) <0.001
Hip circumference [cm, mean (sd)] 93.6 (4.25) 104.2 (8.49) 88.8 (5.07) 94.8 (5.77) <0.001
Thigh circumference [cm, mean (sd)] 46.6 (4.04) 51.9 (5.30) 44.7 (3.63) 47.8 (7.82) <0.001
Arm circumference [cm, mean (sd)] 26.0 (2.78) 29.0 (2.76) 25.4 (2.97) 27.9 (4.63) <0.001
neck circumference [cm, mean (sd)] 36.2 (3.45) 37.6 (3.81) 36.0 (4.34) 38.4 (4.34) <0.001
Waist/ hip ratio [mean (sd)] 0.90 (0.08) 0.98 (0.08) 0.93 (0.06) 1.02 (0.07) <0.001
CD4 cell count [cells/mm3, median 386.0 466.0 509.0 573.0
(min-max)] (2.00-1880.0)  (119.0-1730.0)  (91.0-1657.0)  (9.00-1840.0) 0.011
HIV RnA (<50) [n (%)] 39 (78.0) 71 (85.5) 102 (91.9) 85 (91.4) 0.048
CDC [n (%)]
   A 26 (50.0) 52 (60.5) 62 (56.4) 51 (54.8)
   B 4 (7.7) 1 (1.2) 0 (0.0) 1 (1.1)
   C 22 (42.3) 33 (38.4) 48 (43.6) 41 (44.1) 0.106
ART [n (%)]
   IP 31 (62.0) 51 (60.7) 63 (56.8) 45 (48.4) 0.296
nnRTI 22 (44.9) 37 (44.0) 53 (47.7) 48 (52.2) 0.719
nRTI 47 (95.9) 80 (95.2) 109 (99.1) 91 (98.9) 0.201
Body Fat Mass by Quantitative CT
Total fat [cm2, median (min-max)] 188.4 (63.9-372.1) 391.9 (217.8-850.7) 136.6 (31.4-466.8) 303.1 (137.5-676.6) <0.001
VAT [cm2, median (min-max)] 66.4 (14.5-217.3) 126.1 (31.2-381.8) 67.2 (9.2-262.3) 172.7 (20.0-285.5) <0.001
SAT [cm2, median (min-max)] 100.3 (30.5-229.3) 259.7 (109.0-690.1) 58.1 (5.0-204.6) 136.0 (32.0-418.0) <0.001
VAT/SAT [median (min-max)] 0.54 (0.22-5.46) 0.45 (0.07-2.75) 1.24 (0.17-20.43) 1.32 (0.13-6.36) <0.001
FMR by DXA [median (min-max)] 0.95 (0.40-3.45) 1.17 (0.54-2.65) 1.71 (0.52-4.47) 1.90 (0.43-4.97) <0.001
BMI [kg/m2, n(%)]
<18.5 1 (1.9) 0 (0.0) 16 (14.4) 1 (1.1)
18.5-24.9 42 (80.8) 12 (13.8) 83 (74.8) 29 (30.9)
24.9-29.9 9 (17.3) 43 (49.4) 11 (9.9) 51 (54.3)
>29.9 0 (0.0) 32 (36.8) 1 (0.9) 13 (13.8) <0.001
BMI [kg/m2 (mean (sd)] 23.0 (2.4) 29.4 (4.6) 21.8 (2.9) 26.5 (3.4) <0.001
(BMI - body mass index; CDC - Centers for Disease Control and Prevention criteria for staging of HIV infection; VAT – visceral adipose tissue; 
SAT – subcutaneous adipose tissue; FMR - fat mass ratio; DXA - dual-energy X-ray absorptiometry)
DISCUSSIOn
Although wasting syndrome was common in the 
early HIV epidemic, it is not expected to appear 
in patients successfully treated with cART (16). In 
fact, recent studies have shown that being over-
weight or obese is more common than wasting in 
these patients (Table 5). This may be partly justi-
fied by the increased survival rate in HIV patients 
and by the weight gain that occurs with ageing in 
the general population (14-16, 26, 27). Our data 
also showed that, regardless of gender, being of 
normal weight, overweight or obese is more com-
mon than being underweight in these HIV-infect-
ed patients. 
In some studies, HIV-infected women and men 
were equally or more frequently overweight, al-
though women were more likely to be obese than 
men (Table 5). When we compared our prevalence 
figures with other studies (Table 5), we found a 
lower prevalence of underweight patients (except 
for the Crum-Cianflone paper (16)), and a similar 
prevalence of overweight subjects regardless of 
gender (similar to Amorosa (15)), although there 
was more obesity among women in our popula-
tion.
Comparing our data with the Portuguese national
Survey for the same age group (40 to 49 years), 
we observed that our HIV-infected female popu-
lation had a higher prevalence of being under-
weight or obese with a lower prevalence of being 
overweight (28). Our population of HIV-infected 
male patients had a higher prevalence of being 
underweight or normal, but contrary to the wom-
en, there was a lower frequency of being over-
weight or obese than in the general population. 
In a retrospective study of HIV-infected male pa-
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Table 4: Association between clinical lipodystrophy and demographic, clinical and anthropometric characteristics.
Crude OR (95%CI) Adjusted OR (95%CI)**
Sex
 Male 1* 1*
 Female 0.45 (0.29-0.71) 0.42 (0.23-0.76)
Age (years) 1.02 (1.00-1.04) 1.05 (1.02-1.07)
Duration of infection 1.18 (1.11-1.25) 1.12 (0.99-1.25)
cART duration 1.24 (1.16-1.32) 1.16 (1.03-1.30)
CD4 cell count 1.00 (1.00-1.00) --
HIV RNA (<50) 2.06 (1.08-3.91) 3.00 (1.28-7.00)
HIV risk factor 
   Inject 1* 1*
   Homosexual 1.14 (0.52-2.48) 0.60 (0.25-1.71)
   Heterosexual 0.52 (0.32-0.87) 0.91 (0.44-1.89)
   Other 4.92 (0.60-40.12) 2.17 (0.24-19.47)
BMI (Kg/m2)
   < 18.5 1* 1*
>18.5<25 0.35 (0.10-1.24) 0.33 (0.08-1.89)
>25<30 0.20 (0.06-0.72) 0.21 (0.05-0.92)
   > 30 0.06 (0.07-0.25) 0.05 (0.01-0.26)
*reference class.
**OR adjusted for all the variables in the table, with the exception of CD4 cell count.
Table 5: Studies of prevalence of obesity in HIV-infected patients by author
Prevalences
Author, year Underweight Overweight Obese
Amorosa V, 2005 (15) 9% 31% 14%
(31% men; 30% women) (28.3% women; 10.7% men)
Hendricks KM, 2006 (14) 39.6% men 12.5% men
33.9% women 28.6% women
Hodgson LM, 2001 (26) 12% 34% 9%
Shuter J, 2001 (27) 10.6% 21.7% 10.6%
(11.7% men; 9.3% women)  (12.6% men; 32.5% women)
Crum- Cianflone N, 2008 (16) 1% (men) 46% (men) 17% (men)
Jaime PC, 2004 (32) 2.3% men; 7,7% women 25.1% men; 26.9% women 3.5% men; 9.6% women
Freitas P, this paper 5.7% 33.2% 13.9%
(4.3% men; 8.8% women)  (33.1% men; 33.3% women) (10.2% men; 21.9% women)
tients, 54% were already overweight or obese at 
the time of HIV diagnosis, suggesting that the risk 
of becoming overweight or obese over the course 
of infection may not be higher when compared to 
the general population (16). On the other hand, 
weight gain may be a sign of the efficacy of cART 
in reducing the occurrence of AIDS and wasting. 
As patients with HIV live longer and the infection 
has been relegated to a chronic illness, HIV pa-
tients may be now facing similar problems to the 
general population, including excessive weight 
gain due to poor lifestyle habits (14, 29). 
More important than diagnosing obesity is as-
sessing the types of fat distribution. The best 
way to quantify the visceral adipose tissue (VAT) 
is through CT or MRI scanning. In our patients, 
those with CL, despite having a similar VAT and 
lower total and subcutaneous adipose tissue 
(SAT) at abdominal level, had a higher WHR and 
a higher VAT/SAT ratio by CT. The presence of 
a similar VAT and a higher VAT/SAT ratio results 
from a lower SAT. The same phenomenon is ob-
served with WHR because they had a decrease in 
SAT that is the predominant adipose tissue in the 
hip. When we analysed the data according to the 
4 groups of fat redistribution, patients with iso-
lated lipoatrophy had a higher VAT/SAT fat ratio 
indicating not an increase in visceral adipose tis-
sue, but lower subcutaneous fat. These patients 
with low SAT and VAT had a similar fat distribution 
to patients with Berardinelli-Seip congenital gen-
eralized lipodystrophy (30). We do not know if this 
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difference in fat distribution pattern in HIV patients 
is related to a different cardiovascular risk. Older 
age in the general population and CD4 cell count 
in HIV-patients were associated with increased 
BMI. Also, CL was associated with older age, lon-
ger HIV and cART duration, and higher CD4 cell 
count, most of them linked with increased BMI. 
Thus we would expect that CL patients would 
have a higher prevalence of obesity and of be-
ing overweight, which is not true. After adjust-
ment for the demographic and clinical features 
significantly associated with the presence of CL, 
these patients were significantly less overweight 
or obese, and this association was independent 
of age, gender, duration of infection, cART regi-
men, virological suppression and HIV-infection 
risk factor. In the Amorosa study, in the multivari-
ate analysis, a CD4 count > 200 cells/mm3, inde-
pendent of gender, was associated with obesity 
and with being overweight. Compared with men, 
HIV-infected women had a higher prevalence of 
obesity. Female gender, CD4 cell count, and non-
smoking status correlated with obesity and with 
being overweight within the overall group. Wom-
en far surpassed men in prevalence of obesity, 
even when factoring in other risks, including the 
women’s earlier stage of the disease as assessed 
by CD4+ cell count. For patients with known spe-
cific antiretroviral regimens, no correlations were 
seen with any of the following: BMI, being anti-
retroviral naïve, being on ART currently, or with 
PI use (15).
In the Crum-Cianflone study, multivariate analysis 
showed that weight gain during HIV infection was 
significantly related to younger age at HIV diag-
nosis and longer time of HIV follow-up (16). High-
er CD4 cell count was associated with weight 
gain. cART use was not predictive of weight gain 
in the final model. Subjects with a CD4 cell na-
dir greater than 200 cells/mm3 had a higher BMI. 
This suggests that those who do not experience 
end stage HIV disease are more likely to be over-
weight. Patients with HIV who were overweight/
obese, as well as those who gained weight dur-
ing the course of their HIV infection, were more 
likely to have higher CD4 cell counts. Also in a 
cross-sectional obesity study, no association was 
found between weight and current cART regimen 
(15). Successful virological responses were also 
associated with weight gain (13, 31).
One of the strengths of our study is that it ad-
dresses the prevalence of obesity according to 
the presence of CL and this has not been report-
ed previously. Despite having a lower prevalence 
of being overweight or obese when compared 
to patients without lipodystrophy, lipodystrophic 
patients had an increased proportion of VAT, as 
reflected by the increased VAT/SAT fat ratio de-
termined by CT at abdominal level. This probably 
suggests that these patients have a comparable 
risk of metabolic and cardiovascular complica-
tions, in spite of the actual frequency of obesity 
being lower. 
Limitations of our study
One of the limitations of our study is that the li-
poatrophy definition is clinical, having been per-
formed by the same experienced observer (PF), 
so the findings of this study may not be gener-
alized to all HIV populations nor to less experi-
enced centres. Also, objective measurements of 
body composition (FMR and CT) were not used 
for the definition of obesity.
COnCLUSIOnS
In this HIV-infected patient population on cART, 
about 22% were overweight and 10% were 
obese. Patients with clinical diagnoses of lipodys-
trophy were less frequently overweight or obese. 
As expected, BMI was higher in patients with 
abdominal prominence (patients with isolated 
central fat accumulation and patients with mixed 
forms of lipodystrophy) and lower in patients with 
isolated lipoatrophy. Patients with CL had lower 
mean WC, higher waist/hip ratio and FMR and, 
in quantitative CT at abdominal level, lower to-
tal and subcutaneous fat, without a significantly 
different visceral fat mass but with a higher vis-
ceral/subcutaneous fat ratio. HIV-infected male 
patients were more often underweight than the 
general population. Obesity instead of wasting is 
a new reality after the introduction of anti-retrovi-
ral therapy in HIV-infected patients.
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tribution (based on the presence or absence of lipoatrophy 
and abdominal prominence), isolated lipoatrophy was not 
significantly associated with hypertension, but patients with 
isolated central fat accumulation and mixed forms of lipodys-
trophy had a significantly higher prevalence of hypertension. 
Hypertensive HIV patients had significantly higher total fat, 
central, and central/peripheral mass ratio than normoten-
sive ones. After adjustment for age, sex, smoking, and body 
mass index, hypertension remains significantly associated 
with central/peripheral fat mass ratio (odds ratio, 1.258; 95% 
confidence interval, 1.008-1.569). Hypertension was not 
more prevalent in lipodystrophic HIV-infected patients, but 
was significantly associated with central/peripheral fat mass 
ratio. J Clin Hypertens (Greenwich). 2012;00:00–00©2012 
Wiley Periodicals, Inc.
The widespread use of combination antiretroviral ther-
apy (cART) has changed HIV-1 infection into a chronic 
manageable illness. However, together with chronic HIV 
infection and aging, lifelong cART is associated with ad-
verse effects including cardiovascular disease and lipo-
dystrophy1-4.
In contrast with metabolic abnormalities, few and 
sometimes controversial studies are available on the ef-
fect of cART and lipodystrophy on blood pressure in 
HIV-infected patients5-13.
Regular blood pressure monitoring to rule out hyper-
tension in HIV-infected patients has been recently rec-
ommended 14, and some authors have suggested a high 
prevalence of hypertension among these patients11,15-18,
which was not confirmed by others 12,16,19,20. In some 
studies, the higher risk for hypertension in HIV-infected 
patients is associated with lipodystrophy21-25, which is in 
opposition to data from uninfected HIV patients with ge-
netic lipoatrophies, for whom diabetes is a common fea-
ture but not hypertension21-25. Given this controversy, the 
aim of this study was to estimate the association between 
lipodystrophy [clinically and Fat Mass Ratio (FMR) de-
fined] and body composition with the prevalence of hy-
pertension in HIV-1 patients on antiretroviral therapy.
MEthODs
subjects
As part of a cross-sectional study, we evaluated all 364 
non-institutionalized, HIV-1 infected Caucasian adult pa-
tients, consecutively referred from the Infectious Diseas-
es Clinic to the Endocrinology Outpatient Clinic. Patients 
1The study protocol was approved by the Hospital Ethics 
Committee and all patients provided informed consent. 
For each patient, the following information was collect-
ed using a standardized protocol: demographic data (age, 
gender), duration of HIV infection, probable transmission 
route of HIV infection, duration of cART, anti-hyperten-
sive drug therapy and characterization of the infection 
using the “Centers for Disease Control and Prevention” 
(CDC) staging criteria 26.
A blood sample was collected and CD4 cells, HIV-1 
RNA, and fasting glucose and insulin were determined. 
Insulin resistance was defined by the homeostatic model 
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The data on the risk of hypertension in human immuno-
deficiency virus (HIV)-infected patients, particularly in 
those with lipodystrophy, are controversial. The authors 
assessed the impact of lipodystrophy on hypertension in 
a cohort of HIV-infected adults receiving combination anti-
retroviral therapy. This was a cross-sectional study in which 
lipodystrophy (clinically and fat mass ratio [FMr]-defined), 
blood pressure, and body composition (dual-energy x-ray 
absorptiometry and computed tomography) were evalu-
ated in 368 HIV adults. The prevalence of hypertension 
in HIV patients with or without clinically or FMr-defined li-
podystrophy was similar (with clinical lipodystrophy 35.3% 
vs without 32.9%, not significant; with FMr lipodystrophy 
41.7% vs without 32.2%, not significant). When HIVin-
fected patients were classified into 4 categories of fat dis-
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assessment 27. Body weight was measured using TANITA 
(Tanita®, model TBF 300) scale, with patients wearing 
light clothes without shoes, and height was measured to 
the nearest centimetre in the standing position using a wall 
stadiometer (Holtain Limited Crymych, Dyfed®). Neck, 
hip, waist, thigh and arm circumferences were measured 
by the same observer with standard techniques28.
Blood pressure (BP) was measured after the subject had 
remained seated for 5 minutes, with the elbow flexed at the 
heart, using a standard aneroid sphygmomanometer with 
the cuff on the upper right arm. Two blood pressure read-
ings were taken and the mean of the two readings was calcu-
lated. Hypertension was defined as systolic blood pressure 
>140mmHg and/or diastolic blood pressure > 90mmHg, or 
self-reported medication for high blood pressure29.
Clinical lipodystrophy was defined as a peripheral li-
poatrophy with or without a central fat accumulation as-
sessed by both practitioner and patient as we previously 
described30-33. Central fat accumulation or abdominal 
prominence was defined using the last International Dia-
betes Federation (IDF) criteria for metabolic syndrome34,
as having waist circumference ≥94 cm in men and 80 cm 
in women35. The clinical assessment was performed by 
the same practitioner (PF). Patients were classified into 
4 different groups according the presence or absence of 
either lipoatrophy or abdominal prominence: group 1- No 
lipodystrophy (patients without clinical lipoatrophy and 
without abdominal prominence); group 2-  Isolated cen-
tral fat accumulation (patients without clinical lipoatro-
phy and with abdominal prominence); group 3- Isolated 
lipoatrophy (patients with clinical lipoatrophy and with-
out abdominal prominence); group 4- Mixed forms of li-
podystrophy (patients with clinical lipoatrophy and with 
abdominal prominence).
Body composition and laboratory definitions
Body composition was assessed with whole-body dual-
energy X-ray absorptiometry (DXA) (DXA – Lunar Ex-
pert XL, 1999). DXA measurements were performed 
while the patient was in a supine position, with standard 
positioning of the arms and feet. Cut lines separating re-
gions of interest were those indicated by the manufactur-
er. Regional fat mass values were grouped and analysed 
for the following anatomical regions: arms, legs, trunk 
and total body. The fat mass ratio (FMR) was calculated 
as the ratio between the percentage of the trunk fat mass 
and the percentage of the lower limb fat mass (FMR= % 
of the trunk fat mass/ % of the lower limb fat mass)36. For 
the definition of lipodystrophy using FMR, we used the 
cut-off values of 1.961 for men and 1.329 for women30.
The quantification of total, visceral, and peripheral fat 
was performed using a 64-slice CT scanner (Siemens 
Sensation 64 Cardiac). Based on a coronal topogram, a 
single 10 mm thick slice was obtained in all patients at 
the level of the transverse processes of L4. Radiological 
evidence of fat was considered as any area with an at-
tenuation value comprised between -190 and -30 Houn-
sfield units37,38. Total fat area was calculated by drawing 
a region of interest (ROI) including all the abdomen and 
subcutaneous tissue. Visceral fat area was calculated by 
manually drawing a ROI along the internal contour of 
the abdominal wall muscles, anterior border of the psoas 
muscles, and anterior contour of the L4 vertebral body. 
Peripheral fat area was obtained by subtracting the value 
of visceral fat area from total fat area. All values were ex-
pressed in cm2 rounded to the nearest centesimal37,38. The 
CD4+ cell count was determined by flow cytometry and 
plasma HIV-1 RNA load was measured by a quantitative 
reverse transcriptase polymerase chain reaction, which 
has a lower limit of detection of 50 copies/mL.
statistical analysis
Statistical analysis was performed using SPSS version 
17.0 software (SPSS Inc., Chicago, Illinois, USA). All 
probabilities were two tailed and p values <0.05 were re-
garded as significant. Data were described as mean and 
standard deviation (SD) for quantitative variables and 
compared using the Student-t test or the Mann-Whitney 
test as appropriate. Kruskal-Wallis test was used for the 
comparison between the four groups of fat distribution. 
Categorical variables were described as counts and pro-
portions, and compared using the chi-square or Fisher’s 
exact test. 
Odds ratio (OR) and respective 95% confidence inter-
vals (95% CI) were computed using unconditional lo-
gistic regression, for estimating the association between 
hypertension and anthropometric measures and insulin 
resistance.
REsults
Characteristics of the population
In this sample of 364 HIV-1 infected patients (250 men 
and 114 women) on antiretroviral therapy (cART), 59.1% 
patients presented clinical lipodystrophy (CL). Table 1 
shows the characteristics of the study sample according to 
the presence of CL. Patients with CL were more frequent-
ly males, older, had longer HIV infection duration, length 
PubLicAçõES
	 	 0
Official Journal of the American Society of Hypertension, Inc. The Journal of Clinical Hypertension 3
Hypertension and HIV Lipodystrophy   | Freitas et al.
TABLE I. Sample Characteristics According to the Presence of Clinical Lipodystrophy  
  Without CL With CL p
N (%) 149 (40.9) 215 (59.1)
Sex [n(%)]
Male 87 (58.4) 163 (75.8) <0.001
Female 62 (41.6) 52 (24.2)
Age [years, mean (sd)] 44.4 (12.0) 47.0 (11.0) 0.010
Duration [years, mean (sd)] 6.7 (3.9) 9.2 (4.1) <0.001
cART [years, mean (sd)] 5.0 (3.8) 8.0 (4.0) <0.001
Weight [Kg, mean (sd)] 73.7 (14.3) 66.2 (12.5) <0.001
Height [m, mean (sd)] 1.65 (0.09) 1.66 (0.09) 0.383
BMI [(kg/m2), mean (sd)] 27.1 (5.1) 24.0 (3.9) <0.001
Waist circumference [cm, mean (sd)] 95.5 (13.3) 89.5 (10.6) <0.001
Hip circumference [cm, mean (sd)] 100.7 (9.4) 91.6 (6.2) <0.001
Thigh circumference [cm, mean (sd)] 50.4 (6.2) 46.1 (6.1) <0.001
Arm circumference [cm, mean (sd)] 28.2 (3.4) 26.6 (4.0) <0.001
Neck circumference [cm, mean (sd)] 37.0 (3.9) 37.2 (4.0) 0.856
Waist/ hip circumference ratio [mean (sd)] 0.95 (0.09) 0.98 (0.08) 0.006
CD4 cell count [cells/mm3, mean (sd)] 503.5 (311.6) 573.4 (324.0) 0.010
HIV RNA (<50) [n (%)] 121 (83.4) 197 (91.2) 0.026
HIV risk factor [n (%)]
Inject 31 (20.8) 63 (29.4) 0.002
Homosexual 12 (8.1) 30 (14.0)
Heterosexual 105 (70.5) 111 (51.9)
Other 1 (0.7) 10 (4.7)
CDC [n (%)]
A 82 (55.4) 118 (55.7) 0.056
B 6 (4.1) 1 (0.5)
C 60 (40.5) 93 (43.9)
ART [n (%)]
IP 88 (61.1) 116 (54.2) 0.263
NNRTI 63 (44.1) 104 (48.8) 0.438
NRTI 137 (95.8) 210 (98.6) 0.064
Body Fat Mass by Quantitative CT
Total fat [cm2, mean (sd)] 345.8 (163.2) 230.9 (133.1) <0.001
Central fat [cm2, mean (sd)] 131.2 (86.5) 127.1 (79.9) 0.886
Peripheral fat [cm2, mean (sd)] 214.6 (125.0) 103.8 (82.9) <0.001
Central/peripheral [mean (sd)] 0.82 (0.84) 2.06 (2.41) <0.001
FMR by DXA [mean (sd)] 1.24 (0.53) 1.98 (0.98) <0.001
Systolic blood pressure [mean (sd)] 120.6 (19.0) 120.5 (17.2) 0.978
Diastolic  blood pressure [mean (sd)] 75.6 (13.3) 75.6 (10.9) 0.945
Taking anti-hypertension medications [n (%)] 21 (14.1%) 44 (20.6%) 0.149
Smoking history [n (%)]
Never 66 (45.2) 71 (34.5) 0.103
Current 59 (40.4) 94 (45.6)
Former 21 (14.4) 41 (19.9%)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; cART, combination antiretroviral therapy; CDC, Centers for Disease Control and 
Prevention criteria for staging of human immunodeficiency virus (HIV) infection; CL, clinical lipodystrophy; CT, computed tomography; DXA, dua-
lenergy x-ray absorptiometry; FMR, fat mass ratio; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase 
inhibitor; PI, protease inhibitor.; SD, standard deviation.
of cART and presented a lower mean of all the anthropo-
metric measures, with the exception of height and neck 
circumference. In addition, patients with CL had higher 
FMR. Patients with CL had a significantly higher mean 
CD4+ cell count and viral suppression rate. No differ-
ences were observed between patients with and without 
CL regarding the cART regimens. Also, no differences 
between patients with or without clinical lipodystrophy 
were observed regarding the frequency of anti-hyperten-
sive medication use.
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Prevalence of hypertension 
Of the 364 patients 34.3% were hypertensive. No sig-
nificant differences were observed regarding the preva-
lence of hypertension in patients with and without li-
podystrophy, regardless of gender or the definition that 
was used (Table 2). Also, no differences in mean SBP 
or DBP between patients with or without lipodystrophy 
were found (Table 1), defined either by clinical criteria 
or by FMR [SBP: with lipodystrophy 123.7 mmHg (16.8) 
vs. without 119.4 mmHg (18.3); p=0.068 and DBP: with 
lipodystrophy 76.8 mmHg (9.9) vs. without 76.0 mmHg 
(12.5); p=0.411].
When patients were classified into 4 categories of fat 
distribution as previously described, the presence of hy-
pertension was more prevalent in patients with isolated 
central fat accumulation and mixed forms of lipodystro-
phy (patients with abdominal prominence regardless of 
the presence or absence of lipoatrophy) both in men and 
in the total sample (Table 3). 
TABLE II. Prevalence of HTN According to Lipodystrophy Defined Clinically and by FMR
Lipodystrophy defined clinically Lipodystrophy defined by FMR
Total Without CL With CL P value Total Without L With L P value
HTN n=364 n=149 n=215 n=221 n=118 n=103
Without HTN, No. (%) 239 (65.7) 100 (67.1) 139 (64.7) 0.708 140 (63.3) 80 (67.8) 60 (58.3) 0.184
With HTN, No. (%) 125 (34.3) 49 (32.9) 76 (35.3) 91 (36.7) 38 (32.2) 43 (41.7)
No. 250 87 163 147 57 90
Men
Without HTN, No. (%) 157(62.8) 55 (63.2) 102 (62.6) 1.000 92 (62.6) 41 (71.9) 51 (56.7) 0.091
With HTN, No. (%) 93 (37.2) 32 (36.8) 61 (37.4) 55 (37.4) 16 (28.1) 39 (43.3)
No. 114 62 52 74 61 13
Women
Without HTN, No. (%) 82 (71.9) 45 (72.6) 37 (71.2) 1.000 48 (64.9) 39 (63.9) 9 (69.2) 1.000
With HTN, No. (%) 32 (28.1) 17 (27.4) 15 (28.8) 26 (35.1) 22 (36.1) 4 (30.8)
Abbreviations: CL, clinical lipodystrophy; FMR, fat mass ratio; HTN, hypertension; L, lipodystrophy.
TABLE III. Prevalence of Hypertension by Body Composition According to 4 Groups of Fat Distribution and Sex
  Isolated Central Isolated Mixed Forms of
HTN No Lipodystrophy Fat Accumulation Lipoatrophy Lipodystrophy P Value
Total
Without HT [n (%)] 39 (76.5) 54 (52.8) 80 (72.7) 53 (56.4) 0.029
With HT [n (%)] 12 (23.5) 32 (37.2) 30 (27.3) 41 (43.6)
Men
Without HT [n (%)] 31 (73.8) 23 (56.1) 67 (69.8) 29 (51.8) 0.049
With HT [n (%)] 11 (26.1) 18 (43.9) 29 (30.2) 27 (48.2)
Women
Without HT [n (%)] 8 (88.9) 31 (68.9) 13 (92.9) 24 (63.2) 0.119
With HT [n (%)] 1 (11.1) 14 (31.1) 1 (7.1) 14 (36.8)
Abbreviation: HTN, hypertension.
Patient characteristics according the presence 
of hypertension
Patients with hypertension were older, had higher mean 
weight, BMI, waist, arm and neck circumferences and 
higher waist/hip circumference ratio. They also had higher 
total and central fat and central/peripheral fat ratio with-
out difference in the peripheral fat on CT at abdominal 
level (Table 4). There was no difference between patients 
with or without hypertension in gender, duration of HIV 
infection, length of cART, hip and thigh circumferences, 
CD4 cell count and presence of lipodystrophy (clinical or 
FMR-defined).
Anthropometric characteristics and the pres-
ence of hypertension 
After adjustment for age, gender, smoking history and 
BMI, hypertension was not associated either with insu-
lin resistance or the presence of clinical or FMR-defined 
lipodystrophy. Also, total abdominal, central and periph-
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TABLE IV. Sample Characteristics According to the Presence of Clinical Lipodystrophy  
  Without HTN With HTN P Value
N (%) 239 (65.7) 125 (34.3)
Sex [n(%)]
Male 157 (65.7) 82 (34.3) 0.114
Female 93 (74.4) 32 (25.6)
Age [years, mean (sd)] 42.0 (9.3) 53.5 (11.6) <0.001
Duration [years, mean (sd)] 8.2 (4.1) 8.0 (4.6) 0.394
ART [years, mean (sd)] 6.8 (4.0) 6.7 (4.4) 0.739
Weight [Kg, mean (sd)] 67.8 (13.3) 72.1 (14.2) 0.009
Height [m, mean (sd)] 1.66 (0.09) 1.65 (0.08) 0.388
BMI [(kg/m2), mean (sd)] 24.6 (4.5) 26.5 (4.8) <0.001
Waist circumference [cm, mean (sd)] 89.9 (11.9) 96.0 (8.9) <0.001
Hip circumference [cm, mean (sd)] 94.9 (8.8) 96.2 (8.9) 0.151
Thigh circumference [cm, mean (sd)] 48.3 (6.7) 47.0 (6.0) 0.214
Arm circumference [cm, mean (sd)] 27.0 (4.1) 27.8 (3.3) 0.031
Neck circumference [cm, mean (sd)] 36.5 (3.8) 38.2 (3.9) 0.002
Ratio waist/ hip circumference [mean (sd)] 0.95 (0.08) 1.00 (0.08) <0.001
CD4 cell count [cells/mm3, mean (sd)] 554.2 (326.1) 526.8 (309.8) 0.402
HIV risk factor [n (%)]
Inject 85 (35.7) 9 (7.2) <0.001
Homosexual 23 (9.7) 19 (15.2)
Heterosexual 122 (51.3) 94 (75.2)
Other 8 (3.4) 3 (2.4)
CDC [n (%)]
A 126 (53.4) 74 (59.7) 0.031
B 6 (2.5) 1 (0.8)
C 104 (44.1) 49 (39.5)
ART [n (%)]
IP 140 (59.8) 64 (51.6) 0.167
NNRTI 106 (45.3) 61 (50.0) 0.464
NRTI 228 (97.9) 119 (96.4) 0.664
Body Fat Mass by Quantitative CT
Total fat [cm2, mean (sd)] 241.9 (139.4) 329.0 (165.7) <0.001
Central fat [cm2, mean (sd)] 107.2 (72.7) 167.4 (72.7) <0.001
Peripheral fat [cm2, mean (sd)] 134.7 (102.6) 161.5 (129.7) 0.184
Central/peripheral [mean (sd)] 1.30 (1.36) 2.16 (2.90) 0.005
Clinical lipodystrophy [n (%)]
     Without 100 (41.8) 49 (39.2) 0.708
     With 139 (58.2) 76 (60.8)
Lipodystrophy FMR defined [n (%)]
     Without 80 (57.1) 38 (46.9) 0.184
     With 60 (42.9) 43 (53.1)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; cART, combination antiretroviral therapy; CDC, Centers for Disease Control and 
Prevention criteria for staging of human immunodeficiency virus (HIV) infection; CL, clinical lipodystrophy; CT, computed tomography; DXA, dua-
lenergy x-ray absorptiometry; FMR, fat mass ratio; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase 
inhibitor; PI, protease inhibitor.; SD, standard deviation.
eral fat mass evaluated by CT scan were not associated 
with hypertension. On the other hand, central/peripheral 
fat mass ratio was significantly associated with hyperten-
sion, even after adjustment for the previously mentioned 
variables (OR=1.26; 95%CI: 1.01-1.57). Total body, arm 
and trunk fat mass, assessed by DXA, were not associated 
with hypertension, independent of age, gender and smok-
ing history (Table 5). 
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TABLE V. Association Between Anthropometric Characteristics and the Presence of Hypertension
  Crude OR (95% CI) Adjusted OR (95% CI)a Adjusted OR (95% CI)b
Homa score
< 4 1 1 1
> 4 2.13 (1.26-3.60) 1.95 (1.07-3.56) 1.80 (0.97-3.31)
Clinical lipodystrophy 1.12 (0.72-1.74) 0.86 (0.51-1.46) 1.12 (0.64-1.96)
Lipodystrophy defined by FMR 1.51 (0.87-2.62) 0.95 (0.46-1.94) 0.97 (0.47-2.01)
Body Fat Mass by Quantitative CT
Total fat [cm2, mean (sd)] 1.00 (1.00-1.01) 1.00 (1.00-1.01) 1.00 (0.99-1.00)  
Central fat [cm2, mean (sd)] 1.01 (1.01-1.01) 1.01 (1.00-1.01) 1.00 (0.99-1.00)
Peripheral fat [cm2, mean (sd)] 1.00 (1.00-1.01) 1.00 (1.00-1.01) 1.00 (0.99-1.00)
Central/peripheral ratio [mean (sd)] 1.27 (1.06-1.52) 1.15 (0.94-1.40) 1.26 (1.01-1.57)
DXA
Total body fat mass % 1.03 (1.00-1.05) 1.05 (1.01-1.09) 1.02 (0.96-1.08)
Leg body fat mass % 1.01 (0.99-1.03) 1.02 (0.99-1.05) 1.00 (0.96-1.04)
Arm body fat mass % 1.01 (0.98-1.02) 1.04 (1.01-1.08) 1.03 (0.98-1.07)
Trunk body fat mass % 1.04 (1.10-2.00) 1.04 (1.01-1.08) 1.01 (0.96-1.07)
FMR by DXA [mean (sd)] 1.48 (1.10-2.00) 1.17 (0.79-1.74) 1.16 (0.78-1.73)
Abbreviations: CI, confidence interval; CT, computed tomography; DXA, dual-energy x-ray absorptiometry; FMR, fat mass ratio; HOMA, Homeo-
static Model Assessment; SD, standard deviation. aOdds ratio (OR) adjusted for age, sex, and smoking history. bOR adjusted for age, sex, smoking 
history and body mass index (BMI).
DIsCussIOn
Prevalence of hypertension in HIV-infected pa-
tients
In this study, 34.3 % of the HIV-1 infected patients 
[with a mean age of 45.9 (11.5) years] on cART were hy-
pertensive. This prevalence is lower than the 42.1% (18 to 
90 years of age) and 47.1% (35 to 64 years of age) in our 
country’s general population39.
There are few and discrepant studies on hypertension 
in HIV-infected patients. In Bergersen’s study, the preva-
lence of hypertension was 21% in patients on cART, 13% 
(p=0.20) in ART-naïve patients and 24% in HIV-nega-
tive controls (p=0.28)19. Similar results were observed in 
patients on cART and in HIV-negative controls. These 
observations led to the perception that influence of cART 
on the prevalence of hypertension appears to be minor. 
Bergersen argued that the most probable explanation for 
those findings was that HIV-positive patients in general, 
have a lower BMI and thus have a lower blood pressure 
than the general population19.
Gazzaruso studied 287 HIV-positive patients on cART, 
with a mean age of 41.1 years, and the prevalence of hy-
pertension was similar (34.2 %) to our results (34.3%). By 
using multiple logistic regression analysis, it was shown 
that family history of hypertension, metabolic syndrome, 
lipodystrophy and HOMA were predictors of hyperten-
sion in HIV-infected patients16.
Hypertension, insulin resistance and lipodystro-
phy
There is scarce information available on hypertension 
in HIV-infected patients according to the presence of li-
podystrophy10-13. We aimed to evaluate if the loss of sub-
cutaneous adipose tissue shown by lipodystrophy has any 
effect on blood pressure. In our study, the prevalence of 
hypertension in patients with or without lipodystrophy 
clinically or FMR defined was similar, but in men and 
using the four groups of body composition we observed 
an increase in prevalence of hypertension in those with 
lipoatrophy when compared to those without any fat dis-
tribution abnormality, despite patients with central fat ac-
cumulation and mixed forms had higher prevalence. 
Hadigan10 and Sattler11 showed that HIV patients with 
lipodystrophy had high blood pressure. Also, Crane found 
that lipoatrophy and lipohypertrophy were significantly 
associated with hypertension in HIV-infected patients40.
Gazzaruso showed that lipodystrophy and HOMA were 
predictors of hypertension in HIV-infected patients16, and 
that insulin resistance could be involved in the develop-
ment both lipodystrophy and hypertension, suggesting 
that the presence or the development of lipodystrophy in 
an HIV-infected patient should be an indication to check 
for hypertension. In our sample after adjustment for age, 
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gender and smoking history, hypertension remained as-
sociated with insulin resistance but after including BMI 
in the model, no significant association remained. Total 
body, arm and trunk fat mass, assessed by DXA were not 
associated with hypertension, independent of age, gen-
der and smoking history. Also, total abdominal, central 
and peripheral fat mass evaluated by CT scan were not 
associated with hypertension, but, central/peripheral fat 
mass ratio was significantly associated with hypertension, 
even after adjustment for the above mentioned variables. 
Patients with hypertension had higher total, central and 
central/peripheral fat mass ratio. Adipose tissue produc-
es angiotensinogen, which could lead to an activation of 
renin-angiotensin-aldosterone, an important endocrine 
blood pressure regulatory system 41,42. But, the loss of 
subcutaneous peripheral adipose tissue can also contrib-
ute to hypertension through insulin resistance16. The 
presence of hypertension was more prevalent in patients 
with isolated central fat accumulation and mixed forms 
of lipodystrophy (patients with abdominal prominence re-
gardless of the presence or absence of lipoatrophy). This 
could mean that abdominal prominence, as in the general 
population, is more important in determining hyperten-
sion, thus the central/peripheral fat mass ratio combining 
the effect of central fat accumulation with loss of subcu-
taneous adipose tissue is more strongly associated with 
hypertension.
Another important aspect is the association between 
hypertension and smoking. As in our data smokers had 
significantly lower prevalence of hypertension43-47. How-
ever after adjustment for age, no significant differences 
remained in the occurrence of hypertension according to 
smoking history. 
Our study has some limitations. Although, all patients 
referred by the Infectious Diseases Department to our 
Department were included, bias in the referral cannot be 
excluded, since some patients could have been referred be-
cause they had some degree of glucose intolerance or dys-
lipidemia. Nevertheless, the aim of our study is to evaluate 
the influence of HIV-lipodystrophy on the prevalence of 
hypertension. It was not our aim to determine the national 
prevalence of hypertension in the HIV population, because 
these patients are not representative of the general HIV 
population in our country. Our results are cross-sectional 
and therefore to not permit causal inference. 
Some aspects of this study should be highlighted.
The study was performed in a unit that is highly experi-
enced in the assessment of metabolic and body fat abnor-
malities in HIV-infected patients; the clinical assessment 
of lipodystrophy was performed by the same investigator 
(PF); an objective definition of lipodystrophy was used 
(Fat Mass Ratio by DXA), visceral fat by CT, and con-
sistent results with both definitions of lipodystrophy were 
observed.
COnClusIOn
In summary, the prevalence of hypertension was not 
higher in HIV-cART lipodystrophic patients compared 
with patients without lipodystrophy. HIV isolated lipoat-
rophy was not significantly associated with hypertension, 
but patients with isolated central fat accumulation and 
mixed forms of lipodystrophy had a significantly higher 
prevalence of hypertension. Hypertensive HIV patients 
had significantly higher total fat, central and central/pe-
ripheral mass ratio than normotensive. After adjustment 
for age, gender, smoking and BMI, hypertension re-
mained significantly associated with central/peripheral 
fat mass ratio.
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Abstract 
 
Introduction: Combined antiretroviral therapy (cART) in the treatment of HIV-1 
infection has been associated with complications, including lipodystrophy, 
hyperlipidaemia, insulin resistance (IR) and diabetes. Aims:  To compare the 
prevalence of glucose homeostasis disturbances and IR in HIV patients on cART 
according to the presence of lipodystrophy (defined clinically and by Fat Mass Ratio) 
and different patterns of fat distribution and to establish their associations. Design: 
Cross-sectional cohort study. Methods: We evaluated body composition and IR and 
insulin sensitivity indexes in 345 HIV-infected adults. Results: Patients with clinical 
lipodystrophy (CL) had higher plasma glucose levels than patients without CL, without 
significant differences in plasma insulin levels, A1c, HOMA-IR, HOMA-B, QUICKI, 
or MATSUDA index. Patients with lipodystrophy defined by FMR had higher plasma 
glucose and insulin levels, A1c, HOMA-IR, QUICKI and MATSUDA than patients 
without lipodystrophy, without differences in HOMA-B. Higher insulin resistance 
(HOMA-IR   4) was present in patients with FMR-defined lipodystrophy. Patients with 
FMR-defined lipodystrophy had a higher prevalence of IFG, IGT and DM than patients 
without lipodystrophy. Significant associations between HOMA-IR and total, central 
and central/peripheral fat evaluated by CT at abdominal level were found and no 
association between HOMA-IR and peripheral fat. Association between HOMA-IR and 
total and trunk fat but no association with leg and arm fat (evaluated by DXA) was 
found. Conclusions: IR and glucose disturbances were significantly increased in 
patients with FMR-defined lipodystrophy. FMR lipodystrophy definition seems to be a 
more sensitive determinant of insulin resistance and glucose disturbances than clinical 
definition. 
 
Keywords: Lipodystrophy, insulin resistance, HIV, glucose homeostasis disturbances 
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Introduction 
Combined antiretroviral therapy (cART) in the treatment of HIV-1 infection confers 
significant survival benefit and has altered the natural history of this disease [1]. 
However, cART has been associated with metabolic complications, including 
hyperlipidemia, insulin resistance (IR), diabetes mellitus (DM) and lipodystrophy, with 
resultant increased risk of cardiovascular disease [2].    
DM is a known complication of several antiretroviral therapies, being associated with 
both short [3, 4] and long-term [5, 6] exposure to some of these drugs [7]. The reported 
prevalence of DM in HIV-infected populations ranges from 2% to 14%, with 
differences in prevalence explained by differences in demographic characteristics, 
lifestyle, and antiretroviral exposure [7-11]. Some studies have suggested an increased 
risk of premature cardiovascular disease in HIV-infected individuals, and have 
highlighted the need to understand the relationship of HIV infection and cART with the 
risk of DM, a primary cardiovascular risk factor [12, 13]. Diabetes is associated with 
IR, and IR among treated HIV-infected patients is multifactorial: in addition to the 
common contributors to IR (e.g. obesity, physical inactivity and genetic influences), 
antiretroviral drugs and lipodystrophy or alterations in body fat distribution are also 
involved [5]. The term “HIV-associated lipodystrophy syndrome” was coined, but it 
soon became clear that some patients have pure lipoatrophy, while others have central 
fat accumulation, and a subset of patients have a mixed picture of both morphologic 
features. As in congenital lipodystrophy, lipodystrophy related to HIV-infected patients 
is also associated with IR and overt DM [12, 14, 15]. 
The aim of this study was to compare the prevalence of glucose homeostasis 
disturbances and IR in HIV-infected adult patients on cART according the presence of 
lipodystrophy [clinically defined and FMR-defined determined by whole-body dual-
energy X-ray absorptiometry (DXA)] and to different patterns of fat distribution, and to 
establish the main contributors to these alterations in HIV-infected adults.  
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Methods 
 
Subjects 
As part of a cross-sectional cohort study, 345 HIV-infected Caucasian adults, 239 men 
and 106 women, who were non-institutionalized, were evaluated in the Endocrinology 
Outpatient Department of São João Hospital, consecutively referred from the Infectious 
Diseases Clinic. Patients were included on the first visit, and all were on cART. The 
study protocol was approved by the Hospital Ethics Committee for Health and all 
patients provided informed consent.  
 
Clinical assessment 
For each patient the following information was collected using a standardized protocol: 
demographic data (age, gender), duration of HIV infection, HIV infection risk factors, 
duration of cART and characterization of the infection. We used the “Centers for 
Disease Control and Prevention” (CDC) criteria for classifying the degree of infection 
[16]. Clinical history of diabetes, hypertension and use of anti-diabetic, anti-
hypertensive and lipid-lowering drugs, as well as duration of cART, were also 
evaluated. Weight, height, circumferences of neck, waist, hip, thigh and arm were 
measured as previously published [17-20]. Blood pressure (BP) was measured after 5 
minutes seated, with the elbow flexed at the heart, using a standard aneroid 
sphygmomanometer with the cuff on the upper right arm. Two blood pressure readings 
were taken and the mean of the two readings was calculated. Body mass index (BMI) 
was calculated as weight divided by height squared (kg/m2). Clinical lipodystrophy was 
defined as a peripheral lipoatrophy with or without central fat accumulation assessed by 
both patient and practitioner, as we have previously described [17-20]. Presence of 
central fat accumulation or abdominal prominence was defined by the measurement of 
waist circumference using the International Diabetes Federation (IDF) criteria for 
metabolic syndrome [21].  
Patients were classified into 4 different groups according the presence or absence of 
either clinical lipoatrophy or abdominal prominence: no lipodystrophy - patients 
without clinical lipoatrophy and without abdominal prominence; isolated central fat 
accumulation - patients without clinical lipoatrophy and with abdominal prominence; 
isolated lipoatrophy - patients with clinical lipoatrophy and without abdominal 
prominence; mixed forms of lipodystrophy - patients with clinical lipoatrophy and 
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with abdominal prominence. The clinical assessment was performed by the same 
practitioner (PF).   
 
Evaluation of body composition 
Body composition was also assessed with whole-body dual–energy X-ray 
absorptiometry (DXA – Lunar Expert XL). DXA measurement was performed while 
the patient was in a supine position, with standard positioning of the arms and feet. 
Markers used in this study for trunk and lower limbs that defined regions of interest 
were those indicated by the manufacturer. Regional fat mass values were grouped and 
analysed for the following anatomical regions: arms, legs, trunk and total body. The fat 
mass ratio (FMR) is the ratio of the percentage of the trunk fat mass to the percentage of 
the lower limb fat mass (FMR= % of the trunk fat mass/ % of the lower limb fat mass) 
[22]. We define lipodystrophy by FMR using the cut-off value of 1.961 threshold for 
men and 1.329 for women [17].The quantification of total, visceral, and peripheral fat 
was performed with a 64-slice computed tomography (CT) scanner (Siemens Sensation 
64 Cardiac) with the same technique as previously described [23, 24]. All values were 
expressed in cm2 rounded to the nearest centesimal.  
 
Laboratory analysis 
A venous blood sample was drawn after a 12-hour overnight fast. All the samples were 
analysed at the central laboratory of our hospital. Patients without a previous diagnosis 
of diabetes were submitted to a glucose tolerance test (OGTT). The test was performed 
as described by the World Health Organization using a glucose load containing the 
equivalent of 75g anhydrous glucose dissolved in water. 
Hepatitis C was diagnosed by HCV-Ab serostatus. The CD4 cell count was determined 
by flow cytometry and plasma HIV-1 RNA loads were measured by a quantitative 
reverse transcriptase polymerase chain reaction (Roche Diagnostic Systems, Inc., 
Branchburg, NJ, USA), which has a lower limit of detection of 50 copies/mL. 
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Definition of the alterations of glucose metabolism 
Diabetes was defined if two consecutive measurements of fasting plasma glucose were 
≥126 mg/dL and if 2 h plasma glucose was ≥200 mg/dL during the oral glucose 
tolerance test (OGTT).  
Alterations of glucose metabolism were defined by American Diabetes Association 
(ADA) 2009 criteria [25]. We classified patients into 4 different categories of glycaemic 
profile (normoglycaemia – NG, impaired fasting glucose – IFG, impaired glucose 
tolerance – IGT and diabetes mellitus type 2 – DM), according to plasma glucose levels 
at 0’ and 120’ measured during OGTT. 
Measurements of insulin resistance 
IR was defined by the homeostasis model assessment of insulin resistance (HOMA) and 
insulin sensitivity by the quantitative insulin sensitivity check index (QUICKI) and 
Matsuda index. These indexes were calculated using the following formulas: 
HOMA-IR index = (fasting insulin 0 x fasting glucose 0)/22.5 [26].  
HOMA B index = (20x insulin 0 (mU/mL))/(glucose 0 (mMol/L) -3.5) [26]. 
QUICKI = 1/(log fasting insulin in mU/l +log fasting plasma glucose in mg/dL[27]. 
Matsuda Index = 10 000/sqrt [glyc 0x insulin 0 x (glyc mean x insulin mean)]  [28]. 
Glucose expressed in mmol/L and insulin in UI/mL.  
IR was defined when the value of HOMA >4 [29, 30] . 
 
Statistical analysis 
Statistical analysis was performed using SPSS version 17.0 software (SPSS Inc., 
Chicago, Illinois, USA). All probabilities were two tailed and p values <0.05 were 
regarded as significant.  
Data were described as mean and standard deviation (SD) for quantitative variables and 
compared using the Student-t test or the Mann-Whitney test as appropriate. 
Furthermore, analysis of variance or the Kruskal-Wallis test were used for the 
comparison between quantitative variables. Categorical variables were described as 
counts and proportions, and compared using the chi-square or Fisher’s exact test.  
Spearman correlation coefficients were calculated to estimate the associations between 
HOMA-IR and body fat mass evaluated either by CT or DXA.  
After log transformation, linear regression models were computed for estimating the 
association between FMR and HOMA score, fasting and 2 hours glucose and A1C 
levels. Models were adjusted for age, sex, current antiretroviral therapy [protease 
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inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse 
transcriptase inhibitor (NNRTI)], CD4 count cells and plasma HIV-1 RNA load. 
 
Results 
 
Baseline characteristics 
A total of 345 HIV-infected patients on cART were evaluated with a mean age of 
45.0±11.3 years. 69.3% were males. The demographic and clinical characteristics of the 
patients included in this study, according to the presence of lipodystrophy are shown in 
Table 1. Patients with clinical lipodystrophy (CL) were older, had higher duration of 
HIV infection and length of cART. Regarding anthropometric measures, patients with 
CL had lower BMI, waist, hip, thigh, and arm circumferences. Patients with CL had 
higher CD4+ cell count and percentage of viral suppression. With regards to the risk of 
HIV transmission in patients with CL, heterosexuality was responsible for 52.9%, 
followed by drug addiction in 30.6%, homo-bisexuality in 11.2%. In the remaining 
cases, haemophilia, transfusions and unknown causes were responsible for 1.2%, 1.2% 
and 2.9%, respectively. Similarly, in patients without CL, heterosexuality was also the 
leading cause with 65.8%, followed by drug addiction, homo-bisexuality and unknown 
causes in 24.6%, 8.8% and 0.9%, respectively. No significant difference was observed 
in lipodystrophic patients according to HIV risk transmission. The prevalence of co-
infection was similar in patients with and without lipodystrophy [clinically- (Table 1) or 
FMR-defined (data not shown)]. Nevertheless, patients with no lipodystrophy and with 
isolated peripheral lipoatrophy exhibited a higher proportion of hepatitis C co-infection 
when compared to the other two groups (Table 2). 
There was a significant difference in the different stages of CDC criteria between 
patients with or without lipodystrophy, with the majority of patients being in groups A 
or C. No differences were observed in the type of cART between the two groups of 
patients, nor in hypoglycaemic therapy (oral anti-diabetic drug and insulin). FMR 
evaluated by DXA was higher in patients with CL. When body fat mass was evaluated 
using quantitative CT, patients with CL had lower total and peripheral fat, but higher 
central/peripheral fat ratio than patients without CL. 
No differences in smoking status between patients with or without lipodystrophy 
[clinically- (Table 1) or FMR-defined (data not shown)] were found. Patients with no 
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lipodystrophy and with isolated peripheral lipoatrophy were more frequently current 
smokers when compared to the other two groups (Table 2).  
Insulin resistance 
No significant differences in the means of HOMA-IR, QUICKI, MATSUDA, insulin 
and A1c were observed between patients with and without CL. In fact, regarding the 
alterations of glucose metabolism, only for fasting glucose was there a trend for 
significantly higher values in CL. On the other hand, when lipodystrophy was defined 
by FMR, all indicators of insulin resistance and glucose metabolism were significantly 
associated with lipodystrophy with the obvious exception of QUICKI and MATSUDA 
indices (Table 3).   
Higher prevalence of insulin resistance, defined as HOMA-IR  4, was observed in 
patients with lipodystrophy defined by FMR (p=0.019) but not when lipodystrophy was 
clinically defined. Similar results were observed when we compared the prevalence of 
HOMA score thirds according to the definition of lipodystrophy. Again, only when 
lipodystrophy was defined by the FMR were the differences between HOMA score 
thirds statistically significant (p=0.002) (Table 4).  
Glucose homeostasis abnormalities 
When we classified patients into the 4 ADA categories of glycaemic profile, no 
significant differences were found between these categories in patients with or without 
CL. However, patients with lipodystrophy defined by FMR had a higher prevalence of 
IFG, IGT and DM when compared to patients without lipodystrophy (Table 5). When 
patients were stratified into 4 groups of fat distribution (presence or not of clinical 
lipoatrophy and abdominal prominence), no differences were observed in glycaemic 
profile. However, when we divided patients according to the 4 categories of fat 
distribution (presence or not of lipodystrophy defined by FMR and abdominal 
prominence), patients with abdominal prominence independent of the presence of 
lipodystrophy had higher IGT. Moreover, the highest prevalence of DM was observed 
in patients with lipodystrophy and abdominal prominence (Table 6). 
Association between HOMA-IR and body fat mass evaluated by CT and DXA 
After log transformation, significant associations were found between total fat, central 
fat and central/peripheral fat ratio evaluated by CT at abdominal level and HOMA-IR. 
These associations remained significant after adjustments for age, gender, PI, NRTI, 
NNRTI, CD4 cell count and HIV-1 RNA viral load. On the other hand, no significant 
association was found between IR and peripheral fat. Similar results were observed 
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when fat distribution was evaluated by DXA. Significant associations were found 
between total, trunk and arm fat mass evaluated by DXA and HOMA-IR. Also, these 
associations remained significant after adjustments for age, gender, PI, NRTI, NNRTI, 
CD4 cell count and HIV-1 RNA viral load (Table 7). 
Association between FMR and glycaemic parameters and insulin resistance 
After log transformation, a significant positive linear association was observed between 
FMR and insulin resistance evaluated by HOMA. This association was independent of 
age, gender, IP, NRTI, NNRTI, CD4 cell count and HIV-1 RNA viral load. No 
significant association was observed with the glycaemic parameters (Table 8). We 
performed linear regression models of the association between FMR and the variables 
described above, after excluding patients that were on anti-diabetic or insulin therapy, 
and similar results were obtained (data not shown). 
 
Discussion 
We compared the prevalence of glucose homeostasis disturbances and IR in HIV-
infected patients on cART, according to the presence of lipodystrophy (clinically and 
FMR defined) and according to the four different patterns of body fat distribution 
previously described. In our study, all the participants were evaluated by the same 
observer (PF) to increase the accuracy in the clinical definition of lipodystrophy [22]. 
We also used an objective method to evaluate lipodystrophy to overcome the different 
and heterogeneous methodologies for the diagnosis of lipodystrophy of previous studies 
[31]. Since lipodystrophy in HIV-1 infected patients is considered to be an adverse 
effect of cART, not limited to a specific drug or a class of drugs [32], we chose to study 
only patients on cART, since our main goal was to compare the prevalence of glucose 
homeostasis disturbances and IR according to the presence of lipodystrophy. No 
differences were observed between the class of drugs used in patients with or without 
CL, defined either clinically or by FMR (data not shown). Also, similar results were 
observed when the comparison was performed in patients with and without 
lipodystrophy defined by FMR (data not shown). Despite the euglycaemic-
hyperinsulinaemic clamp being the gold standard technique for estimation of IR [33], 
we used simple methods that have shown a good correlation with the gold standard 
method (HOMA-IR, QUICKI and MATSUDA) [28, 34]. There are studies comparing 
the prevalence of DM in HIV patients and the general population, and comparing ART-
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naïve HIV-infected patients with the general population, but fewer compared this 
prevalence between patients with or without lipodystrophy. 
When patients were classified as being lipodystrophic or not, according to FMR, we 
observed that patients with lipodystrophy had higher IR (higher HOMA and lower 
QUICKI and Matsuda values). Matsuda index seems to have a greater ability to predict 
diabetes than its HOMA equivalents [34]. They also had higher fasting plasma glucose, 
insulin and A1C levels, and higher % of IFG, IGT and DM. When we categorised 
patients into 4 categories of body fat distribution using FMR-defined lipodystrophy and 
waist circumference, those patients with lipodystrophy and abdominal prominence had 
higher prevalence of DM and IGT. Patients without FMR-defined lipodystrophy but 
with abdominal prominence only had a high prevalence of IGT. It seems that the loss of 
peripheral adipose tissue is less important than the presence of abdominal prominence 
in the occurrence of IR. However, the role of peripheral adipose tissue cannot be 
completely precluded, since patients with abdominal prominence only and without 
lipodystrophy, defined by FMR, had less marked glucose disturbances i.e. they only had 
increased prevalence of IGT. The discrepancy observed between the results obtained 
using the 2 different lipodystrophy definitions (Tables 3, 5 and 6) could result from the 
higher accuracy of the objective method in detecting slight losses of peripheral adipose 
tissue that were not detected by clinical inspection, as has been previously proposed by 
Bonnet [22].  
Significant associations between IR and total fat, central fat and central/peripheral fat 
ratio and no association with peripheral fat at abdominal level evaluated by CT were 
observed, emphasizing the contribution of the central fat mass to IR. We found an 
association between IR and total and trunk fat evaluated by DXA. As in our results, De 
Wit et al showed that clinical lipodystrophy was significantly associated with new-onset 
diabetes and the abnormal body fat distribution in HIV-positive individuals is strongly 
associated with IR and/or glucose intolerance, with excess trunk or visceral fat being, as 
in the general population, an important risk factor for IR among those with HIV 
infection. In addition, De Wit observed that IR is itself independently associated with 
fat loss in HIV-positive individuals [5].  
In our sample, no association was observed between peripheral fat mass and IR (Table 
7). This result is contrary to that of the De Wit study, where patients had a marked 
peripheral adipose tissue loss that was clinically evident. Also, our patients may have 
had less evident loss of fat mass, which was detected by FMR. In fact, according to De 
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Wit’s conclusions, information on lipodystrophy was rarely collected since the study 
was carried out in 11 centres, which may suggest that only marked lipodystrophies were 
reported.  
The dual contribution of peripheral fat loss and increased abdominal fat has also been 
described by other authors [35-38]. Furthermore, hyperinsulinaemia seems to be more 
severe among the patients with a combined fat redistribution syndrome. 
In our HIV-infected sample, we had a high prevalence of diabetes (20.2%), of IGT (22.5 
%) and IFG (8.3%). This high prevalence could not be extrapolated for the total HIV 
population since we could have a referral bias, but we would like to emphasise that our 
aim was to evaluate the prevalence of glucose homeostasis disturbances and IR 
according to the presence of lipodystrophy. In HIV-infected patients, some studies 
showed a low prevalence of diabetes, around 3.0%, but without performing OGTT, 
which could have resulted in some under-identification of glucose disturbances [39]. 
Others suggested that the prevalence and incidence of diabetes was higher (10-14%) [7, 
8, 40-42] but still lower than that which we observed. Concerning HIV-associated 
lipodystrophy, Carr found a baseline diabetes prevalence of 2% [43] and an over 
threefold increase after 14 months of follow-up [44], which suggests that lipodystrophy 
strongly promotes the progression to hyperglycaemia. The overall prevalence of all 
glucose disturbances (DM, IFG and IGT) was 25% [43]. In the Lipodystrophy Case 
Definition Study, diabetes prevalence was 7% in those with lipodystrophy and 3% in 
those without [45].  
It is extremely difficult to determine which drug is responsible for the risk of diabetes 
because they are always used in combination and therapeutic changes in individual 
participants often occur during the course of the disease. The results are generally 
consistent, indicating a higher risk of diabetes with use of NRTI and NNRTI [46, 47]. 
Also, others have shown that regimens containing PI are associated with new-onset 
diabetes and IR [48, 49]. cART has direct effects on glucose metabolism, or exerts its 
effect on glucose metabolism indirectly by affecting changes in body composition. PIs 
directly and/or indirectly alter body composition, lipid profile, adipokine levels, and 
mediators of inflammation. The newer cART regimens may be less detrimental to 
insulin action than older regimens.  
In our study, FMR as a continuum was significantly associated with insulin resistance 
evaluated by HOMA, even after adjustment for gender, age, IP, NRTI, NNRTI, CD4 
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cell count and HIV RNA viral load. No association between clinical and FMR-defined 
lipodystrophy and glycaemic parameters was observed.  
The association between fat redistribution, glucose disturbances, IR and cART, might 
be explained through several mechanisms: lipoatrophy per se; lipotoxicity (cART or 
visceral fat-induced or both, demonstrated by increased lipolysis and circulating free 
fatty acids) [2]; inflammation (resulting from the infection and demonstrated by 
increased TNF-alpha production, increased serum concentrations of the soluble type 2 
receptor of TNF-alpha [38] and other interleukins), and hormonal factors (leptin, 
resistin or adiponectin).  
We should keep in mind that IR and diabetes are associated with age, so increased life 
expectancy with the use of cART is likely to increase the prevalence of diabetes [7].  
The net risk of diabetes mellitus is determined by a complex interplay of individual 
factors, combining the traditional risk factors and newer risk factors associated with 
HIV-infected patients on cART. The clinical implications and message should be the 
need to aggressively screen for, prevent, and treat diabetes mellitus among HIV-infected 
patients because the presence of diabetes increases the risk of a future CHD event by 
almost 2.5 times [7]. 
 
Our study has some limitations. Although all patients referred from Infectious 
Diseases to our department were included, bias in the referral cannot be excluded, since 
some patients could have been referred because they had some degree of glucose 
intolerance or dyslipidaemia. It was not our aim to determine the prevalence of glucose 
homeostasis disturbances in the HIV population, because these patients are not 
representative of the general HIV population in our country. Our aim was to compare 
the prevalence of glucose homeostasis disturbances and IR in HIV-infected patients 
according the presence of lipodystrophy and to different patterns of fat distribution. 
Also, information regarding other important risk factors for DM (e.g. family history, 
physical inactivity) was not collected and could not be analysed. Some drugs used for 
managing complications of HIV infection may be associated with worsening IR or DM; 
we believe that if there was any effect it was very small, since none of our patients were 
on niacin, megestrol acetate or steroids, and only some of them were on thiazides for the 
management of hypertension.  
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Some aspects of this study should be highlighted. 
The study was performed in a unit that is highly experienced in the assessment of 
metabolic and body fat abnormalities in HIV-infected patients; the clinical assessment 
of lipodystrophy was carried out by the same investigator (PF); and an objective 
definition of lipodystrophy (Fat Mass Ratio by DXA), visceral and subcutaneous fat 
mass by CT was used.  
 
Conclusions 
Insulin resistance and glucose homeostasis abnormalities significantly increased with 
increasing FMR. Abdominal prominence, measured by abdominal circumference, 
waist/hip ratio, visceral and trunk fat defined by CT, was also associated with glucose 
homeostasis disturbances.  
Although no association between glucose disturbances and IR was observed in 
clinically defined lipodystrophy, when this condition was defined by FMR, a significant 
positive association was observed. 
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Table 1: Sample characteristics according to the presence of clinical lipodystrophy. 
 
 Without CL With CL P 
n (%) 139 206  
Gender [n (%)] 
  Male 
  Female 
 
85 (61.2) 
54 (38.8) 
 
154 (74.8) 
52 (25.2) 
 
0.007 
 
Age [years, mean (sd)] 44.2 (12.1) 46.9 (10.7) 0.007 
Duration of HIV infection [years, median 
(IQR)] 
6.0 (5.0) 9.0 (5.0) <0.001 
cART [years, median (IQR)]  4.0 (5.0) 8.0 (5.0) <0.001 
Weight [Kg, mean (sd)] 73.7 (14.1) 66.2 (12.4) <0.001 
Height [m, mean (sd)] 1.65 (0.09) 1.66 (0.09) 0.368 
BMI [(kg/m2), median (IQR)] 26.3 (5.9) 23.8 (5.1) <0.001 
Waist circumference  [cm, median (IQR)] 94.0 (17.0) 89.0 (14.5) <0.001 
Hip circumference  [cm, median (IQR)] 99.0 (11.0) 91.0 (9.0) <0.001 
Thigh circumference  [cm, mean (sd)] 50.0 (5.5) 46.1 (6.1) <0.001 
Arm circumference  [cm, mean (sd)] 28.1 (3.1) 26.6 (4.1) <0.001 
Neck circumference  [cm, mean (sd)] 37.2 (3.7) 37.1 (4.0) 0.940 
CD4 cell count [cells/mm3, median (IQR)] 446.5 (342.2) 544.0 (387.0) 0.008 
HIV RNA (<50) [n (%)] 93 (81.6) 163 (91.1) 0.017 
Smoking history [n (%)] 
Never 
Current 
Former 
 
61 (44.2) 
55 (39.9) 
22 (15.9) 
 
70 (34.8) 
93 (46.3) 
38 (18.9) 
 
 
0.219 
HIV risk factor [n (%)]    
    Injecting drug user 28 (24.6) 52 (30.6)  
 
 
0.247 
    Homosexual contact 10 (8.8) 19 (11.2) 
    Heterosexual contact 76 (65.8) 90 (52.9) 
    Others 1 (0.9) 9 (5.3) 
Hepatitis C co-infection [n (%)] 31 (25.2) 58 (31.4) 0.300 
CDC [n (%)]    
      A 62 (54.9) 94 (53.4)  
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      B 4 (3.5) 0 (0)  
0.037      C 47 (41.6) 82 (46.6) 
ART [n (%)]    
     IP 67 (61.5) 98 (55.4) 0.310 
      NNRTI 47 (43.1) 83 (46.9) 0.534 
      NRTI 104 (95.4) 175 (98.9) 0.110 
Hypoglycemic therapy [n (%)]    
 Oral anti-diabetic drugs 10.1% (14) 14.6% (30) 0.132 
        Insulin  4.3% (6) 7.3% (15) 0.261 
Body fat mass by quantitative CT    
  Total fat [cm2, median (IQR)] 340.5 (196.6) 213.6 (175.2) <0.001 
 Central fat [cm2, median (IQR)] 110.8 (111.4) 114.8 (120.5) 0.800 
 Peripheral fat [cm2, median (IQR)] 186.2 (172.0) 78.7 (104.9) <0.001 
 Central/peripheral fat ratio [cm2, median 
(IQR)] 
0.51 (0.55) 1.34 (2.15) <0.001 
FMR by DXA [median (IQR)] 1.06 (0.57) 1.79 (1.37) <0.001 
(CL- clinical lipodystrophy; CDC - Centers for Disease Control and Prevention criteria for staging of 
HIV infection -; cART- combined antiretroviral therapy; BMI- body mass index; FMR – fat mass ratio; 
DXA –dual-energy X-ray absorptiometry ; CT – computed tomography; PI – protease inhibitor; NNRTI –
non-nucleoside reverse transcriptase inhibitor; NRTI – nucleoside reverse transcriptase inhibitor). 
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Table 2 - Smoking history and hepatitis C co-infection according to the four 
groups of body fat distribution 
 
 
 
 
 
 No 
lipodystrophy 
Isolated 
central fat 
accumulation 
Isolated 
peripheral 
lipoatrophy 
Mixed forms of 
lipodystrophy 
p 
Smoking history 
[n (%)] 
Never 
Current 
Former 
 
 
14 (28.0) 
30 (60.0) 
6 (12.0) 
 
 
46 (52.9) 
25 (28.7) 
16 (18.4) 
 
 
24 (22.4) 
67 (62.6) 
16 (15.0) 
 
 
45 (48.4) 
26 (28.0) 
22 (23.7) 
 
 
 
 
<0.001 
Hepatitis C co-
infection [n (%)] 
 
19 (45.2) 
 
12 (14.8) 
 
46 (47.9) 
 
11 (12.5) 
 
<0.001 
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Table 3: Insulin resistance indices according to lipodystrophy defined clinically 
and by FMR 
 
 
  Lipodystrophy defined 
clinically 
Lipodystrophy defined by FMR 
 Total Without 
CL 
With CL P Without L With L P 
HOMA-IR 
[median 
(IQR)] 
1.9 (2.8) 1.7 (2.4) 2.1 (3.0) 0.229 1.6 (2.6) 2.8 (2.8) <0.001 
HOMA-B 
[median 
(IQR)] 
92.3 
(106.4) 
92.3 
(91.1) 
91.8 
(117.5) 
0.855 92.3 (96.1) 85.4 
(120.8) 
0.633 
QUICKI 
[median 
(IQR)] 
0.34 
(0.06) 
0.35 
(0.06) 
0.34 
(0.06) 
0.229 0.36 (0.07) 0.33 
(0.05) 
<0.001 
MATSUDA 
[median 
(IQR)] 
4.8 (5.1) 5.0 (4.2) 4.7 (5.4) 0.735 5.9 (5.3) 4.1 (4.4) 0.002 
Glucose 
[mg/dL, 
median (IQR)] 
93.5 
(26.0) 
90.0 
(23.0) 
97.0 
(35.5) 
0.046 90.0 (23.0) 97.0 
(35.5) 
0.002 
Insulin 
[U/mL, 
median (IQR)] 
8.1 (9.6) 7.9 (8.2) 9.0 (10.2) 0.365 7.5 (8.1) 10.1 
(9.9) 
0.003 
A1c [% 
median (IQR)] 
5.3 (0.7) 5.2 (0.6) 5.3 (0.9) 0.091 5.2 (0.6) 5.5 (0.9) 0.002 
 
 
(CL- clinical lipodystrophy; L- lipodystrophy). 
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Table 7: Association between HOMA-IR and body fat mass evaluated by CT and 
DXA 
 
 Crude model Model 1* Model 2** 
 β P Β p β p 
Body Fat Mass 
by Quantitative 
CT 
      
Total Fat  0.384 0.001 0.419 0.001 0.415 0.001 
Central Fat  0.516 <0.001 0.486 <0.001 0.490 <0.001 
Peripheral Fat  0.050 0.530 0.127 0.168 0.114 0.222 
Central/peripheral 
fat ratio 
0.258 0.001 0.239 0.015 0.262 0.008 
Body fat mass by 
DXA 
      
Total 0.247 0.024 0.374 0.002 0.420 0.001 
Trunk 0.403 <0.001 0.467 <0.001 0.502 <0.001 
Leg -0.043 0.625 0.049 0.653 0.087 0.438 
Arm 0.162 0.058 0.352 0.001 0.366 0.001 
*-Mode1: adjusted for age and gender 
**-Model 2: adjusted for age, gender, IP, NRTI, CD4 cell count and HIV-1 RNA viral 
load 
(DXA –dual-energy X-ray absorptiometry; CT – computed tomography) 
PubLicAçõES
	 	 
27 
 
 
 
 
 
Table 8: Association between FMR and glycaemic parameters and insulin 
resistance 
 Crude model Model 1* Model 2** 
 β P Β p β p 
HOMA 0.589 <0.001 0.595 0.001 0.266 0.002 
Glucose 0´ 0.124 0.002 0.041 0.367 0.098 0.222 
Glucose 2h 0.079 0.142 0.086 0.139 0.149 0.104 
A1C 0.053 0.015 0.007 0.765 0.083 0.314 
*-Mode1: adjusted for age and gender 
**-Model 2: adjusted for age, gender, IP, NRTI, CD4 cell count and HIV-1 RNA viral 
load 
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Abstract 
Background: Combined antiretroviral therapy (cART) is very effective in the reduction 
of HIV disease progression and mortality, but it is associated with lipodystrophy, lipid 
abnormalities and cardiovascular disease. Emerging risk factors may also predispose 
HIV-infected patients to accelerated atherosclerosis, namely apolipoprotein A1, 
apolipoprotein B, Lp (a), fibrinogen, hs-CRP, homocysteine, microalbuminuria and NT-
proBNP serum levels. Aims: To compare serum lipids and cardiovascular risk factors in 
HIV-infected patients on cART according to the presence of lipodystrophy [defined 
clinically (CL) and by Fat Mass Ratio (FMR-L)] and four different patterns of fat 
distribution. Methods: We evaluated body composition and emerging cardiovascular 
risk factors in 181 HIV-infected adults. Results: Patients with CL had lower total 
cholesterol, LDL-C, HDL-C and Apo A1 and higher triglyceride levels, with no 
differences in the other parameters analysed. Patients with FMR-L had higher 
triglycerides and uric acid and lower Lp(a) levels than patients without FMR-L. Patients 
with abdominal prominence, independent of the presence of lipoatrophy (isolated 
central fat accumulation and mixed forms of lipodystrophy), had higher levels of total 
cholesterol, LDL-C and Apo B. Patients with isolated lipoatrophy and mixed forms of 
lipoatrophy had higher triglycerides and the lowest Apo A1 levels. Significant positive 
linear associations were observed between FMR and triglycerides and Apo B/Apo A 
ratio, and a negative one with Apo A1. Theses associations, with the exception of Apo 
A1, were independent of age, gender, IP and NRTI. Conclusions: The emerging 
cardiovascular risk factors did not vary according to fat redistribution. In HIV-infected 
patients, the 2 components of body fat redistribution syndrome seemed to induce 
different deleterious effects – central fat accumulation induced increased total 
cholesterol, LDL cholesterol and Apo B – and isolated lipoatrophy induced low Apo A1 
and high triglycerides. In the analysis of the components of adipose tissue redistribution 
syndrome, abdominal prominence seemed to be more important than lipoatrophy in this 
association. 
 
Keywords: Lipodystrophy; HIV, Lp(a), apolipoprotein A1, apolipoprotein B, 
cholesterol and triglycerides, homocysteine, fibrinogen, hs-CRP, microalbuminuria, 
NT-proBNP; cardiovascular risk factors 
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Introduction 
Genetic lipodystrophies are rare disorders associated with dyslipidemia and increased 
cardiovascular risk [1]. Lipodystrophy associated with HIV or with its treatment is a 
common manifestation of the disease. Combined antiretroviral therapy (cART) was a 
major advance in the management of HIV infection, being highly effective in the 
reduction of disease progression and mortality [2]. However, cART has been associated 
with changes in serum lipids and with inherent increases in cardiovascular risk, which 
has important implications in HIV therapeutic decision making and long term patient 
management. cART is also associated with changes in body habitus due to fat 
redistribution (lipodystrophy): peripheral lipoatrophy and central fat accumulation. 
These two distinct phenotypes can occur together or separately. There is a suggestion 
that emerging non-traditional risk factors may predispose HIV-infected patients to 
accelerated atherosclerosis. Apolipoprotein A1, apolipoprotein B, lipoprotein (a) [Lp 
(a), fibrinogen, high sensitivity C-reactive protein (hs-CRP), homocysteine, 
microalbuminuria and NT-proBNP serum levels have also been associated with 
increased cardiovascular risk, and some of them are related to inflammation [3-18].  
The aims of this study were to compare the serum lipids, metabolic and cardiovascular 
risk factors in HIV-infected patients on cART according to the presence of 
lipodystrophy [defined clinically (CL) and by Fat Mass Ratio (FMR)] and four different 
defined patterns of fat distribution and to assess the relationship of these parameters 
with FMR.  
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Methods 
 
Subjects 
As part of a cross-sectional study, consecutive clinically stable HIV-infected adults 
receiving cART were evaluated at the Endocrinology Outpatient Department. Of the 
368 HIV-1 infected patients (254 men and 114 women) on cART included in our cohort, 
we excluded 187 patients from this study because they were on lipid lowering drugs 
(statins and/or fibrates). The study protocol was approved by the Hospital Ethics 
Committee and all patients provided informed consent.  
 
Clinical assessment 
For each patient the following information was collected using a standardized protocol: 
demographic data (age, sex), duration of known HIV infection, HIV infection risk 
factors, duration of cART and disease stage. The “Centers for Disease Control and 
Prevention” (CDC) HIV staging classification was used [19]. Weight, height, 
circumferences of neck, waist, hip, thigh and arm were measured, as previously 
described [20, 21] All measurements were performed by the same observer (PF) using 
standard techniques [22]. Clinical lipodystrophy (CL) was defined as a peripheral 
lipoatrophy with or without a central fat accumulation as assessed by both patient and 
practitioner as we previously described [20, 21, 23]. Presence of central fat 
accumulation or abdominal prominence was defined by the measurement of waist 
circumference using the International Diabetes Federation (IDF) criteria for metabolic 
syndrome [24]. The clinical assessment was performed by the same practitioner (PF). 
Patients were distributed into 4 different groups according to the presence of fat 
redistribution features: 1) No lipodystrophy- patients without clinical lipoatrophy and 
without abdominal prominence; 2) Isolated central fat accumulation - patients 
without clinical lipoatrophy and with abdominal prominence; 3)  Isolated lipoatrophy - 
patients with clinical lipoatrophy and without abdominal prominence; 4) Mixed forms 
of lipodystrophy - patients with clinical lipoatrophy and with abdominal prominence. 
The quantification of total, visceral, and peripheral fat was performed with a 64-slice 
computed tomography (CT) scanner (Siemens Sensation 64 Cardiac), as previously 
described [25, 26]. 
Body composition was assessed with whole-body dual-energy X-ray absorptiometry 
(DXA – Lunar Expert XL). DXA measurement was performed while the patient was in 
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a supine position, with standard positioning of the arms and feet. Markers used in this 
study for trunk and lower limbs that defined regions of interest were those indicated by 
the manufacturer. Regional fat mass values were grouped and analysed for the 
following anatomical regions: arms, legs, trunk and total body. The fat mass ratio 
(FMR) is the ratio of the percentage of the trunk fat mass to the percentage of the lower 
limb fat mass (FMR= % of the trunk fat mass/ % of the lower limb fat mass) [27]. We 
used the cut-off value for lipodystrophy defined by FMR for men of 1.961 and for 
women of 1.329 [23].  
The blood samples for biological and inflammatory parameters were drawn in fasting 
patients. The measurements of total cholesterol (TC), low density lipoprotein (LDL) 
cholesterol, high-density lipoprotein (HDL) cholesterol , triglycerides, apolipoprotein 
A1, apolipoprotein B, lipoprotein (a) [Lp (a) , fibrinogen, high sensitivity C-reactive 
protein (hs-CRP), homocysteine, uric acid, lactate, and NT-proBNP serum levels were 
determined using commercial kits in the Central Laboratory at our hospital. “Non HDL-
C” was defined as the difference between total cholesterol and HDL. Microalbuminuria 
was determined in a 24 hour urine sample. hs-CRP was divided into three groups:  < 
1.0; ≥1.0 <3.0 and ≥ 3.0 mg/dL. The presence of an abnormal urine albumin excretion 
was defined as albuminuria in 24 hour urine ≥ 30.0 mg (microalbuminuria). 
Hyperfibrinogenaemia was deemed present if plasma fibrinogen was ≥ 400 mg/dL and 
hyperhomocysteinaemia if homocysteine was ≥12.44 mol/L. The CD4+ cell count was 
determined by flow cytometry and plasma HIV-1 RNA loads were measured by a 
quantitative reverse transcriptase polymerase chain reaction, which has a lower limit of 
detection of 50 copies/mL. 
 
Statistical analysis  
Statistical analysis was performed using SPSS version 18.0 software (SPSS Inc., 
Chicago, Illinois, USA). All probabilities were two tailed and p values <0.05 were 
regarded as significant.  
Data were described as mean and standard deviation (SD) for quantitative variables and 
compared using the Student-t test or the Mann-Whitney test as appropriate. For lipid 
profile and non-traditional cardiovascular risk factor according to the four groups of fat 
distribution, Kruskal-Wallis test was used. Categorical variables were described as 
counts and proportions, and compared using the chi-square or Fisher’s exact test. Linear 
regression models were computed for estimating the association between FMR and lipid 
EStuDo Do SínDroME DA LiPoDiStrofiA E DAS rEPErcuSSõES EnDócrino-MEtAbóLicAS E cArDiovAScuLArES nA infEção Por viH
2
profile and non-traditional cardiovascular risk factors, after log transformation 
whenever necessary. Models were adjusted for age, sex, PI, NNRTI and NRTI. 
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Results 
Of the 181 HIV-1 infected patients (112 men and 69 women) on cART included in this 
study, 50.3 % were classified as having clinical lipodystrophy (CL). Table 1 shows the 
characteristics of the study sample according to the presence of CL. Patients with CL 
were more frequently male, had longer known duration of HIV infection and higher 
cumulative exposure to cART, and lower weight, BMI and waist, hip, thigh and arm 
circumferences. No differences in age, neck circumference or waist/hip ratio 
circumference were found according to the presence of CL. On abdominal fat mass CT 
evaluation, patients with CL had less total and peripheral fat but had a higher 
central/peripheral ratio. No differences in central fat accumulation between patients 
with or without CL were observed on abdominal CT scan. No differences were 
observed between patients with and without CL regarding CD4+ cell count, viral 
suppression, pharmacologic groups of ARTs and CDC classification.  
Compared to patients without CL, patients with CL had lower total cholesterol, LDL-C, 
HDL-C and Apo A1 mean levels and higher triglyceride mean levels. No significant 
differences were observed in the other parameters analysed. Patients with lipodystrophy 
defined by FMR had higher triglyceride and uric acid mean levels and lower Lp(a) 
levels (Table 2).  
When patients were classified according to the four groups of fat distribution, patients 
with abdominal prominence, independently of the presence of lipoatrophy (patients with 
isolated central fat accumulation and with mixed forms of lipodystrophy) had higher 
mean levels of total cholesterol, LDL-C and Apo B (Table 3). Patients with isolated 
lipoatrophy and mixed forms of lipoatrophy had higher mean levels of triglycerides and 
the lower Apo A1 levels. 
FMR was positively associated with triglycerides and Apo B/Apo A1 ratio. A negative 
linear association was observed between FMR and Apo A1 levels. The positive 
association between FMR and triglyceride levels and Apo B/Apo A1 ratio remained 
even after adjustment for age, gender, PI, NRTI and NNRTI (p=0.006 and p=0.053 
respectively). The negative linear association observed between FMR and Apo A1 
remained significant after adjustment for age and gender, but lost its statistical 
significance after adjustment for cART treatment. No significant association was 
observed with the other parameters analysed (Table 4).  
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No significant associations were observed between hs-CRP and cART (r=0.017; 
p=0.863) and CD4 cell count (r=0.009; p=0.929). Also, there was no difference in the 
median values of hs-CRP according to viral load (Table 5).  
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Discussion 
 
Lipid profile 
Disturbances in lipid metabolism, namely elevated cholesterol and often markedly 
elevated triglyceride levels, have been increasingly recognised among HIV-infected 
subjects after the introduction of cART [28]. In the cART era, body fat partitioning 
changes have appeared early after cART initiation and have been progressive [29]. In 
many ways, this HIV-related lipodystrophy syndrome resembles the rare congenital and 
autoimmune disease lipodystrophy syndromes that are also associated with 
abnormalities in lipid profile [30]. The extent of fat redistribution has been described by 
some but not all as related to the severity of metabolic alterations [5, 31-34].  
An atherogenic lipid profile characterised by lower HDL–C and Apo A1 and higher 
triglyceride levels was observed in our HIV-infected patients on cART with CL. 
Patients with isolated lipoatrophy showed a similar pattern. The lowest Apo A1 levels 
were observed in patients with isolated lipoatrophy and mixed forms of lipodystrophy. 
Moreover, higher triglyceride levels were also found in those with FMR-defined 
lipodystrophy. Patients with abdominal prominence, either isolated central fat 
accumulation or mixed forms of lipodystrophy, had an atherogenic lipid profile 
characterised by high total cholesterol, LDL–C and Apo-B. In the general population, 
abdominal prominence is also associated with high total cholesterol, LDL–C and Apo B, 
and reduced Apo A1 [4]. Thus, it seems that patients with abdominal prominence and 
isolated lipoatrophy have a significantly different lipid profile. In Carvalho’s study [35], 
high Apo B was not associated with abdominal fat accumulation (evaluated through 
waist circumference and waist-to-hip ratio), or lipodystrophy, while others reported 
higher levels of Apo B in lipodystrophy [36-38]. So, measuring serum Apo B may be 
especially useful among patients with hypertriglyceridemia in which the cardiovascular 
risk is underestimated with the use of LDL [35]. 
In our study, Apo A1 was found to be lower in those patients with CL and in those with 
isolated lipoatrophy and mixed forms of lipodystrophy, and it was higher in patients 
with isolated central fat accumulation. A significant positive linear association was 
observed between FMR and triglycerides. This association was independent of age, 
gender, PI, NNRTI and NRTI. A negative linear association was observed between 
FMR and Apo A1 (adjusted for gender and age), but it was not significant after 
adjustment for IP, NNRTI and NRTI. This means that HIV fat redistribution syndrome 
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evaluated by FMR is linked to an atherogenic profile that includes low Apo A1 and high 
triglycerides. 
Patients with lipodystrophy defined by FMR had lower Lp(a). Lp(a) is an independent 
risk factor for CVD, mainly resulting from genetic background. It may be of particular 
interest in the context of PI-associated dyslipidemia as the atherogenic potential of 
Lp(a) appears to be enhanced in the presence of elevated concentrations of LDL [39]. In 
our data, the presence of FMR lipodystrophy seems to be protective. 
 
Emerging laboratory cardiovascular risk factors   
No significant difference in hs-CRP between patients with or without lipodystrophy 
(clinical and FMR defined) and the four groups of fat redistribution were observed. hs-
CRP, an inflammatory biomarker,  was proposed to be a valuable adjunct to traditional 
risk factors in estimating overall cardiovascular risk in HIV-infected patients on cART, 
but it remains a controversial issue [6-9, 40-42].  
We found that patients with lipodystrophy defined by FMR (but not clinically defined) 
had higher uric acid levels but we found no differences among the four defined groups 
of fat distribution. Data regarding serum uric acid levels in HIV-infected patients are 
scarce.  Walker confirmed the known factors for hyperuricaemia are relevant in HIV-
infected patients (gender, age, renal function and BMI) and found a quantitatively 
important additional influence of some antiretroviral agents on urate [10]. Urate may 
also be increased due to the mitochondrial toxicity associated with some NRTIs. 
Mitochondrial dysfunction may increase the production of lactate, which competes with 
urate for tubular secretion in the kidney. Respiratory chain failure causes ATP depletion, 
which increases urate production in the purine nucleotide cycle [10, 11]. This 
mechanism may provide an explanation for the association between some 
dideoxynucleoside analogues (stavudine, didanosine or zalcitabine) and elevated urate 
[10].  
No differences in lactate levels were observed in patients with or without lipodystrophy 
(clinical and FMR-defined) and in the four groups of fat redistribution. Lactate is a sign 
of anti-retroviral mitochondrial toxicity [43]. So, cART is associated with mitochondrial 
toxicity and related to peripheral lipoatrophy [43, 44].  
We did not find differences in microalbuminuria measurement between patients with or 
without lipodystrophy (clinical or defined by FMR) or in the four defined groups of fat 
distribution. However, it should be noted that patients with known diabetes mellitus or 
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hypertension were not excluded in our study, which is a limitation. However, in a 
previous study we found no differences in the prevalence of hypertension between 
patients with or without lipodystrophy, either clinically or FMR-defined [45]. To our 
knowledge no study has been done evaluating the influence of lipodystrophy in 
microalbuminuria. The pathophysiological mechanism underlying urinary albumin 
excretion and the increased risk of CVD is not fully understood, although endothelial 
dysfunction and inflammation have been implicated [46, 47], factors known to be 
relevant in HIV infection.  
No differences in homocysteine levels between patients with or without lipodystrophy 
(clinical or defined by FMR) or in the four defined groups of fat distribution were 
observed. Although a substantial body of epidemiological evidence suggests an 
association between cardiovascular risk and moderately increased plasma homocysteine 
levels [16, 48], and elevated plasma homocysteine levels confer an independent risk of 
vascular disease, the exact meaning of hyperhomocysteinemia remains unclear [17, 49, 
50]. 
We found no differences in NT-proBNP measurement between patients with or without 
lipodystrophy (clinical or defined by FMR) and in the four groups of fat distribution. 
NT-proBNP has been shown to be an indicator of cardiac function. Increased levels of 
B-type natriuretic peptides (BNP and/or NT-proBNP) have been associated with an 
increased risk of cardiovascular events, namely myocardial infarction, heart and cardiac 
death in different populations, as well as with the presence of diastolic and systolic 
dysfunction as assessed by echocardiography [51]. No other study has evaluated the 
impact of lipodystrophy on NT-proBNP levels. 
We did not find any differences in fibrinogen levels between patients with or without 
lipodystrophy (clinical or defined by FMR) or in the four defined groups of fat 
distribution. Plasma fibrinogen is a major determinant of blood viscosity and blood flow. 
Increasing evidence from epidemiological studies suggests that elevated plasma 
fibrinogen levels are associated with an increased risk of cardiovascular disorders, 
including ischemic heart disease, stroke, and other thromboembolic manifestations [52].  
Our study had some limitations. Although we included all patients referred from the 
Infectious Diseases Department to our Endocrinology Outpatient Clinic for metabolic 
abnormalities, we cannot exclude selection bias by the infectious disease specialist. 
Some subjects in this study were referred to the Endocrinology Clinic specifically for 
lipodystrophy or metabolic disorders related to cART, and so we might have selected a 
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study population enriched with metabolic complications. We found a high prevalence of 
lipodystrophy but there was no selection bias for the presence of isolated lipoatrophy or 
abdominal prominence since our main goal was to evaluate whether the presence of 
lipodystrophy influences the serum lipids, metabolic and emerging cardiovascular risk 
factors in HIV-infected patients on cART. Finally, this is a study with a cross-sectional 
design and so causality cannot be attributed. 
 
Some aspects of this study should be highlighted. 
Clinical assessment of lipodystrophy was carried out, and a clinical separation of 
patients into 4 patterns of fat distribution was done. Additionally, the presence of 
lipodystrophy was objectively defined using FMR assessed by DXA. The presence of 
visceral fat was objectively measured by CT. This study was performed in a unit that is 
highly experienced in the assessment of metabolic and body fat abnormalities in HIV-
infected patients, and the clinical assessment of lipodystrophy was carried by the same 
investigator (PF). 
We assessed a range of traditional and non-traditional or emerging cardiovascular risk 
factors in relation to lipodystrophy, including some that have not been previously 
reported in HIV-infected patients on cART.  
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Conclusions 
 
We concluded that patients with CL had lower total cholesterol, LDL-C, HDL-C, Apo 
A1 and higher mean levels of triglycerides. Patients with lipodystrophy defined by FMR 
had higher triglycerides and lower Lp(a). When patients were classified according to the 
four groups of fat distribution, patients with abdominal prominence, independent of the 
presence of lipoatrophy, had higher mean levels of total cholesterol, LDL-C, and Apo B.  
Low Apo A1 is a known risk indicator of coronary atherosclerosis [53] and we found 
the lowest Apo A1 plasma levels in patients with isolated lipoatrophy and mixed forms 
of lipodystrophy. Significant positive linear associations were observed between FMR 
and triglycerides and Apo B/Apo A ratio. These associations remained significant after 
adjustment for age, gender, PI and NRTI. Apo A1 had a significant negative linear 
association with FMR that remained significant after adjustment for gender and age, but 
it lost significance after adjustment for cART. The emerging cardiovascular risk factors 
did not vary according to fat redistribution. In HIV infected patients, the 2 components 
of body fat redistribution syndrome seemed to induce different deleterious effects: 
central fat accumulation induced increased total cholesterol, LDL cholesterol and Apo 
B; and isolated lipoatrophy induced low Apo A1 and high triglycerides. In the analysis 
of the components of adipose tissue redistribution syndrome, abdominal prominence 
seems to be more important than lipoatrophy in this association. 
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Table 1: Sample characteristics according to the presence of clinical lipodystrophy  
 
 Without CL With CL  
N (%) 90 (49.7) 91 (50.3) p 
Gender [n (%)] 
  Male  
  Female  
 
45 (50) 
45 (50) 
 
67 (73.6) 
24 (26.4) 
 
 
0.002 
Age [years, mean (sd)] 41.5 (10.1) 44.0 (10.6) 0.078 
Duration [years, mean (sd)] 7.2 (4.1) 9.6 (3.8) <0.001 
cART [years, mean (sd)] 4.9 (3.9) 7.8 (3.6) <0.001 
Weight [Kg, mean (sd)] 72.7 (15.5) 65.6 (13.2) 0.001 
Height [m, mean (sd)] 1.65 (0.09) 1.68 (0.09) 0.094 
BMI [(kg/m2), mean (sd)] 26.8 (5.7) 23.2 (3.8) <0.001 
Waist circumference [cm, mean (sd)] 93.6 (14.4) 87.6 (11.6) 0.004 
Hip circumference [cm, mean (sd)] 101.0 (10.4) 91.8 (6.5) <0.001 
Thigh circumference [cm, mean (sd)] 50.5 (6.8) 46.5 (6.8) <0.001 
Arm circumference [cm, mean (sd)] 28.5 (3.8) 26.9 (5.2) 0.001 
Neck circumference [cm, mean (sd)] 36.3 (3.9) 36.6 (4.2) 0.998 
Ratio waist/ hip circumference [mean 
(sd)]  
0.93 (0.09) 0.95 (0.08) 0.121 
    
CD4 cell count [cells/mm3, mean (sd)] 499.6 (306.1) 545.9 (299.4) 0.131 
HIV RNA (<50) [n (%)] 72 (85.7) 80 (89.9) 0.544 
HIV risk factor [n (%)] 
  Inject 
  Homosexual 
  Heterosexual 
  Other 
 
21 ( 24.4) 
11 (12.8) 
53 (61.6) 
1 (1.2) 
 
36 (41.9) 
8 (9.3) 
37 (43.0) 
5 (5.8) 
 
 
 
 
0.017 
    
CDC [n (%)] 
  A 
  B 
  C 
 
35 ( 55.6) 
3 (4.8) 
25 (39.7) 
 
38 (53.5) 
0 (00.0) 
33 (46.5) 
 
 
 
0.187 
cART [n (%)] 
  PI 
  NNRTI 
  NRTI 
 
50 ( 59.5) 
37 (44.0) 
81 (97.6) 
 
53(59.6) 
40 (44.9) 
88 (98.9) 
 
1.000 
1.000 
0.610 
    
Body Fat Mass by Quantitative CT    
Total fat [cm2, mean (sd)] 332.0 (171.9) 195.7 (131.4) <0.001 
Central fat [cm2, mean (sd)] 106.5 (73.4) 102.8 (80.4) 0.445 
Peripheral fat [cm2, mean (sd)] 225.5 (136.6) 92.7 (77.1) <0.001 
Central/peripheral [mean (sd)] 0.60 (0.56) 1.62 (1.51) <0.001 
    
PubLicAçõES
	 	 
FMR by DXA [mean (sd)] 1.12 (0.44) 1.71 (0.98) 0.002 
(CL – clinical lipodystrophy; cART –  combined antiretroviral therapy; BMI - body mass index; CDC - 
Centers for Disease Control and Prevention criteria for staging of HIV infection; PI – protease inhibitor; 
NNRTI –non-nucleoside reverse transcriptase inhibitor; NRTI – nucleoside reverse transcriptase 
inhibitor; CT – computed tomography; FMR - fat mass ratio; DXA - dual-energy X-ray absorptiometry.) 
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Table 4: Linear regression models of the association between FMR and the 
described variables 
FMR Crude model Model 1* Model 2** 
 β p Β p β p 
Total Cholesterol 0.0005 0.712 0.0002 0.832 0.0005 0.683 
LDL-C -0.0001 0.310 0.0002 0.823 0.0004 0.973 
HDL-C -0.005 0.167 -0.004 0.153 -0.004 0.213 
Non-HDL-C 0.001 0.932 0.001 0.447 0.001 0.383 
Triglycerides*** 0.250 0.007 0.208 0.006 0.225 0.006 
Apo A1*** -0.700 0.008 -0.464 0.039 -0.420 0.082 
Apo B*** -0.031 0.894 0.255 0.212 0.234 0.269 
Apo B/Apo A1 ratio 0.392 0.076 0.394 0.026 0.374 0.053 
Lp (a)*** -0.063 0.209 -0.064 0.121 -0.061 0.165 
Homocysteine 0.026 0.114 -0.006 0.682 -0.008 0.612 
hs CRP*** 0.010 0.885 0.016 0.753 0.028 0.598 
Lactate 0.189 0.112 0.145 0.141 0.128 0.213 
NT-proBNP*** 0.114 0.139 0.044 0.517 0.052 0.476 
Microalbuminuria*** 0.011 0.847 -0.030 0.492 -0.008 0.859 
Fibrinogen -0.003 0.550 -0.001 0.254 -0.001 0.148 
*-Mode1: adjusted for age and gender; **-Model 2: adjusted for age, gender, PI, 
NNRTI and NRTI; ***after log transformation  
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Table 5: hs-CRP according to viral load 
HIV RNA hs-CRP median (IQR) P 
<50 
>50 
0.15 (0.33) 
0.18 (0.41) 
 
0.448 
(IQR – interquartile range) 
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Abstract  
 
Background: Lipodystrophies are characterized by adipose tissue redistribution, insulin 
resistance (IR) and metabolic complications. Adipokines and hormones related to body 
composition may play an important role linking these alterations. Objectives: To 
evaluate adipocyte-derived hormones (adiponectin, leptin, resistin, TNF-, PAI-1), 
ghrelin and IR in HIV-infected patients according to the presence of Fat Mass Ratio 
defined lipodystrophy (FMR-L) and four categories of fat redistribution. Design: Cross-
sectional study. Methods: Anthropometric and metabolic parameters, HOMA-IR, body 
composition by DXA and CT, and adipokines were evaluated in 217 HIV-infected 
patients on cART and 74 controls. Results: Leptin levels were lower in patients with 
FMR-L and isolated lipoatrophy, and higher in those with isolated central fat 
accumulation (ICFA) and mixed forms (MXF) of lipodystrophy. Positive correlations 
were found between leptin and total, trunk, leg, arm fat evaluated by DXA, and total, 
Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT), VAT/SAT ratio 
by CT regardless of FMR-L, and with HOMA-IR in patients with FMR-L. Adiponectin 
correlated negatively with VAT, and its mean levels were lower in patients with ICFA 
and higher in those with no lipodystrophy. Resistin was positively correlated with 
HOMA-IR in FMR-L patients. MXF-patients had higher PAI-1 levels and these were 
positively correlated with VAT in those with FMR-L. Ghrelin was higher in HIV-
infected patients than controls despite BMI-matching. Conclusion: Different degrees of 
peripheral fat atrophy and central fat accumulation characteristics of HIV lipodystrophy 
induces changes in adipokines, hormones related to body composition that maintain a 
complex interplay related to IR and metabolic abnormalities. 
 
Keywords: lipodystrophy, HIV, adipokines, body composition, insulin resistance  
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Introduction 
Changes in body fat distribution are a common finding in patients with HIV infection 
being treated with combined antiretroviral therapy (cART) and this condition has many 
similarities to rare, congenital and acquired lipodystrophies, which are associated with 
depletion of subcutaneous fat, increased triglycerides and profound insulin resistance 
(IR) 1. Adipose tissue was traditionally considered an energy storage organ, but over the 
last decade, it has emerged as a metabolically active endocrine organ secreting multiple 
bioactive peptides, collectively called “adipokines”, other proteins including 
inflammatory mediators such as tumor necrosis factor alpha (TNF-) and plasminogen 
activator inhibitor-1 (PAI-1), which not only influence adipocyte function in an 
autocrine and paracrine fashion, but also affect more than one metabolic pathway 
through the bloodstream’s systemic circulation 2. All adipose tissue products seem to 
contribute significantly in various metabolic processes both at local and systemic levels 
and may induce a proinflammatory state and oxidative damage, leading to initiation and 
progression of atherosclerosis3. On the other hand, these patients have marked changes 
in circulating levels of adipocyte secreted hormones, including leptin and adiponectin, 
which may contribute to metabolic abnormalities, and hormones related to body 
composition, such as ghrelin4. Ghrelin is an orexigenic gut peptide that is the 
endogenous ligand for the GH secretagogue receptor. Low ghrelin may be a marker of 
metabolic dysregulation and altered body fat without specifically contributing to low 
GH 5. 
cART in HIV infection produces widespread metabolic complications, including 
hyperlipidemia, IR, lipodystrophy [peripheral fat wasting (lipoatrophy) with or without 
abdominal/visceral fat accumulation (lipohypertrophy)] 6. The hormonal changes caused 
by increased (in lipohypertrophy) or reduced subcutaneous fat (in lipoatrophy) may be 
central to the metabolic abnormalities observed in HIV-lipodystrophy 5.  
The aim of this study was to evaluate the relationship between fat mass, lipodystrophy 
defined by the Fat Mass Ratio  (FMR-L) and the four different categories of fat 
distribution, and adipocyte derived hormones (adiponectin, leptin, resistin, TNF-), 
orexigenic hormones (ghrelin), prothrombotic factors (PAI-1) and IR in HIV-infected 
patients on cART.  
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Methods 
 
Subjects 
As part of a cross-sectional study, consecutive clinically stable HIV-infected adults 
receiving cART were evaluated at the Endocrinology Outpatient Department. Seventy 
four age-, gender- and BMI-matched HIV-uninfected controls were also evaluated. 
These controls were selected from a previously assembled cohort of non-
institutionalized community adults, the EPI-Porto study 7. The study protocol was 
approved by the Hospital Ethics Committee and all patients provided informed consent. 
 
Clinical assessment 
For each patient the following information was collected using a standardized protocol: 
demographic data (age, gender), duration of HIV infection, HIV infection risk factors, 
duration of cART and characterization of the infection. We used the “Centers for 
Disease Control and Prevention” (CDC) criteria for classifying the degree the infection 8. 
Weight, height, circumferences of neck, waist, hip, thigh and arm were measured as 
previously published9-12. Blood pressure (BP) was measured using the established 
recommendations13.  
Clinical lipodystrophy was defined as a peripheral lipoatrophy with or without a central 
fat accumulation assessed by both patient and practitioner, as previously described9-12. 
Presence of central fat accumulation or abdominal prominence was defined by the 
measurement of waist circumference using the International Diabetes Federation (IDF) 
criteria for metabolic syndrome14. Patients were classified into four different categories 
according the presence or absence of either clinical lipoatrophy or abdominal 
prominence: no lipodystrophy - patients without clinical lipoatrophy and without 
abdominal prominence; isolated central fat accumulation - patients without clinical 
lipoatrophy and with abdominal prominence; isolated lipoatrophy - patients with 
clinical lipoatrophy and without abdominal prominence; mixed forms of lipodystrophy 
- patients with clinical lipoatrophy and with abdominal prominence. The clinical 
assessment was performed by the same practitioner (PF).  
 
Evaluation of body composition 
Body composition was assessed with whole-body dual-energy X-ray absorptiometry 
(DXA – Lunar Expert XL). DXA measurement was performed while the patient was in 
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a supine position, with standard positioning of the arms and feet. Markers used in this 
study for trunk and lower limbs that defined regions of interest were those indicated by 
the manufacturer. Regional fat mass values were grouped and analysed for the 
following anatomical regions: arms, legs, trunk and total body. The fat mass ratio 
(FMR) is the ratio of the percentage of the trunk fat mass to the percentage of the lower 
limb fat mass (FMR= % of the trunk fat mass/ % of the lower limb fat mass)15. We 
define lipodystrophy by FMR using the cut-off value of 1.961 for men and 1.329 for 
women9. The quantification of total, visceral, and peripheral abdominal fat was 
performed with a 64-slice computed tomography (CT) scanner (Siemens Sensation 64 
Cardiac) with the same technique as previously described 16, 17. All values were 
expressed in cm2 rounded to the nearest centesimal.  
 
Laboratory analysis 
A venous blood sample was drawn after a 12-hour overnight fast. All the samples were 
analysed at the central laboratory of our hospital. Patients without a previous diagnosis 
of diabetes were submitted to a glucose tolerance test (OGTT). The test was performed 
as described by the World Health Organization using a glucose load containing the 
equivalent of 75g anhydrous glucose dissolved in water. 
The CD4 cell count was determined by flow cytometry and plasma HIV-1 RNA loads 
were measured by a quantitative reverse transcriptase polymerase chain reaction (Roche 
Diagnostic Systems, Inc., Branchburg, NJ, USA), which has a lower limit of detection 
of 50 copies/mL. 
 
Adipokines and hormones related to body composition 
Leptin (Human Leptin RIA Kit, Linco Research), adiponectin (Human Adiponectin 
RIA Kit, Linco Research), resistin (Human Resistin ELISA Kit, Linco Research), TNF-
 (TNF- IRMA Kit, BioSource), ghrelin (Ghrelin Active RIA Kit, Linco Research) 
and PAI-1 (Human PAI-1 ELISA Kit, IBL International GMBH) were measured in the 
Nobre Laboratory of the Porto Medical School. For leptin, the intra-assay precision is 
4.6 % and inter-assay precision 5.0 %. For adiponectin, the intra-assay precision is 
1.78 % and inter-assay precision 9.25 %. For resistin, the intra-assay precision is 3.2 % 
and inter-assay precision 7.1 %. For TNF-, the intra-assay precision is 3.1% and inter-
assay precision 5.7 %. For ghrelin, the intra-assay precision is 6.7 % and inter-assay 
precision 9.6 %. The overall intra-assay coefficient of variation for PAI-1 was 4.7 %.  
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Insulin resistance evaluation 
Insulin resistance was defined by the homeostasis model assessment of insulin 
resistance (HOMA) and insulin sensitivity by the quantitative insulin sensitivity check 
index (QUICKI). These indexes were calculated by the following formulas: 
HOMA-IR index = (insulin 0 x glucose 0)/22.5 18.  
QUICKI = 1/[log (fasting insulin in mU/l) +log (fasting plasma glucose in mg/dL)19. 
Glucose was expressed in mmol/L and insulin in UI/mL. 
 
Statistical analysis   
Data were described as mean and standard deviation (SD) for quantitative variables and 
compared using the Student-t test or the Mann-Whitney test as appropriate. For the 
comparison between the four groups of fat distribution and adipokine parameters the 
Kruskal-Wallis test was used. Categorical variables were described as counts and 
proportions, and compared using the chi-square or Fisher’s exact test.  
For estimating the association between adipokine levels and anthropometric, metabolic 
and body composition, Spearman correlation coefficients were calculated. Statistical 
analysis was performed using SPSS version 18.0 software (SPSS Inc., Chicago, Illinois, 
USA). All probabilities were two tailed and p values <0.05 were regarded as significant. 
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Results 
 
Sample characteristics, adipokines and hormones related to body composition in 
HIV-infected patients and HIV-uninfected controls 
HIV-infected patients had significantly higher waist/hip ratio, glucose, triglyceride, 
insulin, HOMA, and ghrelin levels, and adiponectin/leptin ratio. However, they had 
lower weight, hip and arm circumferences, HDL-cholesterol levels, QUICKI, resistin, 
adiponectin and leptin levels. No differences were observed between HIV-infected 
patients and HIV-uninfected controls regarding age, gender, BMI, waist circumference, 
systolic and diastolic blood pressure and total cholesterol, LDL-cholesterol, uric acid, 
hsCRP and TNF- levels (Table 1). 
 
Adipokines and hormones related to body composition in HIV-infected patients 
according to gender 
HIV-infected females had a higher hip circumference, total fat mass and subcutaneous 
adipose tissue (SAT) on abdominal CT scan evaluation and total, trunk, leg and arm 
mass fat by DXA. They also had lower visceral adipose tissue (VAT) and VAT/SAT 
ratio on CT scan. Also, females had higher leptin levels and lower TNF- and 
adiponectin/leptin ratios. No gender-related differences were observed in adiponectin, 
resistin, ghrelin and PAI-1 levels (Table 2). 
 
Adipokines and hormones related to body composition according to the four 
categories of body composition  
Patients with isolated central fat accumulation and mixed forms of lipodystrophy were 
older and had higher BMIs. Patients with no lipodystrophy had higher levels of 
adiponectin and patients with isolated central fat accumulation had the lowest levels of 
adiponectin. The levels of leptin were higher in patients with isolated central fat 
accumulation and mixed forms of lipodystrophy and lower in those with isolated 
lipoatrophy. No significant differences were found in resistin, ghrelin and TNF- 
between the four groups of body composition. Patients with no lipodystrophy and mixed 
forms of lipodystrophy had higher levels of PAI-1, and the lowest levels of PAI-1 were 
found in those with isolated central fat accumulation. The adiponectin/leptin ratio was 
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higher in patients who had no lipodystrophy and lower in patients with isolated central 
fat accumulation, followed by the patients with mixed forms of lipodystrophy (Table 3). 
 
Sample characteristics, body composition, metabolic parameters, adipokines and 
hormones related to body composition, according to the presence lipodystrophy 
defined by FMR  
In this sample of 217 HIV-1 infected patients (144 men and 73 women) on cART, 41 % 
of patients presented lipodystrophy defined by FMR (FMR-L). Table 4 shows the 
characteristics of the study sample according to the presence of FMR-L. Patients with 
FMR-L were more frequently males, older and had a longer duration of HIV infection 
and length of cART. No significant differences were found in weight, BMI, waist, arm 
and thigh circumferences among patients with or without FMR-L. Patients with FMR-L 
had a higher neck circumference and waist/hip ratios, but a lower hip circumference. 
Also, they had significantly a higher mean CD4+ cell count, but no significant 
difference in viral suppression rate was observed. No differences were observed 
between patients with and without FMR-L regarding the cART regimens and CDC 
classification. Also, no differences were observed regarding diastolic blood pressure, 
hs-CRP, total cholesterol, LDL and HDL cholesterol levels. The patients with FMR-L 
had higher systolic blood pressure, uric acid, triglycerides, HOMA, fasting glucose and 
insulin levels than those without FMR-L. In relation to OGTT, glucose and insulin at 2 
hours were higher in patients with FMR-L. QUICKI was lower in patients with FMR-L 
than in those without FMR-L.  
On DXA evaluation, patients with FMR-L had lower total, leg and arm fat mass (either 
in % or Kg) than patients without FMR-L with no significant difference in trunk fat 
mass. On CT evaluation at abdominal level, patients with FMR-L had higher VAT and 
lower SAT with a higher central/peripheral fat ratio, with no difference in total fat at 
this level. 
Leptin levels were lower in patients with FMR-L. No significant differences were found 
in the levels of adiponectin, resistin, ghrelin, PAI-1, TNF- and adiponectin/leptin ratio 
among patients with or without FMR-L (Table 4).  
 
Adipokines, body composition hormones and metabolic parameters  
We evaluated the correlations between leptin, resistin, TNF- and adiponectin with age, 
waist/hip circumference ratio, arm, waist, hip circumferences, BMI, fasting glucose and 
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insulin, HOMA, triglycerides and total cholesterol in all the HIV-infected patients and 
HIV-uninfected controls. Leptin was positively associated with arm, waist, hip 
circumferences, BMI and fasting insulin both in the HIV-infected patients and in HIV-
uninfected controls. In HIV-uninfected controls, leptin was also positively correlated 
with HOMA. A negative correlation was found between resistin and hip circumference 
and BMI in the HIV-infected patients, while a positive correlation between resistin and 
triglycerides was found in the HIV-uninfected controls. Also, a negative correlation was 
observed between TNF- and total cholesterol in HIV-infected patients, and between 
adiponectin and arm circumference in controls (Table 5). 
Regarding the effect of lipodystrophy on the association between anthropometric and 
metabolic parameters in HIV-infected patients, a significant positive correlation was 
found between leptin and: insulin at 2 hours on OGTT; total, trunk, leg, arm fat 
evaluated by DXA; and total, SAT, VAT/SAT ratio on abdominal level evaluated by 
CT scan in these patients, regardless of the presence of FMR-L. Leptin was also 
positively associated with arm, thigh, waist, hip circumferences, BMI, glucose at 2 
hours on OGTT, total cholesterol, and was negatively associated with  length of cART 
in patients without FMR-L. Patients with FMR-L also exhibited positive associations 
between resistin levels and duration of HIV-infection, as well as between PAI-1 and 
VAT. A negative association was found between adiponectin and arm fat mass 
measured by DXA in FMR-L patients. A positive correlation was observed between 
TNF-, fasting glucose and A1c in patients without FMR-L (Table 6).  
The adiponectin/leptin ratio was not associated with IR [HOMA (r=-0.148, p=0.066) or 
Quicki (r=0.148, p=0.066)] in HIV patients overall, or in men [HOMA (r=-0.138, 
p=0.164) or Quicki (r=0.126, p=0.206)]. However, a positive correlation between this 
ratio and Quicki was observed [HOMA (r=-0.228, p=0.101); Quicki (r=0.277, p=0.044] 
in women. 
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Discussion 
In acquired or genetic lipodystrophies, altered fat distribution per se is a strong 
determinant of IR and metabolic alterations, and the loss of fat likely precedes the 
metabolic complications20-23. Increased amounts of visceral fat accompanied by 
decrease in peripheral adipose tissue are associated with an increase of lipolysis and free 
fat acid fluxes, which together can alter adipocytokine production24.  
Regarding body fat composition, our data showed that there were differences in body fat 
distribution between HIV-infected patients and HIV-uninfected controls, males and 
females with HIV-infection and patients with or without FMR-L despite similar BMI. 
Actually, HIV-infected patients had higher waist/hip ratio and lower hip and arm 
circumferences. Females had a higher fat mass (hip circumference, total fat mass and 
SAT on abdominal CT evaluation and total, trunk, leg and arm mass fat on DXA) and 
men had higher VAT and VAT/SAT ratios on CT scan.  
FMR-L patients had lower hip circumference, fat mass (total, leg and arm) by DXA and 
SAT at abdominal level by CT, and higher waist/hip ratio, VAT and central/peripheral 
fat ratio evaluated by abdominal CT scan.  
 
Leptin  
Leptin levels were higher in HIV-uninfected controls and lower in patients with FMR-L, 
indicating an association with body fat, demonstrated by the significant positive 
correlation between leptin and arm, thigh, waist, hip circumferences, BMI, total, trunk, 
leg, arm fat mass evaluated by DXA, and total, VAT, SAT, VAT/SAT ratio on 
abdominal level evaluated by CT scan. Like other authors, we also observed that leptin 
concentrations were higher in HIV-infected women compared to HIV-infected men and, 
therefore, the usual gender distribution for this adipocytokine remains unchanged in 
HIV infection25, 26. In genetic lipodystrophy syndromes, very low plasma leptin 
concentrations were found when fat mass was profoundly reduced 27 and that correlated 
positively with total adiposity 28. 
Our HIV-infected patients with isolated central fat accumulation and mixed forms of 
lipodystrophy had higher BMI and leptin levels. Leptin levels were lower in those with 
isolated lipoatrophy, positively proportional to the BMI. Most studies, which have not 
differentiated between subjects with predominant lipoatrophy, lipohypertrophy, and 
mixed patterns of fat redistribution, have failed to find significantly lower leptin levels 
in subjects with HIV lipodystrophy 23, 29, 30, but when subjects with distinctive 
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lipoatrophy have been studied separately, lower leptin levels in this subgroup of HIV 
lipodystrophy patients has been demonstrated. Also, significant associations between 
leptin secretion and subcutaneous fat has been reported and decreased subcutaneous fat 
correlated with reduced leptin levels after controlling for visceral fat quantity31. Total 
and regional adiposity were strongly and positively associated with leptin in healthy 
controls and in HIV-infected patients, both in men and women, suggesting that 
adiposity remains the major determinant of plasma leptin levels in HIV infection 28.  
In a prospective study, there was a significant positive correlation between the 
appearance of lipoatrophy and the leptin levels30, 32. In our sample, leptin was positive 
and significantly associated with fasting insulin both in the HIV-infected patients and in 
HIV-uninfected controls. In controls, leptin was also positive and significantly 
correlated with HOMA. We also observed a significant positive correlation between 
leptin and glucose and insulin at 2 hours on OGTT in patients without FMR-L and 
fasting and 2 hours insulin on OGTT and HOMA in patients with FMR-L.  
The role of leptin in the modulation of insulin sensitivity is complex. Extremely low 
levels of leptin in congenital generalized lipoatrophies were associated with severe IR, 
and significantly improved with replacement of leptin in mice and humans33.  
In conclusion, leptin levels appear to be primarily determined by total adiposity in HIV-
infected individuals, independently of the presence of  lipodystrophy28. 
 
Adiponectin 
Adiponectin levels were higher in HIV-uninfected controls than in HIV-infected 
patients. Patients with no lipodystrophy had higher levels of adiponectin and patients 
with isolated central fat accumulation had the lowest levels of adiponectin. Contrary to 
other authors, who found higher adiponectin levels in HIV-infected women25, 26, no such 
gender difference was observed in our patients. Also, no significant differences were 
found in the levels of adiponectin among patients with or without FMR-L. 
We found a significant negative correlation between adiponectin and total and trunk fat 
mass evaluated by DXA in the HIV-infected patients, and with arm fat mass in patients 
without FMR-L. A negative significant correlation was found between adiponectin and 
arm circumference in HIV-uninfected controls.  
Kosmiski et al, observed that both total and regional adiposity were significant and 
negatively correlated with adiponectin levels in a control group, similar to other reports 
of general populations28. Also, in that same study, HIV-infected patients with leg SAT 
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below the 10th percentile of controls had significantly lower adiponectin levels than 
controls with similar leg SAT volumes 28. In some studies, no association between 
adiponectin and total adiposity was found in HIV-infected patients, while adiponectin 
was positively correlated with both extremity and abdominal SAT34, 35. This relationship 
suggests that the remaining SAT in HIV-infected patients with moderate to severe 
lipoatrophy is dysfunctional rather than simply reduced in size, since in anorexia 
nervosa, a condition characterized by low body weight and severe global fat depletion 
(although not isolated subcutaneous adipose tissue), adiponectin is higher36-38. Findings 
of abnormal function or loss of adipose tissue in partial lipodystrophy syndromes (due 
to lamin A/C or to PPAR- receptor mutations) and low adiponectinemia also support 
the theory that low adiponectin concentrations in HIV-infected subjects with low levels 
of SAT are due to lipodystrophy per se 37, 38. Thus, lipodystrophies are characterized not 
only by decreased fat but also by dysfunction or loss of adipocytes 28. In HIV-infected 
men and women, with or without lipodystrophy, the normal negative relationship 
between visceral adiposity and adiponectin was maintained28, 34, 35, 39.   
In HIV-infected patients, adiponectin levels correlated significantly with the percentage 
of body fat distributed to the limbs and also correlated significantly with insulin 
sensitivity 23, 40, although some authors state that adiponectin predicts insulin sensitivity 
independently of the amount and repartition of body fat 41, no such association was 
found  between adiponectin and markers of IR in our sample. 
It has been reported that in HIV lipodystrophic patients, adiponectin levels are 
significantly lower in patients with fat redistribution and correlate inversely with serum 
triglycerides with the lowest levels, in peripheral lipoatrophic and central 
lipohypertrophic patients, representing a central role in glucose, lipid metabolism and 
IR in these patients 35, 41-43. These findings were independent of age, leptin levels, HIV 
medications and severity of disease35, 41. As we observed for leptin levels, in our sample 
adiponectin levels were lower in patients with lipodystrophy and patients with isolated 
central fat accumulation were the ones with the lowest level of adiponectin. 
 
Ratio adiponectin/leptin 
Adiponectin/leptin ratio is considered to be a better predictor of insulin sensitivity and 
cardiovascular risk, and is usually considered independent of body mass. 
Adiponectin/leptin ratio has been negatively associated with IR, metabolic defects and 
cardiovascular risk markers41. We found a positive correlation between this ratio and 
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Quicki in women. We also showed that the adiponectin/leptin ratio was lower in HIV-
uninfected controls than in HIV-infected patients. This ratio was higher in patients with 
no lipodystrophy and lower in patients with isolated central fat accumulation, followed 
by the patients with mixed forms of lipodystrophy. Women had higher levels of leptin 
and lower adiponectin/leptin ratio. No significant differences were found between 
patients with or without FMR-L. 
 
Resistin 
Elevated resistin levels have been observed in obese and diabetic subjects, and 
increased resistin has been associated with IR in lean and obese subjects 44. However, 
other studies found no association between circulating resistin levels and IR 45, 46.  
In our data, resistin was higher in HIV-uninfected controls and no significant 
differences were found in the four categories of body composition, or according to 
gender and presence of FMR-L in HIV-infected patients, similar to previously 
published data47. Resistin was positively associated with duration of HIV-infection and 
with HOMA in patients with FMR-L. Kamin also demonstrated that HIV-infected 
subjects with lipodystrophy and IR had higher circulating resistin levels48. A negative 
correlation was found between resistin and hip circumference and BMI in the HIV-
infected patients and a positive one with triglycerides in the controls.  
 
TNF-  
HIV lipodystrophy, familial partial lipodystrophy and obesity have been associated with 
high circulating levels of TNF- 37, 49, 50. No significant differences in TNF- levels 
were found between HIV-infected patients and controls, either according to the presence 
of FMR-L, or in the four categories of fat composition. However, we found a positive 
correlation between TNF- and fasting glucose and A1c in patients without FMR-L. 
TNF- homeostasis is profoundly altered by HIV-1 infection itself and it has been 
shown that HIV-1 infected patients have elevated pre-treatment levels of TNF- and 
that these levels dramatically decrease when cART is initiated. However, concentrations 
of the components of TNF- system are not normalized when cART is effective. We 
did not observe any correlation between TNF- and adiponectin levels (r=0.145; 
p=0.060) although that has previously been described 51.   
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PAI-1 
Patients with no lipodystrophy and mixed forms of lipodystrophy had higher levels of 
PAI-1 and the lowest levels of PAI-1 were found in those with isolated central fat 
accumulation. No differences in PAI-1 levels between patients with or without FMR-L 
and according to gender were found, but a significant positive association between PAI-
1 and VAT was observed in patients with FMR-L. 
PAI-1 concentrations are increased in conditions characterized by increased VAT or 
SAT, hypertriglyceridemia, and hyperinsulinemia. Both VAT and SAT produce PAI-1, 
but data are controversial as to whether VAT produces more, similar, or less amounts of 
PAI-1 than SAT. Also, it has been suggested that PAI-1 originates from stromal cells in 
adipose tissue rather than from adipocytes. Patients with cART-associated 
lipodystrophy had elevated plasma PAI-1concentrations52. HIV infected patients with 
fat redistribution had significant elevations in PAI-1, being waist–to-hip ratio the only 
significant predictor of PAI-1 in a univariate regression analysis. Elevated levels of 
PAI-1 were associated with hyperinsulinemia and central adiposity, placing HIV 
infected patients at substantial risk of cardiovascular disease via impaired fibrinolysis53.  
Contrary to our data, He et al, found significantly increased plasma PAI-1 level in 
patients with lipodystrophy as compared with patients without lipodystrophy. They also 
found a positive correlation between plasma PAI-1 level and BMI, waist circumference, 
VAT, plus an inverse correlation with the percentage of limb fat. In a stepwise multiple 
linear regression model, VAT turned out to be the main predictor of plasma PAI-154. 
 
Ghrelin 
Ghrelin was higher in HIV-infected patients than in controls. No significant differences 
were found in ghrelin levels by gender, by four categories of body composition or 
between patients with or without FMR-L. Fasting serum ghrelin level has been 
negatively correlated with BMI, and it is decreased in obesity and increased in 
cachexia55. Ghrelin is a peptide involved in energy homeostasis, mainly inducing food 
intake and GH secretion. In humans, ghrelin stimulates appetite by inducing hunger, 
which leads to increased food consumption and consequent metabolic alterations, with 
increasing body weight, body fat mass, and serum triglycerides55. Contrary to our data, 
lower levels of ghrelin have been reported in HIV-infected lipodystrophic patients4, 56.  
Falasca et al, observed higher levels of ghrelin in patients with hypertriglyceridemia, as 
well as a positive correlation between serum ghrelin and triglyceride levels in patients 
EStuDo Do SínDroME DA LiPoDiStrofiA E DAS rEPErcuSSõES EnDócrino-MEtAbóLicAS E cArDiovAScuLArES nA infEção Por viH
0
16 
 
with hypertriglyceridemia. No such association between ghrelin and triglyceride levels 
were observed in our sample (r=0.064, p=0.424). Falasca concluded that adipokines 
may have crucial roles in the pathogenesis of hypertriglyceridemia and, thus, 
monitoring of serum ghrelin levels could be important to identify subjects with high 
cardiovascular risk55. 
 
Limitations 
Several limitations of this study should be noted. A cross-sectional design cannot prove 
causality between cART use, lipoatrophy, and alterations in adipokine levels. It is not 
possible to determine whether adipokine abnormalities are due to reduced hormone 
expression in adipose tissue, decreased differentiation or decreased adipose cell 
numbers. 
 
Some aspects of the current study should be highlighted. 
The study was performed in a unit that is highly experienced in the assessment of 
metabolic and body fat abnormalities in HIV-infected patients; the clinical assessment 
of lipodystrophy was performed by the same investigator (PF); and objective definitions 
of lipodystrophy (Fat Mass Ratio by DXA), visceral and subcutaneous fat mass by CT 
were used. 
 
Conclusion 
Leptin levels were lower in patients with lipodystrophy, indicating its close relationship 
with total body fat. A significant positive correlation between leptin and HOMA in 
patients with lipodystrophy demonstrated the role of this adipokine in insulin sensitivity. 
Adiponectin was lower in patients with isolated central fat accumulation and negatively 
correlated with visceral adipose tissue. The adiponectin/leptin ratio was lower in 
patients with isolated central fat accumulation. Patients with mixed forms of 
lipodystrophy had higher levels of PAI-1. Resistin was positively associated with 
HOMA in patients with FMR-defined lipodystrophy. Patients with no lipodystrophy and 
mixed forms of lipodystrophy had higher levels of PAI-1 and the lowest levels of PAI-1 
were found in those with isolated central fat accumulation. Ghrelin was higher in HIV-
infected patients than in controls despite the two groups being BMI-matched. Our 
results add to the evidence on the complexity of the relationship between adipokines, 
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hormones related to body composition, and insulin resistance in the HIV redistribution 
syndrome, with different degrees of peripheral fat atrophy and central fat accumulation.  
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Table 1: Sample characteristics, adipokines and hormones related to body 
composition in HIV-uninfected controls and HIV-infected patients  
 
 HIV-uninfected controls HIV-infected patients P 
Age [years, mean (sd)] 47.2 (9.7) 46.6 (11.6) 0.729 
Gender [n(%)] 
  Male 
  Female 
 
40 (54.1) 
34 (45.9) 
 
144 (66.9) 
73 (33.6) 
 
 
0.079 
Weight [Kg, mean (sd)] 71.5 (13.4) 67.8 (12.3) 0.029 
BMI [(kg/m2), mean (sd)] 26.3 (4.3) 35.1 (4.5) 0.050 
Waist circumference [cm, mean (sd)] 90.7 (11.6) 91.2 (11.6) 0.753 
Hip circumference [cm, mean (sd)] 99.8. (7.1) 94.5 (8.4) <0.001 
Waist/hip ratio[mean (sd)] 0.91 (0.08) 0.96 (0.08) <0.001 
Arm circumference [cm, mean (sd)] 30.6 (3.5) 27.0 (3.0) <0.001 
Systolic blood pressure [mmHg, mean (sd)] 122.2 (17.3) 121.9 (17.5) 0.988 
Diastolic blood pressure [mmHg, mean (sd)] 78.9 (10.1) 76.7 (11.3) 0.242 
Glucose [mg/dL, mean (sd)] 91.7 (12.2) 107.7 (41.5) 0.031 
Insulin [U/mL, mean (sd)] 5.5 (4.9) 11.2 (10.6) <0.001 
HOMA [mean (sd)] 1.3 (1.4) 3.1 (3.2) <0.001 
QUICKI  [mean (sd)] 0.39 (0.05) 0.36 (0.08) <0.001 
Total cholesterol [mg/dL, mean (sd)] 217.2 (43.6) 224.2 (58.0) 0.263 
LDL cholesterol [mg/dL, mean (sd)] 134.9 (38.8) 128.5 (49.9) 0.419 
HDL cholesterol [mg/dL, mean (sd)] 57.4 (14.9) 46.1 (13.6) <0.001 
Triglycerides [mg/dL, mean (sd)] 119.8 (57.6) 267.5 (182.8) <0.001 
Uric acid [mg/dL, mean (sd)] 49.6 (15.4) 46.8 (15.0) 0.165 
hs-CRP [mg/dL, mean (sd)] 0.36 (0.54) 0.45 (0.73) 0.547 
Resistin [ng/mL, mean (sd)] 15.5 (11.0-22.2) 10.4 (8.0-13.9) <0.001 
Adiponectin [ng/mL, mean (sd)] 5177.5 (2795.0-7737.5) 2676.5 (1192.1-5458.6) <0.001 
TNF- [pg/mL, mean (sd)] 45.3 (29.9-60.5) 44.6 (30.1-73.6) 0.631 
Ghrelin [pg/mL, mean (sd)] 18.6 (10.5-25.4) 75.0 (47.7-139.5) <0.001 
Leptin [ng/mL, mean (sd)] 11.8 (6.3-21.3) 3.4 (1.9-7.6) <0.001 
Adiponectin/leptin ratio [mean (sd)] 998.5 (1949.9) 2291.8 (5870.5) 0.018 
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Table 2: Body composition, adipokines and hormones related to body composition 
in HIV-infected patients, according to gender 
 
 Male Female P 
Age [years, mean (SD)] 46.8 (11.2) 46.2 (12.5) 0.724 
BMI [(kg/m2), mean (SD)] 24.7 (3.8) 26.1 (5.6) 0.050 
Waist circumference [cm, mean (SD)] 91.2 (10.6) 91.2 (13.5) 0.980 
Hip circumference [cm, mean (SD)] 93.1 (6.7) 97.2 (10.5) 0.003 
Total fat mass CT [cm3, mean (SD)] 243.4 (136.2) 356.0 (166.7) <0.001 
VAT CT [cm3, mean (SD)] 140.7 (86.2) 113.6 (69.9) 0.020 
SAT CT [cm3, mean (SD)] 102.6 (76.9) 242.4 (125.7) <0.001 
VAT/SAT ratio 2.2 (2.4) 0.55 (0.40) <0.001 
Total fat mass DXA [%, mean (SD)] 16.8 (8.1) 33.3 (10.0) <0.001 
Trunk fat in DXA [%, mean (SD)] 20.6 (9.8) 33.4 (10.3) <0.001 
Leg fat mass  DXA [%, mean (SD)] 12.2 (9.1) 31.9 (12.5) <0.001 
Arm fat mass DXA [%, mean (SD)] 15.2 (8.9) 42.3 (11.4) <0.001 
    
Adiponectin [ng/mL, median (25th and 75th 
percentile)] 
3341.8 (1790.0-6594.4) 3000.0 (1359.0-6550.0) 0.391 
Leptin [ng/mL, median (25th and 75th percentile)] 3.0 (1.8-5.8) 11.2 (5.7-18.0) <0.001 
Resistin [ng/mL, median (25th and 75th percentile)] 11.2 (8.4-17.0) 11.2 (8.9-16.8) 0.421 
Ghrelin [pg/mL, median (25th and 75th percentile)] 55.5 (26.9-99.2) 44.0 (21.4-79.2) 0.069 
PAI-1 [pg/mL, median (25th and 75th percentile)] 61.3 (38.5-104.3) 43.4 (30.8-95.8) 0.368 
TNF- [pg/mL, median (25th and 75th percentile)] 49.9 (31.6-72.4) 39.7 (27.2-60.0) 0.028 
Adiponectin/leptin ratio, median (25th and 75th 
percentile) 
944.8 (344.1-2035.3) 244.6 (94.1-630.0) <0.001 
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Table 4: Sample characteristic, body composition, adipokines and hormones 
related to body composition according to the presence of lipodystrophy defined by 
FMR  
 Without 
lipodystrophy 
With 
lipodystrophy 
P 
n (%) 128 (59.0) 89 (41.0) - 
Gender [n (%)] 
  Male 
  Female 
 
76 (59.4) 
52 (40.6) 
 
68 (76.4) 
21 (23.6) 
 
 
0.014 
Age [years, mean (sd)] 44.7 (12.2) 49.4 (10.2) 0.003 
Duration of HIV infection [years, mean (sd)] 7.4 (3.9) 8.6 (3.6) 0.007 
cART [years, mean (sd)] 5.8 (3.8) 8.0 (3.4) <0.001 
Weight [Kg, mean (sd)] 67.4 (13.0) 68.3 (11.1) 0.599 
BMI [(kg/m2), mean (sd)] 25.0 (4.8) 25.3 (4.5) 0.684 
Waist circumference  [cm, mean (sd)] 90.2 (12.2) 92.7 (10.5) 0.102 
Hip circumference  [cm, mean (sd)] 95.9 (9.2) 92.5 (6.7) 0.002 
Thigh circumference  [cm, mean (sd)] 48.3 (5.6) 46.9 (4.8) 0.066 
Arm circumference  [cm, mean (sd)] 26.7 (3.2) 27.2 (2.7) 0.275 
Neck circumference  [cm, mean (sd)] 36.4 (3.8) 37.9 (3.7) 0.010 
Waist/hip circumference ratio 0.94 (0.08) 1.00 (0.07) <0.001 
CD4 cell count [cells/mm3, mean (sd)] 498.9 (289.4) 644.6 (354.1) 0.001 
HIV RNA (<50) [n (%)] 109 (85.2) 81 (91.0) 0.448 
HIV risk factor [n (%)]    
    Injecting drug user 36 (28.6) 17 (19.1)  
    Homosexual contact 7 (5.6) 16 (18.0)  
    Heterosexual contact 81 (64.3) 54 (60.7)  
    Others 2 (1.6) 2 (2.2) 0.017 
 
CDC [n (%)]    
      A 67 (52.8) 57 (64.0)  
 
 
0.155 
      B 2 (1.6) 0 (0) 
     C 58 (45.7) 32 (36.0) 
ART [n (%)]    
     IP 65 (52.0) 48 (53.9) 0.888 
      NNRTI 62 (49.6) 45 (50.6) 0.890 
      NRTI 121 (96.8) 86 (96.6) 1.000 
Total Cholesterol [mg/dL, mean (sd)] 218.1 (56.4) 233.1 (59.5) 0.061 
LDL-cholesterol [mg/dL, mean (sd)] 125.4 (50.2) 133.0 (49.4) 0.272 
HDL- cholesterol [mg/dL, mean (sd)] 47.2 (14.6) 44.4 (11.7) 0.136 
Triglycerides [mg/dL, mean (sd)] 244.8 (117.6) 300.1 (195.3) 0.028 
Uric acid [mg/L, mean (sd)] 43.8 (14.3) 51.0 (15.1) <0.001 
Systolic blood pressure  [mmHg, mean (sd)] 120.0 (18.6) 124.8 (15.6) 0.039 
Diastolic blood pressure [mmHg, mean (sd)] 75.7 (11.8) 78.1 (10.5) 0.138 
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Glucose 0 [mg/dL, mean (sd)] 103.0 (39.5) 114.4 (43.7) 0.002 
Glucose 2h at OGTT [mg/dL, mean (sd)] 123.9 (42.9) 139.7 (49.0) 0.030 
Insulin 0 [U/mL, mean (sd)] 9,96 (10.50) 12.96 (10.55) 0.005 
Insulin 2h at OGTT [U/mL, mean (sd)] 49. 8 (40.1) 88.3 (142.2) 0.005 
HOMA [mean (sd)] 2.65 (3. 01) 3.70 (3.28) <0.001 
QUICKI [mean (sd)] 0.37 (0.10) 0.34 (0.4) <0.001 
hsCRP [mg/dL, mean (sd)] 0.50 (0.90) 0.36 (0.27) 0.275 
Adiponectin [ng/mL, mean (sd)] 5634.6 (7393.4) 3953.9 (4491.7) 0.228 
Leptin [ng/mL, mean (sd)] 7.3 (8.5) 3.9 (3.3) 0.008 
Resistin [ng/mL, mean (sd)] 12.8 (13.4) 12.8 (7.4) 0.373 
Ghrelin[pg/mL, mean (sd)] 117.4 (133.6) 118.1 (106.7) 0.446 
PAI-1 [pg/mL, mean (sd)] 62.6 (43.6) 102.1 (110.1) 0.262 
TNF- [pg/mL, mean (sd)] 61.9 (50.3) 52.3 (33.9) 0.425 
Adiponectin/leptin ratio [ mean (sd)] 2721.5 (7207.8) 1691.4 (3132.2) 0.418 
Fat mass [%, mean (sd)] DXA 
   Total 
   Trunk 
   Leg 
   Arm 
 
24.8 (13.1) 
25.7 (13.3) 
24.4 (14.7) 
27.2 (17.1) 
 
19.3 (8.5) 
24.3 (9.0) 
11.1 (7.4) 
20.3 (13.6) 
 
0.002 
0.532 
<0.001 
0.001 
Fat mass [Kg, mean (sd)] DXA 
   Total 
   Trunk 
   Leg 
   Arm 
 
17.3 (11.1) 
9.3 (6.0) 
5.2 (3.6) 
2.1 (1.9) 
 
13.2 (7.3) 
9.0 (4.8) 
2.1 (1.6) 
1.5 (1.2) 
 
0.016 
0.686 
<0.001 
0.008 
Body Fat Mass by Quantitative CT  
Total [cm2, mean (sd)] 
 
 
282.9 (174.9) 
 
 
276.5 (126.6) 
 
 
0.917 
VAT [cm2, mean (sd)] 111.2 (85.4) 139.4 (68.7) <0.001 
SAT [cm2, mean (sd)] 171.7 (125.9) 117.0 (92.4) 0.001 
VAT/SAT ratio [mean (sd)] 1.07 (1.46) 2.44 (2.60) <0.001 
 
Note: cART – combined antiretroviral therapy; BMI. Body mass index; OGTT- oral glucose 
tolerance test; DXA - dual-energy X-ray absorptiometry CT – computed tomography; VAT- 
visceral adipose tissue; SAT – subcutaneous adipose tissue. 
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Abstract 
 
Background: HIV-infected patients may be at increased risk of cardiovascular (CV) 
events, and lipodystrophy is generally associated with proatherogenic metabolic 
disturbances. The carotid intima-media thickness (cIMT) has been used as a surrogate 
marker for atherosclerosis and it has been shown to be an independent risk factor for CV 
disease. Aims: To evaluate the cIMT in HIV-infected patients on combined anti-retroviral 
therapy (cART) with and without lipodystrophy defined by fat mass ratio (L-FMR) and 
according to 4 categories of fat distribution (based on the presence or absence of 
lipoatrophy and abdominal prominence) and to determine the association of lipodystrophy 
with cIMT. Methods: Cross-sectional study of 199 HIV-infected patients. Body 
composition by DXA and abdominal CT, lipids, blood pressure, inflammatory markers, and 
cIMT by ultrasonography were performed. Results: L-FMR was present in 41.2 % patients. 
cIMT is higher in patients with L-FMR than patients without [0.81 (0.24) vs. 0.76 (0.25); 
p=0.037)]. Lipodystrophic patients had higher central fat mass (FM), lower peripheral FM 
and higher central/peripheral FM ratio. Patients with isolated central fat accumulation and 
with mixed forms of lipodystrophy had a higher cIMT. cIMT is associated with total and 
central FM and with central/peripheral FM ratio. No association was found between cIMT 
and the leg FM but patients with isolated peripheral lipoatrophy had a higher cIMT than 
patients with no lipodystrophy. Conclusions: Central fat accumulation had a major impact 
on cIMT in HIV cART treated patients. Nevertheless, despite lack of statistical 
significance, the role of isolated lipoatrophy should not be disregarded. 
 
Keywords: lipodystrophy; HIV, carotid intima media thickness, fat mass ratio, body 
composition 
 
 
EStuDo Do SínDroME DA LiPoDiStrofiA E DAS rEPErcuSSõES EnDócrino-MEtAbóLicAS E cArDiovAScuLArES nA infEção Por viH
20
4 
 
Introduction  
The development of atherosclerosis lesions is a slow and progressive process.  The use of 
surrogate markers of atherosclerosis that are obtainable noninvasively may improve the 
prognostic stratification of HIV-infected patients with CV risk factors and may clarify some 
of the pending issues about this disease in HIV infection. Ultrasound is a safe, inexpensive 
and rapid technique, which allows an accurate evaluation of atherosclerosis (1). Intima-
media thickness (IMT) of the carotid arteries has been used as a surrogate marker for 
atherosclerosis and it has been shown to be an independent risk factor for CV disease. The 
role of  age,  prolonged survival,  traditional and non-traditional risk factors,  direct effect 
of HIV infection and cART, in relation to surrogate markers of atherosclerosis are under 
continuing debate (1). Thus, due to the long term survival associated with cART, 
deleterious effects of the treatment and the chronic inflammatory state emerge. However, 
HIV itself may also promote atherosclerosis by activating the vascular endothelium directly 
or indirectly by systemic cytokine stimulation by the virus (2). The higher rates of sub-
clinical atherosclerosis seen in HIV-1-infected patients, although controversial, are usually 
also attributed to classic CV risk factors and to side effects of cART (3-5). 
 Although the disease can cause alterations in several metabolic pathways, such as lipid and 
glucose metabolism, the lipodystrophic patients per se might also be at an even higher risk 
of atherosclerosis, since the fat redistribution is associated with presence of several known 
metabolic risk factors for CVD (6).  It has been previously shown that patients with clinical 
lipodystrophy have a significantly higher risk of coronary heart disease at 10 years, 
measured by the Framingham risk score, than patients without clinical lipodystrophy and 
those with clinical lipodystrophy and with metabolic syndrome were more frequently in 
moderate and high risk categories than those without metabolic syndrome (7). 
The aims of this study were to evaluate IMT in HIV-infected patients on cART with and 
without lipodystrophy, objectively defined by FMR, and in four groups of fat distribution, 
and to evaluate the association of lipodystrophy with cIMT. 
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Methods  
 
Subjects 
As part of a cross-sectional study, clinically stable HIV-infected non-institutionalized 
Caucasian adults receiving antiretroviral therapy, consecutively referred from the Infectious 
Diseases Outpatient Clinic, were evaluated. Only patients on cART were included. The 
study protocol was approved by the Hospital Ethics Committee for Health and each patient 
provided informed consent.  
 
Clinical assessment 
For each patient the following information was collected using a standardized protocol: 
age, gender, known duration of HIV infection and duration of cART exposure, HIV risk 
factor, characterization of the infection, smoking history (past, current, or never), family 
history of CV diseases, and use of anti-hypertensive, anti-diabetic, or lipid lowering drugs. 
 We used the “Centers for Disease Control and Prevention” (CDC) HIV staging 
classification (8). Weight, height, circumferences of neck, waist, hip, thigh and arm were 
measured as previously described (9) . All measurements were performed by the same 
observer using standard techniques (10). 
Clinical lipoatrophy was defined as a peripheral lipoatrophy assessed by both patient and 
practitioner as previously described (9, 11). Presence of central fat accumulation or 
abdominal prominence was defined by the measurement of waist circumference using the 
IDF criteria for metabolic syndrome (12). The clinical assessment was performed by the 
same practitioner (PF).  Resting blood pressure (BP) in a supine position was measured in a 
standardized fashion as previously described (7). 
Each patient was categorized into one of 4 groups according to the presence or absence of 
either lipoatrophy or abdominal prominence: 1 ) No lipodystrophy - patients without 
clinical lipoatrophy and without abdominal prominence; 2) Isolated central fat 
accumulation - patients without clinical lipoatrophy and with abdominal prominence; 3)  
Isolated lipoatrophy - patients with clinical lipoatrophy and without abdominal 
prominence; 4) Mixed forms of lipodystrophy - patients with clinical lipoatrophy and 
with abdominal prominence.  
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Evaluation of body composition 
Body composition was assessed with whole-body dual-energy X-ray absorptiometry 
(DXA) (DXA – Lunar Expert XL, 1999). DXA measurements were performed while the 
patient was in a supine position, with standard positioning of the arms and feet. Markers 
used in this study for trunk and lower limbs that defined regions of interest were those 
indicated by the manufacturer. Regional fat mass values were grouped and analyzed for the 
following anatomical regions: arms, legs, trunk and total body. The fat mass ratio (FMR) 
was calculated as the ratio between the percentage of the trunk fat mass and the percentage 
of the lower limb fat mass (FMR= % of the trunk fat mass/ % of the lower limb fat mass) 
(13). We used the cut-off value for lipodystrophy defined by FMR for men of 1.961 and for 
women of 1.329 (11). 
The quantification of total, visceral, and peripheral fat was performed with a 64-slice 
abdominal computed tomography (CT) scanner (Siemens Sensation 64 Cardiac) with the 
same technique as previously described (14, 15).  All values were expressed in cm2 rounded 
to the nearest centesimal.   
  
Laboratory analysis 
Biological and inflammatory parameters: a venous blood sample was drawn after a 12-hour 
overnight fast. All the samples were analyzed at the central laboratory of our hospital. The 
measurements of total cholesterol (TC), low density lipoprotein (LDL) cholesterol, high-
density lipoprotein (HDL) cholesterol, triglycerides, apolipoprotein A1 (apo A1), 
apolipoprotein B (apo B), lipoprotein (a) [Lp (a) , fibrinogen, high sensitivity C-reactive 
protein (hsCRP), homocysteine, uric acid, lactates, NT-proBNP, glucose, insulin, A1c  
serum levels were determined using commercial kits. Non HDL-C was defined as TC-
HDL. Microalbuminuria was determined in a 24 hour urine sample.  Patients without a 
previous diagnosis of diabetes were submitted to an oral glucose tolerance test (OGTT). 
The test was performed as described by the World Health Organization (16). 
The CD4+ cell count (x106 cell/L) was determined by flow cytometry and plasma HIV-1 
RNA loads were measured by a quantitative reverse transcriptase polymerase chain 
reaction (Roche Diagnostic Systems, Inc., Branchburg, NJ, USA), which had a lower limit 
of detection of 50 copies/mL. 
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Measurements of insulin resistance 
Insulin resistance was defined by the homeostasis model assessment of insulin resistance 
(HOMA) and insulin sensitivity by the quantitative insulin sensitivity check index 
(QUICKI). These indexes were calculated using the following formulas: 
HOMA-IR index = (insulin 0 x glucose 0)/22.5  (17).  
QUICKI = 1/(log fasting insulin in mU/l +log fasting plasma glucose in mg/dL)(18). 
 
Carotid IMT measurement 
High-resolution B-mode and Doppler ultrasonography of the carotid arteries was performed 
on a Philips iU22 machine (Philips Medical, The Netherlands), equipped with a 17 - 5 MHz 
high-frequency linear-array transducer. Patients were examined in the supine position, with 
the head in a neutral position or slightly turned away from the side being scanned. The left 
and right common carotid arteries (CCA) were examined in multiple directions and 
measurements were performed using the images with the best wall definition. The IMT was 
measured 3 cm below the carotid bulb in a longitudinal image. Three measurements were 
obtained on each side and the mean IMT of these values was calculated. All studies were 
performed by a single radiologist with 12 years of experience in vascular ultrasound, and 
were carried out using the same machine. 
The presence of subclinical carotid atherosclerosis was defined as IMT > 0.80 mm, 
presence of plaque, or both (19-21).   
 
Statistical analysis 
Data were described as mean and standard deviation (SD) for quantitative variables and 
compared using Student-t or Mann-Whitney tests as appropriate. Categorical variables were 
described as counts and proportions, and compared using the chi-square or Fisher’s exact 
test. To study the association between cIMT and clinical and metabolic characteristics, 
Spearman correlation coefficients were estimated. Means of cIMT (adjusted for age and 
body fat distribution measured by central vs. peripheral fat ratio estimated by quantitative 
CT) were computed using generalized linear models.  
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Statistical analysis was performed using SPSS version 17.0 software (SPSS Inc., Chicago, 
Illinois, USA). All probabilities were two tailed and p values <0.05 were regarded as 
significant.  
 
PubLicAçõES
	 	 2
9 
 
Results  
 
Patient characteristics 
In this sample of 199 HIV-1 infected patients (132 men and 67 women) on cART, 41.2 % 
patients presented lipodystrophy defined by FMR. Table 1 shows the characteristics of the 
study sample according to the presence of lipodystrophy defined by FMR. Patients with 
lipodystrophy were older, had longer duration of HIV infection and length of cART. There 
were no differences in weight, height, BMI, waist and arm circumference among patients 
with or without lipodystrophy. Patients with lipodystrophy had lower hip and thigh 
circumferences but higher neck circumference and a higher waist/hip circumference ratio 
than those without lipodystrophy. Patients with lipodystrophy had higher systolic blood 
pressure and leukocyte count than patients without lipodystrophy. 
Patients with lipodystrophy had a significantly higher mean CD4+ cell count. No 
differences were observed between patients with and without lipodystrophy regarding viral 
suppression rate, HIV risk factor, CDC classification and ART regimens that were used, 
smoking history, family history of CV disease and medication history (statins, fibrates, oral 
anti-diabetics, insulin and anti-hypertension drugs).  
 
Body composition by DXA 
In the evaluation of body composition by DXA, patients with lipodystrophy had lesser 
total, leg and arm fat mass, both in % and Kg, than patients without lipodystrophy. No 
difference was found in trunk fat mass (in % and Kg) between the two groups. 
  
Metabolic parameters 
Patients with lipodystrophy had higher glucose and insulin at 0 minutes and insulin at 120 
minutes on OGTT, HOMA, non-HDL cholesterol, triglycerides, uric acid, and lactates than 
patients without lipodystrophy. QUICKI index was lower in patients with lipodystrophy. 
No significant differences were found in the 2-hour value of glucose on OGTT, total 
cholesterol, LDL-cholesterol, HDL-cholesterol, apo A1 , apo B, ratio Apo B/Apo A1, 
Lp(a), homocysteine, CRP, hsCRP, NT-ProBNP, fibrinogen and microalbumin urinary 
excretion between the two groups. 
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Carotid IMT measurements 
Carotid IMT was higher in patients with lipodystrophy than patients without lipodystrophy 
[mean (SD) 0.81 (0.24) vs. 0.76 (0.25); p=0.037)]. 
When patients were classified into 4 categories of fat distribution, cIMT mean was similar 
in patients with isolated central fat accumulation [0.80 (0.29)] and with mixed forms of 
lipodystrophy [0.80 (0.28)] and significantly higher than patients with no lipodystrophy 
[0.68 (0.15)] and isolated lipoatrophy [0.72 (0.17)] (p<0.001).   
Carotid IMT correlated positively with age, waist/hip ratio, neck circumference, trunk fat 
mass evaluated by DXA, systolic blood pressure, glucose at 0 and 120 minutes on OGTT, 
A1c, non-HDL cholesterol, uric acid, CRP, hsCRP and homocysteine. No significant 
correlations were found between IMT and duration of HIV infection, length of cART, thigh 
circumference, total, leg and arm fat mass evaluated by DXA, CD4 cell count, leukocyte, 
insulin at 0 and 120 minutes on OGTT, HOMA, triglycerides, and lactates (Table 2). 
Using generalized linear models, cIMT means were adjusted for age and body fat 
distribution measured by central vs. peripheral fat ratio estimated by quantitative CT. No 
significant differences remained after this adjustment when patients with and without 
lipodystrophy were compared. The adjusted mean of cIMT was 0.776 (95%CI: 0.739-
0.812) in patients without lipodystrophy and 0.777 (95%CI: 0.734-0.820) in those with 
lipodystrophy (p=0.968). 
 
PubLicAçõES
	 	 2
11 
 
Discussion 
It was our aim to evaluate the association of lipodystrophy per se in cIMT. Prior studies 
evaluating the effect of lipodystrophy on cIMT have had conflicting results (22-24). We 
found that cIMT is higher in patients with lipodystrophy defined by FMR than in patients 
without lipodystrophy [0.81 (0.24) vs. 0.76 (0.25); p=0.037)]. Coll et al showed that the 
presence of lipodystrophy defined by clinical parameters increased by 3-fold the risk of 
sub-clinical carotid atherosclerosis in patients with HIV-infection (23). Mercié et al showed 
a significant association between cIMT and lipodystrophy in a univariate analysis of 161 
HIV-1-infected patients with lipodystrophy (38.1% of the patients), but the effect 
disappeared in the multivariate model (22). Coll et al suggest that this discrepancy with his 
results may be attributed to the Mercié et al sample being a younger and healthier 
population, since the mean cIMT was 0.54 mm (range 0.50-0.60), while in the Coll´s 
samples the mean cIMT was 0.80 (range 0.40-1.80). In Coll’s study the mean age of the 
patients with lipodystrophy was 42.38 (1.09) years while in Mercié’s it was 43.7 (8.3) 
years. The mean age of Coll’s patients without lipodystrophy was 40.59 (0.75), while in the 
Mercié et al study, it was 39.4 (8.7) years. Our patients either with lipodystrophy [49.2 
(10.2) years] or without lipodystrophy [44.8 (12.1) years] were older. In our results the 
mean cIMT was similar to that found by Coll [with lipodystrophy cIMT 0.88 (0.04) vs. 
without lipodystrophy 0.76 (0.02) mm; p=0.007], despite our patients being older than 
those of Coll et al. 
Visceral obesity is another independent risk factor for CVD in the background population 
(25) and independent associations of obesity and abdominal adiposity with cIMT were 
observed (26). However, the mechanisms by which the obesity is linked to early carotid 
atherosclerosis are not clearly established, even though the role of metabolic factors, such 
as insulin resistance and altered plasma adiponectin levels, has been proposed. Yet, body 
composition and fat distribution may influence systemic hemodynamics, both systemic 
blood pressure and total blood volume (27). When our patients were divided into 4 
categories of fat distribution, those with abdominal prominence, independently of having 
clinical lipoatrophy (patients with isolated central fat accumulation and patients with mixed 
forms of lipodystrophy) had a higher cIMT. We also found that cIMT was positively 
correlated with waist/hip ratio, neck circumference, and trunk fat mass evaluated by DXA. 
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Insulin resistance has been independently associated with vascular disease and accelerated 
CV disease in HIV-infected adults (28). In our results, patients with lipodystrophy had 
higher glucose and insulin at 0 and 120 minutes on OGTT and HOMA than patients 
without lipodystrophy, and lower QUICKI without significant differences in glucose at 120 
min on OGTT. Carotid IMT correlated positively with glucose at 0 and at 120 minutes on 
OGTT and A1c. Despite the higher insulin resistance evaluated by HOMA and lower 
insulin sensitivity evaluated by QUICKI, no significant correlations were found between 
cIMT and insulin at 0 and 120 minutes on OGTT and HOMA. 
Some studies have demonstrated that traditional CV risk factors overshadow the role of 
HIV infection and/or cART and are the major determinants of cIMT progression  (4, 29-32) 
and another has shown that HIV infection and/or cART were associated with increased 
cIMT independent of traditional CV risk factors (33), and yet another has pointed to the 
combination of all parameters (34). Older age is a traditional CV risk factor associated with 
higher mean cIMT and higher prevalence of carotid lesions (32, 35). A growing body of 
evidence indicates that cIMT below certain levels may not reflect atherosclerotic disease, 
but rather vascular aging and adaptive response to hemodynamic changes leading to 
alterations in shear and/or tensile stress (27, 36). We also found that cIMT correlated 
positively with age in our patients. In the Mercié study, cIMT was significantly associated 
with age and also with male gender, BMI, waist- to-hip ratio, systolic BP, total cholesterol, 
glucose disorders and homocysteine, smoking, alcohol consumption, lipodystrophy and 
cART. However, after adjustment for other CV risk factors the effects of lipodystrophy and 
cART disappeared, leading the authors to conclude that only conventional CV risk factors 
(age, BMI and smoking) are independently associated with increased cIMT in HIV-infected 
patients (22). In another study with 77 patients (23 with lipodystrophy) cIMT was 
significantly higher in HIV patients, but after adjustment for the presence of classical CV 
risk factors, no independent association was found between lipodystrophy and cIMT (24).  
In addition, adverse lipid and other metabolic changes associated with HIV infection or 
cART exposure may be important pro-inflammatory factors (37). Plasma lipid alterations 
have also been associated with an increased cIMT (38). Increasing levels of HDL-C and 
apo A-I have been associated with a decreased cIMT, but this association lost significance 
on multivariate analysis (33). We also found that cIMT was positively correlated with non-
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HDL cholesterol. Contrary to the literature on non-HIV patients (39), total cholesterol and 
blood pressure were not associated with IMT measures in the multivariate analysis model 
of Mercié et al. However, we found that cIMT was positively correlated with systolic blood 
pressure.  Mercié proposed a possible explanation for this discrepancy: the mean age of 
their population was low (41 years). Like Mercié et al, we also observed an association 
between total plasma homocysteine and cIMT in HIV-infected patients on cART, as was 
demonstrated in non-infected patients (22). 
It should be noted that certain “classical” vascular risk factors are over-represented in the 
HIV-infected population e.g. smoking. However, we observed no differences between 
patients with and without lipodystrophy regarding smoking history and so cannot ascribe 
the differences between the groups to smoking habits. Also, we observed no differences 
between patients with and without lipodystrophy regarding viral suppression rate, HIV risk 
factor, CDC classification and ART regimens that were used, family history of CV disease, 
and medications taken (oral anti-diabetic drugs, insulin and anti-hypertension drugs). 
Statins are known to have beneficial effects on the arterial wall (40) but we observed no 
differences in the taking of medications (statins and fibrates) between patients with or 
without lipodystrophy. 
 In HIV-negative patients, both leukocyte counts and CRP and hsCRP have been linked to 
endothelial dysfunction and future CV events (41, 42).  Like Hsue, we found that hsCRP 
was associated with cIMT. However, in Hsue’s study, after adjusting for all traditional risk 
factors, the association between hsCRP and cIMT was no long significant. In our results, no 
significant differences were found in CRP and hsCRP according to the presence of 
lipodystrophy, although lipodystrophic patients had higher leukocyte counts but no 
significant correlation was found between cIMT and leukocyte count. The hsCRP levels 
were not consistently associated with cIMT after adjusting for other factors (43). Mangili 
found that hsCRP independently predicted cIMT and that this correlation might become 
more evident with prolonged HIV disease and prolonged exposure to treatment (1). Van 
Wijk observed elevated blood leukocyte counts and elevated CRP levels in these patients. 
In HIV-infected patients, the endothelium could be activated either directly by HIV or by a 
leukocyte-mediated inflammatory cascade triggered by HIV infection (41).  
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Study limitations 
The limitations of this study are mainly related to the observational design and cross-
sectional nature of the current analyses. The results reported herein are only associations 
from which no causality conclusions can be drawn. Subclinical atherosclerosis evaluated by 
carotid IMT reflects the cumulative effects of risk factors acting over many years, whereas 
we measured risk factors at one time point only. Thus, blood lipid concentrations, blood 
pressure, and the other CV risks estimated at one time point may not accurately represent 
lifetime exposure. Use of cART, CD4 + T-cell count, HIV viral load, and CVD risk 
mediators are dynamic variables that change over time.  
Another important point to be noted is that up to 38 % of the cIMT variability might be 
attributed to genetic conditions, and those were not studied here.  
 
Some aspects of the present study should be highlighted. 
To evaluate body composition we used objective methods: the presence of lipodystrophy 
was defined by FMR by DXA and visceral fat by CT scan.  
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Conclusions 
Patients with lipodystrophy had a higher central fat mass, a lower peripheral fat mass and a 
higher central/peripheral fat mass, and a higher cIMT. cIMT is associated with total and 
central fat mass and with the ratio central/peripheral fat. Patients with abdominal 
prominence, independently of having clinical lipoatrophy (patients with isolated central fat 
accumulation and patients with mixed forms of lipodystrophy) had a higher cIMT, but 
patients with isolated peripheral lipoatrophy had a higher cIMT than patients with no 
lipodystrophy. Thus, it seems that central fat accumulation had a major impact on cIMT but 
the role of isolated lipoatrophy cannot be disregarded.   
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Table 1: Sample characteristics according to the presence of lipodystrophy defined by 
FMR 
 
 Without L With L P 
n (%) 117 82 - 
Gender [n(%)] 
  Male 
  Female 
 
71 (60.7) 
46 (39.3) 
 
61 (74.4) 
21 (25.6) 
 
0.063 
 
Age [years, mean (sd)] 44.8 (12.1) 49.2 (10.2) 0.002 
Duration of HIV infection [years, mean 
(sd)] 
7.2 (3.8) 8.5 (3.5) 0.005 
cART [years, mean (sd)] 5.7 (3.7) 7.9 (3.3) <0.001 
Weight [Kg, mean (sd)] 68.0 (14.3) 68.0 (10.6) 0.805 
Height [m, mean (sd)] 1.64 (0.09) 1.64 (0.08) 0.518 
BMI [(Kg/m2), mean (sd)] 25.2 (5.0) 25.3 (4.0) 0.637 
Waist circumference  [cm, mean (sd)] 90.6 (12.7) 92.6 (10.2) 0.174 
Hip circumference  [cm, mean (sd)] 96.1 (9.4) 92.5 (6.4) 0.005 
Thigh circumference  [cm, mean (sd)] 48.5 (5.5) 47.0 (4.9) 0.025 
Arm circumference  [cm, mean (sd)] 26.7 (3.2) 27.2 (2.6) 0.285 
Neck circumference  [cm, mean (sd)]  36.6 (3.8) 37.8 (3.8) 0.045 
Waist/ hip circumference ratio [mean 
(sd)]  
0.94 (0.09) 1.00 (0.07) <0.001 
CD4 cell count [cells/mm3, mean (sd)]  502.7 (265.0) 631.8 (340.8) 0.006 
HIV RNA (<50) [n (%)] 102 (87.2) 74 (90.2) 0.660 
HIV risk factor [n (%)]    
    Injecting drug user   32 (27.8) 15 (18.3)  
 
 
 
 
0.050 
    Homosexual contact  7 (6.1) 14 (17.1) 
    Heterosexual contact  74 (64.3) 51 (62.2) 
    Others  2 (1.7) 2 (2.4) 
CDC [n (%)]    
      A 63 (54.3) 53 (64.6)  
0.209 
 
 
      B 1 (0.9) 0 (0) 
     C 52 (44.8) 29 (35.4) 
ART [n (%)]    
     PI 59 (51.3) 48 (58.5) 0.390 
      NNRTI 58 (50.4) 38 (46.3) 0.673 
      NRTI 112 (97.4) 79 (96.3) 0.695 
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Smoking history [n (%)]    
Never 44 (37.9) 36 (43.9)  
Current  55 (47.4) 27 (32.9)  
Former 17 (14.7) 19 (23.2) 0.092 
    
Familial history of CVD [n (%)] 51 (43.6) 40 (48.8) 0.563 
    
Taking medications [n (%)]    
Statins 22 (19.0) 25 (30.5) 0.088 
Fibrates 39 (33.6) 39 (47.6) 0.067 
Oral anti-diabetics  13 (11.2) 16 (19.5) 0.154 
Insulin 6 (5.2) 4 (4.9) 1.000 
Anti-hypertensive drugs 21 (17.9) 19 (23.5) 0.442 
    
Fat mass [%, mean (sd)] DXA 
   Total 
   Trunk 
   Leg 
   Arm 
 
24.8 (13.1) 
25.7 (13.3) 
24.4 (14.7) 
27.2 (17.1) 
 
19.3 (8.5) 
24.3 (9.0) 
11.1 (7.4) 
20.3 (13.6) 
 
0.003 
0.446 
<0.001 
0.007 
Fat mass [Kg, mean (sd)] DXA 
   Total 
   Trunk 
   Leg 
   Arm 
 
17.3 (11.1) 
9.3 (6.0) 
5.2 (3.6) 
2.1 (1.9) 
 
13.2 (7.3) 
9.0 (4.8) 
2.1 (1.6) 
1.5 (1.2) 
 
0.013 
0.918 
<0.001 
0.019 
Body Fat Mass by Quantitative CT    
 Total fat [cm2, mean (sd)] 282.2 (174.5) 276.6 (124.0) 0.865 
 Central fat [cm2, mean (sd)] 111.5 (85.8) 158.2 (63.2) <0.001 
 Peripheral fat [cm2, mean (sd)] 170.8 (125.7) 118.3 (93.1) 0.002 
 Central/peripheral Fat [cm2, mean (sd)] 1.08 (1.46) 2.43 (2.62) <0.001 
Systolic blood pressure [mmHg, mean 
(sd)] 
120.0 (18.9) 124.6 (15.8) 0.039 
Diastolic  blood pressure [mmHg, mean 
(sd)] 
75.8 (11.9) 78.0 (10.6) 0.139 
    
Leukocytes [109/L, mean (sd)] 5.66 (1.67) 6.39 (1.88) 0.007 
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Glucose 0 min [mg/dL, mean (sd)] 104.4 (45.1) 114.7 (44.2) 0.003 
Glucose 2 hours [mg/dL, mean (sd)] 123.6 (42.9) 139.2 (50.3) 0.051 
Insulin 0 min  [U/mL, mean (sd)] 9,49 (10.28) 13.00 (10.68) 0.002 
Insulin 2 hours [U/mL, mean (sd)] 52.43 (46.65) 91.32 (147,24) 0.007 
HOMA [mean (sd)] 2,54 (2.90) 3.73 (3.31) <0.001 
QUICKI [mean (sd)] 0.38 (0.10) 0.34 (0.04) <0.001 
A1c [% mean (sd)] 5.50 (1.06) 5.77 (0.06) 0.001 
Total cholesterol [mg/dL, mean (sd)] 218.6 (53.2) 233.6 (61.0) 0.093 
LDL-cholesterol [mg/dL, mean (sd)] 126.1 (47.1) 132.3 (50.7) 0.461 
HDL-cholesterol [mg/dL, mean (sd)] 47.0 (14.4) 44.3 (12.0) 0.262 
Non-HDL cholesterol [mg/dL, mean 
(sd)] 
171.6 (48.9) 189.3 (56.5) 0.019 
Triglycerides[mg/dL, mean (sd)] 247.5 (170.9) 307.2 (198.5) 0.006 
Apo A1 [mg/dL, mean (sd)] 118.8 (25.8) 114.3 (18.3) 0.204 
Apo B [mg/dL, mean (sd)] 104.7 (26.7) 106.1 (25.4) 0.827 
Ratio apo B/apo A1 [mean (sd)] 0.91 (0.27) 0.95 (0.25) 0.297 
Lp(a) [mg/dL, mean (sd)] 30.2 (31.2) 31.1 (39.7) 0.421 
Homocysteine [mol/L, mean (sd)] 9.6 (4.1) 9.8 (3.7) 0.435 
CRP [mg/L, mean (sd)] 5.4 (12.9) 4.0 (4.2) 0.913 
hsCRP [mg/dL, mean (sd)] 0.48 (0.91) 0.37 (0.28) 0.185 
Lactates [mmol/L, mean (sd)] 1.12 (0.47) 1.36 (0.58) 0.001 
NT-ProBNP [pg/mL, mean (sd)] 39.1 (67.3) 28.6 (27.1) 0.414 
Fibrinogen [mg/dL, mean (sd)] 344.8 (98.3) 336.2 (92.1) 0.463 
Microalbumin [mg/L, mean (sd)] 49.1 (150.6) 26.0 (67.7) 0.435 
Uric acid [mg/L, mean (sd)] 44.4 (15.2) 51.2 (15.4) <0.001 
    
Carotid IMT [mm, mean (sd)] 0.76 (0.25) 0.81 (0.24) 0.037 
 
(L- Lipodystrophy FMR defined; CDC - Centers for Disease Control and Prevention 
criteria for staging of HIV infection; cART- combined antiretroviral therapy; BMI- body 
mass index; FMR – fat mass ratio; CVD – cardiovascular disease; DXA – dual-energy X-
ray absorptiometry; CT – computed tomography; PI – protease inhibitor; NNRTI –non-
nucleoside reverse transcriptase inhibitor; NRTI – nucleoside reverse transcriptase 
inhibitor, IMT – intima-media thickness). 
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Table 2: Correlations between cIMT and body composition and metabolic 
parameters. 
 
Correlations between cIMT and R P 
 
Age 0.709 <0.001 
Duration of HIV infection  -0.019 0.779 
cART 0.024 0.727 
Waist/ hip ratio 0.387 <0.001 
Thigh circumference   -0.095 0.169 
Neck circumference   0.202 0.007 
CD4 cell count -0.027 0.701 
Systolic blood pressure 0.419 <0.001 
Leukocytes -0.049 0.478 
Glucose 0 min 0.284 <0.001 
Glucose 2 hours OGTT 0.220 0.006 
Insulin 0 min   0.026 0.711 
Insulin 2 hours OGTT -0.089 0.271 
HOMA 0.094 0.185 
A1c 0.285 <0.001 
Triglycerides 0.109 0.113 
Non-HDL cholesterol 0.254 <0.001 
CRP 0.196 0.005 
hsCRP 0.334 0.003 
Homocysteine 0.150 0.032 
Uric acid 0.146 0.034 
Lactates 0.081 0.253 
Fat mass Total 0.084 0.236 
 Trunk 0.168 0.018 
Leg -0.037 0.604 
Arm 0.029 0.686 
  Total fat on abdominal CT scan 0.218 0.002 
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 Central fat on abdominal CT scan 0.418 <0.001 
 Peripheral fat on abdominal CT scan -0.009 0.901 
 Central/peripheral fat ratio on 
abdominal CT scan 
0.290 <0.001 
 
(IMT – intima-media thickness; cART – combined antiretroviral therapy; CDC - Centers 
for Disease Control and Prevention criteria for staging of HIV infection; cART –  combined 
antiretroviral therapy; OGTT – oral glucose tolerance test; HOMA – the homeostasis model 
assessment of insulin resistance; HDL-high density cholesterol; CPR –C protein reactive; 
CT – computed tomography)  
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6. disCussão
A more detailed discussion is made in each of the articles. in this section a 
more general discussion of the results is proposed.
Human lipodystrophies are a heterogeneous group of diseases with generalized 
or partial fat loss, with rare genetic etiology or more frequent acquired forms, old 
or more recently described as for example the lipodystrophy related with retrovirus 
[1]. We focused on the most recent - the lipodystrophy associated to Hiv-infection. 
Lipodystrophy is a general term used to describe various features and degrees of 
fat redistribution, including lipoatrophy and lipohypertrophy, in different body regions 
[2-5]. Some patients present mainly lipoatrophy, others mixed form of lipoatrophy and 
trunk/abdominal fat accumulation while others have isolated trunk/ abdominal fat 
accumulation, and the global picture of the syndrome seems to represent a clinical 
continuum [6]. Different methodologies have been used to assess the prevalence of 
this syndrome: patient self-report, clinical evaluation and a complex case report de-
finition. This last definition attempted to develop an objective case definition of lipo-
dystrophy, including age, sex, duration of Hiv infection, Hiv disease stage, waist to 
hip ratio, anion gap, serum high-density lipoprotein (HDL) cholesterol concentration, 
trunk to peripheral fat ratio, percentage leg fat, and intra- to extra-abdominal fat ratio 
[7]. However, the model is complex and with limited clinical usefulness. therefore, the 
need for a simple, evidence-based, and validated definition of lipodystrophy was ex-
perienced by researchers working in this area. We proposed a ratio of trunk fat mass 
evaluated by DXA with different thresholds for men and women, because it was our 
believe that gender differences in body composition are present either in the general 
population or in patients with or without lipodystrophy. our proposed threshold values 
enabled a more precise identification of lipodystrophic patients. FMR is an objective 
tool to define HIV-related lipodystrophy, allowing a more clinically useful definition for 
identification of patients with abnormal fat distribution. Use of gender-specific FMR 
thresholds as a diagnostic tool in metabolic studies of Hiv-infected patients would 
enable the comparison of different studies and should be useful to monitor lipodys-
trophy progression in this population [8].
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bioelectrical impedance (biA) was an already established method to monitor 
nutritional status in Hiv infected patients before the introduction of cArt, when pa-
tients had almost exclusively the wasting syndrome with sarcopenia, mainly charac-
terized by losses of both fat and free fat mass (before the description of lipodystrophy 
syndrome) [9]. the results of biA demonstrated similar fat-free mass along the fat 
distribution spectrum and describing a precise body composition of the patients and 
enables exclude sarcopenia. biA, an objective way to evaluate body fat, also sho-
wed an increase in fat mass in patients with isolated central fat accumulation and 
mixed forms of lipodystrophy. Patients with lipoatrophy and no lipodystrophy presen-
ted lower fat mass, being this picture of body composition impossible to show using 
more traditional anthropometric measures [10]. in a clinical setting, biA is an easy and 
useful tool to evaluate fat mass and the amount of fat-free mass. biA is operator-in-
dependent, repeatable, non-invasive, widely available method of body composition 
evaluation that requires less training than anthropometry and is less expensive than 
DXA [11]. biA may also be a useful method in the evaluation of clinical lipodystrophy 
(cL) evolution [12].
Despite cART has changed the course of HIV infection, leading to a significant 
reduction in AiDS related morbidity and mortality [13], it was associated with changes 
in fat distribution (lipodystrophy) and metabolic abnormalities, including insulin resis-
tance (ir), dyslipidemia, and increased blood pressure (bP) [14, 15]. the metabolic syn-
drome (MS), a common condition in the general population, refers to a constellation 
of cardiovascular disease (cvD) risk factors, including increased waist circumference 
(Wc), glucose and lipid metabolism disorders, and hypertension [16, 17]. Each of these 
risk factors, individually, increase the risk of cardiovascular disease, but MS itself 
has shown to be a powerful independent risk factor for cardiovascular morbidity and 
mortality and for type 2 diabetes [18]. it is still controversial if the MS improves the 
identification of high risk individuals [19-21].
to our knowledge, our paper “impact of lipodystrophy on the prevalence and 
components of metabolic syndrome in HIV-infected patients” was the first study 
conducted in HIV-infected patients focusing specifically on the role of subcutaneous 
adipose tissue atrophy defined by presence of clinical lipodystrophy (CL) on the pre-
valence of the MS. Another particularity is that all patients were on cArt. other stu-
dies analyzed the presence of the MS in naïve or on cArt Hiv-infected patients, with 
sub-analyses concerning the presence of cL in patients with the MS [22-24]. in men, 
high blood pressure and MS were more frequent in those with isolated central fat 
accumulation and mixed forms of lipodystrophy (AtPiii and iDf criteria) and high fas-
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ting glucose levels were significantly more frequent in same two groups using ATPIII 
criteria. in women, hypertriglyceridemia, low c-HDL levels, high Wc and presence of 
MS were more frequent in those with isolated central fat accumulation and mixed 
forms of lipodystrophy using either AtPiii or iDf criteria. the observation that patients 
with CL had significantly higher 10 year-risk of coronary heart disease , measured by 
the framingham risk score, than patients without cL and that those with cL and with 
MS had higher frequencies of moderate and high risk categories than those without 
MS emphasizes the importance of the clinical diagnosis of this condition [25]. our data 
showed that among Hiv patients on cArt, the prevalence of MS may be remarkably 
high, especially when taking into account the mean age of our sample and the obser-
vation that patients with CL had a significantly higher 10 year-risk of coronary heart 
disease, measured by the framingham risk score.
Another factor that can contribute to the increased cv risk in Hiv-infected pa-
tients is obesity [26-28]. this condition is associated with a chronic, systemic state of 
inflammation that may contribute to CV diseases and other obesity-related co-morbi-
dities [29-31]. Although, lipodystrophy in HIV-infected patients was first reported more 
than 10 years ago, the available information on obesity in Hiv-infected patients is still 
scarce [14].
in fact, recent studies have shown that being overweight or obese is more com-
mon than wasting in these patients, and this may be partly justified by the increased 
survival rate in Hiv patients and by the weight gain that occurs with ageing, as it 
happens in the general population [26-28, 32, 33]. our data also showed that, regardless 
of gender, being of normal weight, overweight or obese is more common than being 
underweight in these Hiv-infected patients. As patients with Hiv live longer and the 
infection has been relegated to a chronic condition, Hiv patients may be now facing 
similar problems to the general population, including excessive weight gain due to 
poor lifestyle habits [26, 34]. but, more important than the obesity diagnose, is the as-
sessment of the fat distribution. the best way to quantify the visceral adipose tissue 
(vAt) is through ct or Mri scanning. in our patients, those with cL, despite having 
a similar vAt and lower total and subcutaneous adipose tissue (SAt) at abdominal 
level, had a higher WHr (wais/hip ratio) and a higher vAt/SAt ratio by ct. the pre-
sence of a similar vAt and a higher vAt/SAt ratio resulted from a lower SAt. the 
same phenomenon was observed with WHr because they had a decrease in SAt that 
was predominantly adipose tissue in the hip. When we analyzed the data according 
to the 4 groups of fat redistribution, patients with isolated lipoatrophy had a higher 
vAt/SAt fat ratio indicating not only an increase in visceral adipose tissue, but also 
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lower subcutaneous fat. these patients with low SAt and vAt had a similar fat distri-
bution to patients with berardinelli-Seip congenital generalized lipodystrophy [35]. one 
of the strengths of our study is that it addressed the prevalence of obesity according 
to the presence of cL and this has not been reported previously. Despite having a 
lower prevalence of overweight or obesity when compared to patients without lipo-
dystrophy, lipodystrophic patients had an increased proportion of VAT, as reflected by 
the increased vAt/SAt fat ratio determined by ct at abdominal level. this probably 
suggests that these patients have a comparable risk of metabolic and cardiovascular 
complications, in spite of the actual frequency of obesity being lower. 
there are few and discrepant studies on hypertension in Hiv-infected patients 
and scarce information is available on hypertension in Hiv-infected patients accor-
ding to the presence of lipodystrophy [36-39]. There is a perception that cART influence 
on the prevalence of hypertension appears to be minor. bergersen argued that the 
most probable explanation for these findings was that HIV-positive patients usually 
have lower bMi, thus having a lower blood pressure than the general population [40]. 
in our study, hypertension was not associated with lipodystrophy: only in men, 
with lipoatrophy presented an increased prevalence of hypertension when compared 
to those without any fat distribution abnormality, when lipodystrophy was clinically 
defined. Gazzaruso stated that the strong association of lipodystrophy with hyper-
tension appears to be of interest for two reasons. Firstly, it confirms that IR could be 
involved in the development of both lipodystrophy and hypertension. Secondly, this 
association suggests that the presence or the development of lipodystrophy in an 
Hiv-infected patient should be a precise indication to check for hypertension. they 
concluded that hypertension was frequent in Hiv-infected patients on cArt and that 
hypertension appears to be linked to ir [39]. in our patients, after adjustment for age, 
gender, smoking history and bMi, hypertension was not associated either with ir or 
the presence of clinically or FMR-defined lipodystrophy. Also, total abdominal, central 
and peripheral fat mass were not associated with hypertension. on the other hand, 
central/peripheral fat mass ratio evaluated by CT scan was significantly associated 
with hypertension, even after adjustment for the above mentioned variables. total 
body, arm and trunk fat mass, assessed by DXA, were not associated with hyperten-
sion, independent of age, gender and smoking history. However, patients with isolated 
lipoatrophy (patients with lipoatrophy and without abdominal prominence) presen-
ted more frequently absence of hypertension and the presence of hypertension was 
more prevalent in patients with isolated central fat accumulation and mixed forms of 
lipodystrophy (patients with abdominal prominence regardless of the presence or ab-
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sence of lipoatrophy). this could mean that abdominal prominence, as in the general 
population, is more important in determining hypertension than lipoatrophy and may 
in fact, overcome the effect of lipoatrophy. this could also help in the explanation 
of the apparent paradox of lipodystrophy being associated with insulin resistance, 
insulin resistance being associated with hypertension, but hypertension not being 
associated with lipodystrophy. in summary, hypertension was not associated with ir, 
lipodystrophy or fat mass (total abdominal, central and peripheral), but was associa-
ted with central/peripheral fat mass ratio.
combined antiretroviral therapy in the treatment of Hiv-1 infection has been 
associated with other complications, including ir and diabetes. in our population, no 
differences were observed between ir or categorization of the glucose homeostasis 
according to clinical lipodystrophy classification, in spite of the well-established asso-
ciation between visceral fat and IR. Also, when patients were classified according to 
4 categories of fat distribution by clinical lipoatrophy and waist circumference, again 
no differences were found. When patients were classified as being lipodystrophic or 
not according to fMr, we observed that patients with lipodystrophy had higher ir 
(higher HoMA and lower QuicKi and Matsuda values). they also had higher fasting 
plasma glucose, insulin and A1c levels, and higher % of ifG, iGt and DM. When we 
divided the patients into 4 categories of body fat distribution by using FMR-defined 
lipodystrophy and waist circumference, those patients with lipodystrophy and abdo-
minal prominence had a higher prevalence of DM and iGt. Patients without fMr-
defined lipodystrophy but with abdominal prominence only had a high prevalence 
of iGt. it seems that the loss of peripheral adipose tissue is less important than 
the presence of abdominal prominence in the occurrence of ir, but we cannot com-
pletely rule out its role, since patients with only abdominal prominence and without 
lipodystrophy, defined by FMR, had less marked glucose disturbances i.e. they only 
had increased prevalence of iGt. As previously proposed by bonnet, the discrepancy 
observed between the results using the 2 different lipodystrophy definitions, could be 
the result from the higher accuracy of the objective method in reporting small losses 
of peripheral adipose tissue that may have been undetected by clinical inspection [41]. 
Significant associations between IR and total fat, central fat and central/peripheral 
fat ratio and no association with peripheral fat at abdominal level evaluated by ct 
were observed, emphasizing the contribution of the central fat mass to ir. We also 
found an association between ir and total and trunk fat evaluated by DXA. As in our 
results, De Wit et al, showed that clinical lipodystrophy was significantly associated 
with new-onset diabetes and the abnormal body fat distribution in Hiv-positive indivi-
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duals is strongly associated with ir and/or glucose intolerance, with excess trunk or 
visceral fat being, as in the general population, a risk factor for ir in patients with Hiv 
infection. in addition, De Wit observed that ir is itself was independently associated 
with fat loss in Hiv-infected individuals [42]. 
in our sample, no association was observed between peripheral fat mass with 
ir. this result is contrary to the De Wit study, where patients had a marked peripheral 
adipose tissue loss that was clinically evident. Also, our patients had less evident low 
fat mass, detected only by fMr. in fact, according to De Wit statement, information 
on lipodystrophy was rarely collected since the study was carried out in 11 centers, 
which suggests that only marked lipodystrophies were reported. in our study, fMr 
as a continuum was significantly associated with IR evaluated by HOMA, even after 
adjustment for gender, age, iP, nrti, cD4 cell count and Hiv rnA viral load. in conclu-
sion, insulin resistance and glucose homeostasis abnormalities significantly increa-
sed with increasing fMr. Abdominal prominence, an important factor impacting the 
fMr, expressed by abdominal circumference, waist/hip ratio, visceral and trunk fat 
defined by CT, was also associated with glucose homeostasis disturbances. 
in addition, being associated with lipodystrophy, cArt is also related to lipid 
abnormalities and cardiovascular disease. And, there is a suggestion that emerging 
non-traditional risk factors may predispose Hiv-infected patients to accelerated athe-
rosclerosis. Apolipoprotein A1, apolipoprotein B, lipoprotein (a) [Lp (a)], fibrinogen, 
high sensitivity c-reactive protein (hs-crP), homocysteine, microalbuminuria and nt-
probnP serum levels also have been associated with increased cardiovascular risk 
and some of them are related to inflammation [43-58]. in our cohort, patients with cL 
had lower total cholesterol, LDL-c, HDL-c, Apo A1 and higher mean levels of triglyce-
rides. Patients with lipodystrophy defined by FMR had higher triglycerides and lower 
Lp(a). When patients were classified according to the four groups of fat distribution, 
patients with abdominal prominence, independent of the presence of lipoatrophy, 
had higher mean levels of total cholesterol, LDL-c, and Apo b. Low Apo A1 is a known 
risk indicator of coronary atherosclerosis [59] and we found the lowest Apo A1 plasma 
levels in patients with isolated lipoatrophy and mixed forms of lipodystrophy. Signifi-
cant positive linear associations were observed between fMr and triglycerides and 
Apo B/Apo A ratio. These associations remained significant after adjustment for age, 
gender, PI and NRTI. Apo A1 had a significant negative linear association with FMR 
that remained significant after adjustment for gender and age, but it lost significan-
ce after adjustment for cArt. the emerging cardiovascular risk factors did not vary 
according to fat redistribution. in Hiv infected patients, the 2 components of body fat 
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redistribution syndrome seemed to induce different deleterious effects: central fat 
accumulation induced increased total cholesterol, LDL cholesterol and Apo b; and 
isolated lipoatrophy induced low Apo A1 and high triglycerides. in the analysis of the 
components of adipose tissue redistribution syndrome, abdominal prominence see-
ms to be more important than lipoatrophy in this association.
Lipodystrophies are characterized by redistribution of adipose tissue, ir, and 
metabolic complications and adipokines may play an important role as an interme-
diary, linking these alterations. Adipose tissue has emerged as a metabolically active 
endocrine organ secreting multiple bioactive peptides, collectively called “adipoki-
nes” and other proteins including inflammatory mediators such TNF-a and PAi-1 [60]. 
Ghrelin, an orexigenic gut peptide, is a marker of metabolic dysregulation and altered 
body fat distribution [61]. our aim was to evaluate the relationship between adipocyte 
derived hormones (adiponectin, leptin, resistin, tnf-a), orexigenic hormones (ghre-
lin), protrombotic factors (PAi-1) and ir in Hiv-infected patients on cArt according 
to the presence of Fat Mass Ratio defined lipodystrophy (FMR-L) and four categories 
of fat distribution. in our data, leptin levels were lower in patients with lipodystro-
phy, indicating its close relationship with total body fat. A significant positive corre-
lation of leptin with HoMA in patients with lipodystrophy demonstrated the role of 
this adipokine in insulin sensitivity. Adiponectin was lower in patients with isolated 
central fat accumulation and negatively correlated with visceral adipose tissue. the 
adiponectin/leptin ratio was lower in patients with isolated central fat accumulation. 
Patients with mixed forms of lipodystrophy had higher levels of PAI-1. No significantly 
differences were found in resistin, PAi-1 and ghrelin levels in patients with or without 
lipodystrophy defined by FMR. 
Hiv-infected patients may be at increased risk of cardiovascular (cv) events, 
and lipodystrophy is generally associated with proatherogenic metabolic disturban-
ces. the carotid intima-media thickness (ciMt) has been used as a surrogate marker 
for atherosclerosis and it has been shown to be an independent risk factor for cv 
disease [62]. the role of age, prolonged survival, traditional and non-traditional risk 
factors, direct effect of Hiv infection and cArt, in relation to surrogate markers of 
atherosclerosis are under continuing debate [62]. thus, due to the long term survival 
associated with cART, deleterious effects of the treatment and the chronic inflamma-
tory state emerge [63]. Although the disease can cause alterations in several metabolic 
pathways, such as lipid and glucose metabolism, as we demonstrated, the lipodys-
trophic patients per se might also be at a higher risk of atherosclerosis, since the fat 
redistribution is associated with presence of several known metabolic risk factors for 
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cvD [64]. Previously, we demonstrated that patients with clinical lipodystrophy have 
a significantly higher risk of coronary heart disease at 10 years, measured by the 
framingham risk score, than patients without clinical lipodystrophy and those with 
clinical lipodystrophy and with metabolic syndrome had higher frequencies of mo-
derate and high risk categories than those without metabolic syndrome [65]. Also, we 
demonstrated that carotid iMt was higher in patients with lipodystrophy than patients 
without lipodystrophy. Patients with lipodystrophy had a higher central fat mass, a lo-
wer peripheral fat mass and a higher central/peripheral fat mass. ciMt is associated 
with total and central fat mass and with the ratio central/peripheral fat. Patients with 
abdominal prominence, independently of having clinical lipoatrophy (patients with 
isolated central fat accumulation and patients with mixed forms of lipodystrophy) had 
a higher mean ciMt. nevertheless, patients with isolated peripheral lipoatrophy had a 
higher ciMt when compared to patients with no lipodystrophy. it was concluded that 
central fat accumulation had a major impact on ciMt in Hiv cArt treated patients, 
however, despite lack of statistical significance, the role of isolated lipoatrophy should 
not be disregarded.
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7. ConCLusõEs
Hiv-infected patients can have different patterns of body composition with seve-
ral fat distribution spectrums, but with similar fat-free mass (excluding the presence 
of sarcopenia). Some patients had mainly lipoatrophy, others had increased trunk 
and abdominal fat accumulation, and a subset of patients had mixed forms of lipo-
dystrophy. Lipodystrophic patients had an increased proportion of VAT, as reflected by 
the increased vAt/SAt fat ratio determined by ct at abdominal level. this probably 
suggests that these patients have a comparable risk of metabolic and cardiovascular 
complications, in spite of the actual frequency of obesity being lower in patients with 
lipodystrophy.
in this sample of Hiv-infected patients, hypertension was not associated with ir, 
lipodystrophy or fat mass (total abdominal, central and peripheral), but was associa-
ted with central/peripheral fat mass ratio.
IR and glucose homeostasis abnormalities significantly increased with increa-
sing fMr. Abdominal prominence, an important factor impacting the fMr, expressed 
by abdominal circumference, waist/hip ratio, visceral and trunk fat defined by CT, 
was also associated with glucose homeostasis disturbances. Also, it seems that lost 
of peripheral adipose tissue was less important than the presence of abdominal pro-
minence in the occurrence of ir, but one cannot completely disregard its role, since 
patients with isolated abdominal prominence and without lipodystrophy, defined by 
fMr, had less marked glucose disturbances i.e. they only had increased prevalence 
of iGt.
Again, in Hiv infected patients, the 2 components of body fat redistribution syn-
drome seemed to induce different deleterious effects: central fat accumulation indu-
ced increased total cholesterol, LDL cholesterol and Apo b; and isolated lipoatrophy 
induced low Apo A1 and high triglycerides levels. in the analysis of the components 
of adipose tissue redistribution syndrome, abdominal prominence seems to be more 
important than lipoatrophy in this association.
in what concern adipokines and body composition hormones, leptin levels were 
lower in patients with lipodystrophy, indicating its close relationship with total body 
fat. A significant positive correlation of leptin with HOMA in patients with lipodystro-
phy could add to the importance of this adipokine in insulin sensitivity. Adiponectin 
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was lower in patients with isolated central fat accumulation and negatively correlated 
with visceral adipose tissue. the adiponectin/leptin ratio was lower in patients with 
isolated central fat accumulation. Patients with mixed forms of lipodystrophy had hi-
gher levels of PAI-1. No significantly differences were observed in resistin, PAI-1 and 
ghrelin levels in patients with or without lipodystrophy defined by FMR. The HIV redis-
tribution syndrome, with different degrees of peripheral fat atrophy and central fat 
accumulation, had a complex relationship with adipokines, body composition related 
hormones and ir.
Patients with CL had a significantly higher risk of coronary heart disease at 10 
years, measured by the framingham risk score, than patients without cL. Patients 
with CL and with MS were more frequently classified in the moderate and high risk 
categories than those with cL but without MS.
carotid iMt, a surrogate marker for atherosclerosis, was higher in patients with 
lipodystrophy than patients without lipodystrophy. ciMt was associated with total and 
central fat mass and with the ratio central/peripheral fat. Patients with abdominal 
prominence, independently of having clinical lipoatrophy had a higher ciMt, but pa-
tients with isolated peripheral lipoatrophy had a higher ciMt than patients with no li-
podystrophy. central fat accumulation had a major impact on ciMt in Hiv cArt treated 
patients; nevertheless, the role of isolated lipoatrophy should not be disregarded.
in conclusion, lipodystrophy had a greatest impact in metabolic and cardiovas-
cular abnormalities in these Hiv-infected patients, being the patients with higher cen-
tral/peripheral fat ratio (patients with central fat accumulation and mixed forms of 
lipodystrophy) those with more alterations, however, one should not overlook the role 
of peripheral lipoatrophy, as a contributor to these changes.
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A infeção viH e a terapêutica antirretrovírica combinada (tArc) têm sido asso-
ciadas a alterações morfológicas (lipodistrofia), metabólicas e endócrinas que po-
dem estar ligadas a aumento do risco cardiovascular. Os doentes com lipodistrofia 
têm vários graus de redistribuição da gordura, incluindo lipoatrofia, lipohipertrofia e 
formas mistas de lipodistrofia. O nosso objetivo foi estudar a composição corporal, 
as alterações metabólicas e endócrinas e a doença cardiovascular de acordo com 
a presença de lipodistrofia. Conduzimos vários estudos clínicos observacionais, em 
doente infetados pelo viH e sob tArc, de forma a responder a estas questões. 
Apesar das diferentes metodologias utilizadas previamente na definição de li-
podistrofia, havia a necessidade de um método de definição que fosse simples, ob-
jetivo e especifico para o género. Utilizando a “razão massa gorda tronco/membros” 
(rMGtM = % de gordura do tronco/% gordura dos membros inferiores avaliada por 
densitometria), definimos novos pontos de corte, tendo sido pela primeira vez defini-
dos pontos de corte específicos para o género feminino. 
A avaliação da composição corporal através de impedância bioelétrica (biA) 
permite-nos ter um quadro da composição corporal que não é possível apenas com 
a antropometria. os resultados da biA demonstram que nestes doente, a massa não 
gorda é semelhante nos vários tipos de redistribuição da gordura, que há ausência de 
sarcopenia e que existe um aumento da massa gorda nos doentes com acumulação 
isolada da gordura central e nas formas mistas de lipodistrofia. Independentemente 
do género, ter peso normal, sobrecarga ponderal ou obesidade é mais comum do 
que ter peso baixo nos nossos doentes infetados pelo viH. Apesar dos doentes com 
lipodistrofia terem uma menor prevalência de sobrecarga ponderal ou obesidade, 
estes têm um aumento do tecido adiposo visceral, tal como refletido no aumento da 
razão do tecido adiposo visceral/tecido adiposo subcutâneo determinado por tomo-
grafia computadorizada (TC) a nível abdominal. 
A prevalência de síndrome metabólica (SM) nestes doentes é elevada, espe-
cialmente tendo em conta a média de idade da nossa amostra. observámos que os 
doentes com lipodistrofia clínica tinham um risco aos 10 anos de doença coronária 
significativamente maior, determinado pelo score de Framingham. Os doentes simul-
taneamente com lipodistrofia clínica e com SM tinham uma maior frequência de ca-
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tegorias de risco moderado e elevado do que aqueles com lipodistrofia clínica mas 
sem SM, enfatizando a importância do diagnóstico clínico desta condição. 
na nossa coorte, a hipertensão arterial não estava associada com insulino-re-
sistência, lipodistrofia ou massa gorda (abdominal total, central ou periférica), mas 
estava associada com a razão da massa gorda central/periférica.
A insulino-resistência e as alterações da homeostase da glicose aumentavam 
significativamente com o aumento do RMGTM. A presença de proeminência abdomi-
nal, é um importante fator com impacte na rMGtM, expressa pelo perímetro abdo-
minal, razão cintura/anca, razão da gordura visceral/subcutânea a nível abdominal 
definida por TC, e estava também associada a alterações da homeostase da glicose. 
não encontrámos qualquer associação entre a massa gorda periférica com insulino-
resistência.
nos doentes infectados pelo viH, os 2 componentes do síndrome de redistribui-
ção da gordura corporal parecem induzir efeitos deletérios diferentes: a acumulação 
de gordura central induz aumento do colesterol total, C-LDL e Apo B; e a lipoatrofia 
isolada induz baixa das Apo A1 e aumento dos triglicerídeos. na análise dos compo-
nentes do síndrome de redistribuição do tecido adiposo, a proeminência abdominal 
parece ser mais importante do que a lipoatrofia nesta associação.
no que concerne a relação entre os níveis de adipocinas e composição corpo-
ral, os níveis de leptina eram menores nos doentes com lipodistrofia, indicando sua 
relação com a gordura corporal total. Encontrámos uma correlação significativa po-
sitiva da leptina com HOMA nos doentes com lipodistrofia, o que demonstra o papel 
desta adipocina na insulino-sensibilidade. A adiponectina é menor nos doentes com 
acumulação isolada de gordura central e correlaciona-se negativamente com o teci-
do adiposo visceral. A razão adiponectina/leptina era menor nos doentes com acu-
mulação isolada de gordura central. Os doentes com formas mistas de lipodistrofia 
tinham níveis mais elevados de PAI-1. Não encontrámos diferenças significativas nos 
níveis de resistina, PAI-1 e ghrelina nos doentes com ou sem de lipodistrofia definida 
pela rMGtM.
A espessura da íntima média carotídea (EiMc), um marcador precoce de ate-
rosclerose, era maior nos doentes com lipodistrofia do que naqueles sem lipodis-
trofia. A EIMC estava associada com a massa gorda total, central e com a razão da 
gordura central/periférica a nível abdominal. os doentes com proeminência abdomi-
nal, independentemente de terem lipoatrofia clínica tinham uma maior EIMC, mas os 
doentes com lipoatrofia periférica isolada tinham uma maior EIMC do que doentes 
sem lipodistrofia. A acumulação da gordura central tinha um maior impacte na EIMC 
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nos doentes VIH tratados sob TARc; não obstante, o papel da lipoatrofia isolada não 
deve ser desconsiderado.
Em conclusão, a lipodistrofia tem um importante impacte nas alterações me-
tabólicas e cardiovasculares. no entanto, deverá ser realçado, que os doentes com 
maior razão da gordura central/periférica (doentes com acumulação da gordura cen-
tral e formas mistas de lipodistrofia) eram aqueles que apresentavam mais altera-
ções. Porém, não podemos ignorar o papel da lipoatrofia periférica como possível 
contribuinte para estas alterações metabólicas e cardiovasculares. 
EStuDo Do SínDroME DA LiPoDiStrofiA E DAS rEPErcuSSõES EnDócrino-MEtAbóLicAS E cArDiovAScuLArES nA infEção Por viH
20
summaRY
Hiv infection and combined antiretroviral therapy (cArt) have been associated 
with morphologic abnormalities (lipodystrophy) and linked through metabolic and en-
docrine alterations to increased cardiovascular risk. Patients with lipodystrophy had 
various features and degrees of fat redistribution, including lipoatrophy, lipohypertro-
phy or mixed forms of lipodystrophy. We aimed to study body composition, metabolic, 
endocrine alterations and cardiovascular disease according to the presence of lipo-
dystrophy. We conducted several observational clinical studies in order to answer to 
above research questions. Despite different methodologies have been used to define 
lipodystrophy, there was a need of a simple, objective and gender-specific definition. 
We defined new gender-specific cutoffs to FMR (FMR=% of trunk/% of lower limbs fat 
mass by DXA) and for the first time in female patients. Body composition evaluation 
through bioelectrical impedance (biA) gave us a picture of body composition that is 
not possible to have with anthropometry. the results of biA demonstrated a similar 
fat-free mass along the fat distribution spectrum, absence of sarcopenia and increa-
se in fat mass in patients with isolated central fat accumulation and mixed forms of 
lipodystrophy. regardless of gender, being of normal weight, overweight or obese is 
more common than being underweight in our Hiv-infected patients. Despite having a 
lower prevalence of overweight or obesity, lipodystrophic patients had an increased 
proportion of VAT, as reflected by the increased VAT/SAT fat ratio determined by CT at 
abdominal level. the prevalence of MS was high, especially taking into account the 
mean age of our sample and it was also observed that patients with CL had a signifi-
cantly higher risk of coronary heart disease at 10 years, measured by the framingham 
risk score. Also, those with cL and with MS had higher frequencies of moderate and 
high risk categories than those with cL but without MS, emphasizes the importance 
of the clinical diagnosis of this condition. 
in our cohort, hypertension was not associated with ir, lipodystrophy or fat mass 
(total abdominal, central and peripheral), but was associated with central/peripheral 
fat mass ratio.
IR and glucose homeostasis abnormalities significantly increased with increa-
sing fMr. Abdominal prominence, an important factor impacting the fMr, expressed 
by abdominal circumference, waist/hip ratio, visceral and trunk fat defined by CT, was 
also associated with glucose homeostasis disturbances. no association was obser-
ved between peripheral fat mass with ir.
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in Hiv infected patients, the 2 components of body fat redistribution syndrome 
seemed to induce different deleterious effects: central fat accumulation induced in-
creased total cholesterol, LDL cholesterol and Apo b; and isolated lipoatrophy indu-
ced low Apo A1 and high triglycerides. in the analysis of the components of adipose 
tissue redistribution syndrome, abdominal prominence seems to be more important 
than lipoatrophy in this association.
in what concern adipokines and body composition hormones, leptin levels were 
lower in patients with lipodystrophy, indicating its close relationship with total body 
fat. A significant positive correlation of leptin with HOMA in patients with lipodystrophy 
demonstrates the role of this adipokine in insulin sensitivity. Adiponectin was lower in 
patients with isolated central fat accumulation and negatively correlated with visceral 
adipose tissue. the adiponectin/leptin ratio was lower in patients with isolated cen-
tral fat accumulation. Patients with mixed forms of lipodystrophy had higher levels of 
PAI-1. No significantly differences in resistin, PAI-1 and ghrelin levels in patients with 
or without lipodystrophy defined by FMR were found. 
carotid iMt, a surrogate marker for atherosclerosis, was higher in patients with 
lipodystrophy than patients without lipodystrophy. ciMt was associated with total and 
central fat mass and with the ratio central/peripheral fat. Patients with abdominal 
prominence, independently of having clinical lipoatrophy had a higher ciMt, but pa-
tients with isolated peripheral lipoatrophy had a higher ciMt than patients with no li-
podystrophy. central fat accumulation had a major impact on ciMt in Hiv cArt treated 
patients; nevertheless, the role of isolated lipoatrophy should not be disregarded.
in conclusion, lipodystrophy had an important impact in metabolic and cardio-
vascular abnormalities, nonetheless, patients with higher central/peripheral fat ratio 
(patients with central fat accumulation and mixed forms of lipodystrophy) were those 
that presented more alterations. one should not however ignore the role of peripheral 
lipoatrophy as a contributor to these metabolic and cardiovascular changes.
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